CA2316921C - Aryl fused azapolycyclic compounds - Google Patents
Aryl fused azapolycyclic compounds Download PDFInfo
- Publication number
- CA2316921C CA2316921C CA002316921A CA2316921A CA2316921C CA 2316921 C CA2316921 C CA 2316921C CA 002316921 A CA002316921 A CA 002316921A CA 2316921 A CA2316921 A CA 2316921A CA 2316921 C CA2316921 C CA 2316921C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- formula
- mmol
- compound
- dodeca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and n are defined as in the specification intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.
Description
ARYL FUSED AZAPOLYCYCLIC COMPOUNDS
Background of the Invention This invention relates to aryl fused azapolycyclic compounds, as defined more specifically by formula I below. Compounds of formula I bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function.
Such compounds are useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.~c ., dependencies on, or addictions to nicotine (andlor tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
The compounds of this invention may also be used in combination with an antidepressant such as, for example, a tricyclic antidepressant or a serotonin reuptake inhibiting antidepressant (SRI), in order to treat both the cognitive decline and depression associated with AD, PD, stroke, Huntington's Chorea or traumatic brain injury (TBI); in combination with muscarinic agonists in order to stimulate both central muscarinic and nicotinic receptors for the treatment, for example, of ALS, cognitive dysfunction, age related cognitive decline, AD, PD, stroke, Huntington's Chorea and TBI; in combination with neurotrophic factors such as NGF in order to maximize cholinergic enhancement for the treatment, for example, of ALS, cognitive dysfunction, age related cognitive decline, AD, PD stroke, Huntington's Chorea and TBI; or in combination with agents that slow or arrest AD such as cognition enhancers, amyloid aggregation inhibitors, secretase inhibitors, tau kinase inhibitors, neuronal antiinflammatory agents and estrogen-like therapy.
.2-Other compounds that bind to neuronal nicotinic receptor sites are referred to in United States Patent No. 6,020,335, which was filed on November 4, 1997. The foregoing application is owned with the present application.
Summary of the Inventron This invention relates to aryl fused azapolycycl'~c compounds of the formula Rz N R' R' is hydrogen, (C,-C°)alkyl, unconjugated (C'-C°)alkenyl, benzyl, XC(=O)R" or -CHzCHTO-(C,-C,)alkyl;
R= and R' are selected, independently, from hydrogen, (C=-C°)alkenyl, (C~)alkynyl, hydroxy, riiVo, amino, halo, c~rano, -SOo(C,-C°)alkyl wherein q is zero, one or two, (C,.C°)alkyiamino-, [(C,-C°)alkytJzamino-, -COzR~, -CONRSR°, -SOiNR'R°, -C(=O)R", -XC(=O)R", aryl-(Co -G~)alkyl- or aryl-(Co-C3)alkyl-0-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C~-C3)alkyl- or heteroaryf-(Co-C~)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and Xi(Co-C°)alkyl- and X=(C,-C°)alkoxy-(Co-C6)alkyl-, wherein X' is absent or X' is (C,-C°~lkylamino- or [(C,-C°)alky(Jzamino-, and wherein the (C~-C°)alkyl- or (C,-C°)alkoxy-(Co-C°)a0cyf- moieties of said X'(Co-C6)alkyl- and Xz(C,-C°)alkoxy-(C~-C6)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (Ca-C°)alkyl- or (C,-C°)alkoxy-(C~-C°)alkyl-moieties may optionally be replaced by an oxygen, rirtrogen or suNur atom, with the proviso that any two such heteroa~ms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C~-C°)alkyl- or (C,.C°)alkoxy-(C~-C°)alkyl- may be optionally substrtuted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(Co-G3)alkyl- and said heteroaryl-(Cfl-G~)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C,-C°~llcyl optionally substituted with from one to seven fluorine atoms, (C,-C°)alkoxy optionally substituted with from two to seven fluorine atoms, halo Le.c~,., chloro, fluoro, bromo or iodo), (C~)alkenyl, (C=-C°)atkynyt, hydroxy, vitro, cyano, amino, (C,-f 1 f t 1 f ! r 1 « If ' f n C i I 1 (( ! ( ! f 1 1 C
( ~ a f f « r « f r ! r f -3; I f ! t ! f f ! < f f 1 ! , f 1 f ! f i f , ( f t r f o ( ! « t ! r !U r < 1 C6)alkylamino-, [(C~-C6) alkyl]Zamino-, -COZR4, -CONR5R6, -SOZNR'Re, -C{=O)R'3 and -XC(=O)R'3;
or RZ and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or a ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the non-fused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, preferably from zero to two substituents for the monocyclic rings and from zero to three substituents for the bicyclic rings, that are selected, independently, from (Co-C6)alkyl- or (C~ -C6)alkoxy-(Co-Cs)alkyl-, wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; vitro, oxo, cyano, halo, {CZ-C6)alkenyl, (CZ-C6)alkynyl, hydroxy, amino, (C,-C6)alkylamino-, [(C~-C6)alkyl]zamino-, -C02R4, -CONRSR6, -SOZNR'Re, -C(=O)R'3, and -XC(=O)R'3;
each R', R5, R6, R', RB and R'3 is selected, independently, from hydrogen and (C, -C6) alkyl, or RS and R6, or R' and RB together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C~-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C~-C6)alkylene;
with the proviso that: (a) at least one of R', RZ and R3 must be the other than hydrogen, and (b) when RZ and R3 are hydrogen, R' cannot be hydrogen, (C,-Cs)alkyl, or unconjugated (C3-C6)alkenyl;
and the pharmaceutically acceptable salts of such compounds.
Examples of heteroaryl groups that each of R2 and R3 can be are the following:
thienyl, oxazoyl, isoxazolyl, pyridyl, pyrimidyl, thiazolyl, tetrazolyl, isothiazolyl, triazolyl, imidazolyl, tetrazolyl, pyrroyl and the following groups:
SUBSTITUTE PAGE
AN~N~t'9 SHEET
c t r < « « c « t r t t t r < ~ r t r a c t ~ f ( f 1 t -4-~ , f f , ( , f a r ( ( 1 f ( t t t t 1 < f f ( t ( f f ( ( ( f i t t ( f f t 1 ( 1 f ( ( f ( ( 1 t ( t < 1 Rya N
~Rs R'a Rs R' 8 O Rs O-N
N-~O N N
N R' a s s ~a 'N ('~N~-R R~ 'N
R ERs N~ NON
R' a wherein one of R9 and R'8 is hydrogen or (C~-C6)alkyl, and the other is a bond to the benzo ring of formula I.
Examples of compounds of this invention are compounds of the formula I, and their pharmaceutically acceptable salts, wherein RZ and R3, together with the benzo ring of formula I, form a bicyclic ring system selected from the following:
N Rio N N
~~R~a ~ ~~R~o ~ R~~
''N ~O N
R"
O~N O ~~R~o N
Rio wherein R'° and R" are selected, independently, from {C°-C6)alkyl- and (C,-C6)alkoxy-(C°-Cs)alkyl- wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; nitro, cyano, halo, amino, (C,-C6)alkylamino-, [(C,-C6) aIkyIJ2amino-, -COZR4, -CONRSR6, -SOzNR'Ra, -C(=O)R'3, -XC(=O)R'3, phenyl and monocyclic heteroaryl wherein said heteroary!
is defined as RZ and R3 are defined in the definition of compounds of the formula I above;
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein R2 and R3, together with the benzo ring of formula I, form a bicyclic or tricyclic ring system selected from the following:
SUBSTITUTE PAGE
AN~N~~ SHEE'~
r r rr (( r; r « rf I t ( f ( ( t t ( f 1 r f f l f ( ( -5-( ((r r ( f r ( r t ( f f f . r ( ( f ( f ( f ! f . ( r f f 1 l f ( ( rff( « ( (( l1( l« I
N
~N
i N
Rio S
~N
Rio Rio R~7 / N\
N O \ 'NO
-N ~R~~ -N-~CN O ~N
N N N
Rio Rio O
R» N Rio )m ~ ~ \ \
~I
~N ~ N A ~ N
wherein R'° and R'7 are defined as above and m is zero, one or two, and wherein one of the carbon atoms of ring A can optionally be replaced with oxygen or -N(C,-C6)alkyl.
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein neither RZ nor R3 is attached to the benzo ring of formula I via an oxygen atom.
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein RZ and R3 do not, together with the benzo ring of formula I, form a bicyclic or tricyc(ic ring system.
SUBSTITUTE PAGE
AI~t~,~D SHEErt , r c; t Cf r! fr '. ~ f- ! f' < i C I r i f r ! t , < f I (i f ( ( ! f l ~5A- . f . ! f r . ~ i f f , a ! !~ f ~ ! ! ~ f f , !
. ! a !~f( it r! !!t fr !r 5 Other embodiments of this invention relate to compounds of the formula I
wherein one or both of RZ and R3 are -C(=O)R'3, wherein R'3 is (C~-C6)alkyl. Further embodiments of this invention relate to compounds of the formula I wherein one or both of R2 and R3 are -C(=O)R'3, wherein R'3 is (C~-C6)alkyl or (C1-C3)alkyl optionally substituted with from one to seven fluorine atoms. Other embodiments relate to compounds of the formula I wherein one of RZ and R3 is CF3, fluoro, cyano or CZFS. -, Other embodiments of this invention relate to compounds of the formula I
wherein R' is not methyl.
Examples of speck compounds of the formula I are the following:
6-methyl-5, 7-dioxo-6,13-diazatetracyclo(9.3.1.02''°.04'8]pentadeca-2(10), 3, 8-triene hydrochloride;
SUBSTITUTE PAGE
t~ ~~
6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.OZ''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
5,7-dimethyl-6-oxo-5,7,13-triazatetracyclo[9.3.1.02'' °.04'8]pentadeca-2( 10), 3, 8-triene hydrochloride;
5,7-dioxo-6,13-diazatetracyclo[9.3.1.0z.'°.04.a]pentadeca-2(10),3,8-triene hydrochloride;
5-oxo-6,13-diazatetracyclo[9.3.1.Oz''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
6-oxo-5,7,13-triazatetracyclo[9.3.1.02''°.048]pentadeca-2(10),3,8-triene hydrochloride;
4,5-difluoro-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene hydrochloride;
5-fluoro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene hydrochloride;
5-ethynyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
5-chloro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.OZ''°.048]pentadeca-2(10),3,8-triene hydrochloride;
4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
5-trifluoromethyl-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
6-methyl-5-thia-5-dioxa-6,13-Diazatetracyclo[9.3.1.Oz''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
7-dimethylamino-5-thia-5-dioxa-6,13-Diazatetracyclo(9.3.1.02''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
6,7-dioxa-5,8,14-triazatetracyclo[10.3.1.OZ~".048]hexadeca-2(11 ),3,9-triene hydrochloride; and 5,8-dimethyl-6,7-dioxa-5,8,14-triazatetracyclo[10.3.1.0z~".049]hexadeca-2(11),3,9-triene hydrochloride.
This invention also relates to compounds of the formula ( ( (( (( (~ ( (( (( c ~r ( - 7 ( ( (( ( ( ( ( ( ( ( ( ( ( ( ~ (~ ( r ( ( ( ( ( ( w r « ( ( ( ( ( ( ( ( ( ( ( ( ( « r ( ( r r ( ( .. ( ( ( a ( f c ( ( ( ( f c ( ( «
P
i N
R~a~ R~s wherein P is hydrogen, methyl, COOR'6 wherein R's is (C~-Cs)alkyl, allyl, 2,2,2-trichloroethyl or (C~-C6)alkyl; -C(=O)NR$R6 wherein RS and R6 are defined as in formula I
above; -C(=O)H, -C(=O)(C,-C6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl or t-butoxycarbonyl (t-Boc); and R'4 and R'S are selected, independently, from hydrogen, (C,-C6)alkyl optionally substituted with from one to seven fluorine atoms; -C(=O)(C~-C6)alkyl, cyano, hydroxy, vitro, amino, -O(C,-C6)alkyl or halo; with the proviso that R'4 and R'S can not both be hydrogen when P is hydrogen, (C~-C6)alkyl, or unconjugated (C3-C6)alkenyl. Such compounds are useful as intermediates in the synthesis of compounds of the formula I.
The invention also relates to a compound of the formula y SNP( Eli) R3 _ wherein RZ and R3 are defined above; and P( is COOR's wherein R'6 is allyl, 2,2,2-trichloroethyl or (C,-C6)alkyl; -C(=O)NR$Rs wherein RS and R6 are defined as in claim 2; -C(=O)H, -C(=O){C,-Cs)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl, or t-butoxycarbonyl (t-Boc).
Unless otherwise indicated, the term "halo", as used herein, includes fluoro, chloro, bromo and iodo.
Unless otherwise indicated, the term "alkyl", as used herein, includes straight, branched or cyclic, and may include straight and cyclic alkyl moieties as well as branched and cyclic moieties.
The term "alkoxy", as used herein, means "alkyl-O= , wherein "alkyl" is defined as above.
The term "alkylene, as used herein, means an alkyl radical having two available bonding sites i.e., -alkyl-), wherein "alkyl" is defined as above.
SUBSTITUTE PAGE
'. r ' ' ' ' ' '' r '' c ''-7A= ' ' ' ~ '' ' a'' ' ' "' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ', ' ' ' ' a ' ' ' ' ' ' a ' ' a - ' ' "" " '' "< " ~' Unless otherwise indicated, the term "one or more substituents", as used herein, refers to from one to the maximum number of substituents possible based on the number of available bonding sites.
The term "treatment', as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such condition or disorder. The term °treatment", as used herein, refers to the act of treating, as "treating° is defined immediately above.
The compounds of formula I may have optical centers and therefore may occur in different enantiomeric configurations. The invention includes all enantiomers, diastereomers, and SUBSTITUTE PAGE
~~~ s ( f f ( ( f f ( ! ( l f ( 1 ( t « - ~ f (( ( ( ! ( 1 f ! ( 1 -( t < ( f ( f 1 1 ( ( ( ( ( f ( ( ! f f ( I
( f f t ( ( ( f ( l ( t t f ( I (' f ( ( f l f 1 ( ( ( l f other stereoisomers of such compounds of formula I, as well as racemic and other mixtures thereof.
The present invention also relates to all radiolabeled forms of the compounds of the formula I. Preferred radiolabeled compounds of formula I are those wherein the radiolabels are selected from as 3H, "C, '4C, 'BF, '231 and '~I. Such radiolabeled compounds are useful as research and diagnostic tools in metabolism pharmacokinetics studies and in binding assays in both animals and man.
The present invention also relates to a pharmaceutical composition for use in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use and a pharmaceutically acceptable carrier.
The present invention also relates to a method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.
The present invention also relates to a method of treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac spree, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac anythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.~C .,, dependencies on, or addictions to nicotine (andlor tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
SUBSTITUTE PAGE
The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourett's Syndrome in a mammal, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, which comprises (a) an amount of a compound of the formula:
NH
or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use, and (b) a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, which comprises (a) an amount of a compound of the formula:
\
NH
or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and (b) a pharmaceutically acceptable carrier.
This invention also relates to the pharmaceutically acceptable acid addition salts of the compounds of formula I.
- l0a -Examples of pharmaceutically acceptable acid addition salts of the compounds of formula I are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, malate, di-p-toluoyl tartaric acid, and mandelic acid.
As well-known in the art, the pharmaceutical composition mentioned above, may be put in a commercial package. This invention also relates to such a commercial package. The commercial package usually carries a written matter which states that the pharmaceutical composition is to be used for the purpose described in this specification.
Detailed Description of the Invention Except where otherwise stated, R1 through R18, m and P, and structural formula I in the reaction schemes and discussion that follow are defined as above.
Scheme 1 I / ~NH . HCI III
O
I N~CF3 IV
OzN O
I N
O
N
I / ~N CF3 IIB
HZN
Scheme 2 O
\ ~ IIA
N-tBoc VIA
N-tBoc VIB
Scheme 2 continued VIB
H
N
R'~ \ \N-tBoc VII
N
R"
N
R~~~\ I \N-tBoc VII' N
H
N
v R \ / NH IA
N
R"
I
N
R' ~--C\ I \N H
N ~ IB
Scheme 3 ~N-tBoc VIA
R"H N \
~N-tBoc XXIII
R"HN
N-tBoc XXIV
R"
l N \
R'°--C~ \N-tBoc XXV
N
R"
I
N \
v R~°~~ I / NH IB
N ~--' Scheme 4 ~N-tBoc VIB
R N /
~NH IC
R17 wN \
Scheme 5 II
I \N~-CFs XXII
OZN
HO / II
~N--~-CF3 VIII
OZN
O
\NH IE
N U ~--' Scheme 6 Pc~rnB9siolsi3 NH III
O
N-C-CF
Background of the Invention This invention relates to aryl fused azapolycyclic compounds, as defined more specifically by formula I below. Compounds of formula I bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function.
Such compounds are useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.~c ., dependencies on, or addictions to nicotine (andlor tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
The compounds of this invention may also be used in combination with an antidepressant such as, for example, a tricyclic antidepressant or a serotonin reuptake inhibiting antidepressant (SRI), in order to treat both the cognitive decline and depression associated with AD, PD, stroke, Huntington's Chorea or traumatic brain injury (TBI); in combination with muscarinic agonists in order to stimulate both central muscarinic and nicotinic receptors for the treatment, for example, of ALS, cognitive dysfunction, age related cognitive decline, AD, PD, stroke, Huntington's Chorea and TBI; in combination with neurotrophic factors such as NGF in order to maximize cholinergic enhancement for the treatment, for example, of ALS, cognitive dysfunction, age related cognitive decline, AD, PD stroke, Huntington's Chorea and TBI; or in combination with agents that slow or arrest AD such as cognition enhancers, amyloid aggregation inhibitors, secretase inhibitors, tau kinase inhibitors, neuronal antiinflammatory agents and estrogen-like therapy.
.2-Other compounds that bind to neuronal nicotinic receptor sites are referred to in United States Patent No. 6,020,335, which was filed on November 4, 1997. The foregoing application is owned with the present application.
Summary of the Inventron This invention relates to aryl fused azapolycycl'~c compounds of the formula Rz N R' R' is hydrogen, (C,-C°)alkyl, unconjugated (C'-C°)alkenyl, benzyl, XC(=O)R" or -CHzCHTO-(C,-C,)alkyl;
R= and R' are selected, independently, from hydrogen, (C=-C°)alkenyl, (C~)alkynyl, hydroxy, riiVo, amino, halo, c~rano, -SOo(C,-C°)alkyl wherein q is zero, one or two, (C,.C°)alkyiamino-, [(C,-C°)alkytJzamino-, -COzR~, -CONRSR°, -SOiNR'R°, -C(=O)R", -XC(=O)R", aryl-(Co -G~)alkyl- or aryl-(Co-C3)alkyl-0-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C~-C3)alkyl- or heteroaryf-(Co-C~)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and Xi(Co-C°)alkyl- and X=(C,-C°)alkoxy-(Co-C6)alkyl-, wherein X' is absent or X' is (C,-C°~lkylamino- or [(C,-C°)alky(Jzamino-, and wherein the (C~-C°)alkyl- or (C,-C°)alkoxy-(Co-C°)a0cyf- moieties of said X'(Co-C6)alkyl- and Xz(C,-C°)alkoxy-(C~-C6)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (Ca-C°)alkyl- or (C,-C°)alkoxy-(C~-C°)alkyl-moieties may optionally be replaced by an oxygen, rirtrogen or suNur atom, with the proviso that any two such heteroa~ms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C~-C°)alkyl- or (C,.C°)alkoxy-(C~-C°)alkyl- may be optionally substrtuted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(Co-G3)alkyl- and said heteroaryl-(Cfl-G~)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C,-C°~llcyl optionally substituted with from one to seven fluorine atoms, (C,-C°)alkoxy optionally substituted with from two to seven fluorine atoms, halo Le.c~,., chloro, fluoro, bromo or iodo), (C~)alkenyl, (C=-C°)atkynyt, hydroxy, vitro, cyano, amino, (C,-f 1 f t 1 f ! r 1 « If ' f n C i I 1 (( ! ( ! f 1 1 C
( ~ a f f « r « f r ! r f -3; I f ! t ! f f ! < f f 1 ! , f 1 f ! f i f , ( f t r f o ( ! « t ! r !U r < 1 C6)alkylamino-, [(C~-C6) alkyl]Zamino-, -COZR4, -CONR5R6, -SOZNR'Re, -C{=O)R'3 and -XC(=O)R'3;
or RZ and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or a ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the non-fused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, preferably from zero to two substituents for the monocyclic rings and from zero to three substituents for the bicyclic rings, that are selected, independently, from (Co-C6)alkyl- or (C~ -C6)alkoxy-(Co-Cs)alkyl-, wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; vitro, oxo, cyano, halo, {CZ-C6)alkenyl, (CZ-C6)alkynyl, hydroxy, amino, (C,-C6)alkylamino-, [(C~-C6)alkyl]zamino-, -C02R4, -CONRSR6, -SOZNR'Re, -C(=O)R'3, and -XC(=O)R'3;
each R', R5, R6, R', RB and R'3 is selected, independently, from hydrogen and (C, -C6) alkyl, or RS and R6, or R' and RB together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C~-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C~-C6)alkylene;
with the proviso that: (a) at least one of R', RZ and R3 must be the other than hydrogen, and (b) when RZ and R3 are hydrogen, R' cannot be hydrogen, (C,-Cs)alkyl, or unconjugated (C3-C6)alkenyl;
and the pharmaceutically acceptable salts of such compounds.
Examples of heteroaryl groups that each of R2 and R3 can be are the following:
thienyl, oxazoyl, isoxazolyl, pyridyl, pyrimidyl, thiazolyl, tetrazolyl, isothiazolyl, triazolyl, imidazolyl, tetrazolyl, pyrroyl and the following groups:
SUBSTITUTE PAGE
AN~N~t'9 SHEET
c t r < « « c « t r t t t r < ~ r t r a c t ~ f ( f 1 t -4-~ , f f , ( , f a r ( ( 1 f ( t t t t 1 < f f ( t ( f f ( ( ( f i t t ( f f t 1 ( 1 f ( ( f ( ( 1 t ( t < 1 Rya N
~Rs R'a Rs R' 8 O Rs O-N
N-~O N N
N R' a s s ~a 'N ('~N~-R R~ 'N
R ERs N~ NON
R' a wherein one of R9 and R'8 is hydrogen or (C~-C6)alkyl, and the other is a bond to the benzo ring of formula I.
Examples of compounds of this invention are compounds of the formula I, and their pharmaceutically acceptable salts, wherein RZ and R3, together with the benzo ring of formula I, form a bicyclic ring system selected from the following:
N Rio N N
~~R~a ~ ~~R~o ~ R~~
''N ~O N
R"
O~N O ~~R~o N
Rio wherein R'° and R" are selected, independently, from {C°-C6)alkyl- and (C,-C6)alkoxy-(C°-Cs)alkyl- wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; nitro, cyano, halo, amino, (C,-C6)alkylamino-, [(C,-C6) aIkyIJ2amino-, -COZR4, -CONRSR6, -SOzNR'Ra, -C(=O)R'3, -XC(=O)R'3, phenyl and monocyclic heteroaryl wherein said heteroary!
is defined as RZ and R3 are defined in the definition of compounds of the formula I above;
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein R2 and R3, together with the benzo ring of formula I, form a bicyclic or tricyclic ring system selected from the following:
SUBSTITUTE PAGE
AN~N~~ SHEE'~
r r rr (( r; r « rf I t ( f ( ( t t ( f 1 r f f l f ( ( -5-( ((r r ( f r ( r t ( f f f . r ( ( f ( f ( f ! f . ( r f f 1 l f ( ( rff( « ( (( l1( l« I
N
~N
i N
Rio S
~N
Rio Rio R~7 / N\
N O \ 'NO
-N ~R~~ -N-~CN O ~N
N N N
Rio Rio O
R» N Rio )m ~ ~ \ \
~I
~N ~ N A ~ N
wherein R'° and R'7 are defined as above and m is zero, one or two, and wherein one of the carbon atoms of ring A can optionally be replaced with oxygen or -N(C,-C6)alkyl.
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein neither RZ nor R3 is attached to the benzo ring of formula I via an oxygen atom.
Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein RZ and R3 do not, together with the benzo ring of formula I, form a bicyclic or tricyc(ic ring system.
SUBSTITUTE PAGE
AI~t~,~D SHEErt , r c; t Cf r! fr '. ~ f- ! f' < i C I r i f r ! t , < f I (i f ( ( ! f l ~5A- . f . ! f r . ~ i f f , a ! !~ f ~ ! ! ~ f f , !
. ! a !~f( it r! !!t fr !r 5 Other embodiments of this invention relate to compounds of the formula I
wherein one or both of RZ and R3 are -C(=O)R'3, wherein R'3 is (C~-C6)alkyl. Further embodiments of this invention relate to compounds of the formula I wherein one or both of R2 and R3 are -C(=O)R'3, wherein R'3 is (C~-C6)alkyl or (C1-C3)alkyl optionally substituted with from one to seven fluorine atoms. Other embodiments relate to compounds of the formula I wherein one of RZ and R3 is CF3, fluoro, cyano or CZFS. -, Other embodiments of this invention relate to compounds of the formula I
wherein R' is not methyl.
Examples of speck compounds of the formula I are the following:
6-methyl-5, 7-dioxo-6,13-diazatetracyclo(9.3.1.02''°.04'8]pentadeca-2(10), 3, 8-triene hydrochloride;
SUBSTITUTE PAGE
t~ ~~
6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.OZ''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
5,7-dimethyl-6-oxo-5,7,13-triazatetracyclo[9.3.1.02'' °.04'8]pentadeca-2( 10), 3, 8-triene hydrochloride;
5,7-dioxo-6,13-diazatetracyclo[9.3.1.0z.'°.04.a]pentadeca-2(10),3,8-triene hydrochloride;
5-oxo-6,13-diazatetracyclo[9.3.1.Oz''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
6-oxo-5,7,13-triazatetracyclo[9.3.1.02''°.048]pentadeca-2(10),3,8-triene hydrochloride;
4,5-difluoro-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene hydrochloride;
5-fluoro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene hydrochloride;
5-ethynyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
5-chloro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.OZ''°.048]pentadeca-2(10),3,8-triene hydrochloride;
4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
5-trifluoromethyl-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-4-carbonitrile hydrochloride;
4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene hydrochloride;
6-methyl-5-thia-5-dioxa-6,13-Diazatetracyclo[9.3.1.Oz''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
7-dimethylamino-5-thia-5-dioxa-6,13-Diazatetracyclo(9.3.1.02''°.04'8]pentadeca-2(10),3,8-triene hydrochloride;
6,7-dioxa-5,8,14-triazatetracyclo[10.3.1.OZ~".048]hexadeca-2(11 ),3,9-triene hydrochloride; and 5,8-dimethyl-6,7-dioxa-5,8,14-triazatetracyclo[10.3.1.0z~".049]hexadeca-2(11),3,9-triene hydrochloride.
This invention also relates to compounds of the formula ( ( (( (( (~ ( (( (( c ~r ( - 7 ( ( (( ( ( ( ( ( ( ( ( ( ( ( ~ (~ ( r ( ( ( ( ( ( w r « ( ( ( ( ( ( ( ( ( ( ( ( ( « r ( ( r r ( ( .. ( ( ( a ( f c ( ( ( ( f c ( ( «
P
i N
R~a~ R~s wherein P is hydrogen, methyl, COOR'6 wherein R's is (C~-Cs)alkyl, allyl, 2,2,2-trichloroethyl or (C~-C6)alkyl; -C(=O)NR$R6 wherein RS and R6 are defined as in formula I
above; -C(=O)H, -C(=O)(C,-C6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl or t-butoxycarbonyl (t-Boc); and R'4 and R'S are selected, independently, from hydrogen, (C,-C6)alkyl optionally substituted with from one to seven fluorine atoms; -C(=O)(C~-C6)alkyl, cyano, hydroxy, vitro, amino, -O(C,-C6)alkyl or halo; with the proviso that R'4 and R'S can not both be hydrogen when P is hydrogen, (C~-C6)alkyl, or unconjugated (C3-C6)alkenyl. Such compounds are useful as intermediates in the synthesis of compounds of the formula I.
The invention also relates to a compound of the formula y SNP( Eli) R3 _ wherein RZ and R3 are defined above; and P( is COOR's wherein R'6 is allyl, 2,2,2-trichloroethyl or (C,-C6)alkyl; -C(=O)NR$Rs wherein RS and R6 are defined as in claim 2; -C(=O)H, -C(=O){C,-Cs)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl, or t-butoxycarbonyl (t-Boc).
Unless otherwise indicated, the term "halo", as used herein, includes fluoro, chloro, bromo and iodo.
Unless otherwise indicated, the term "alkyl", as used herein, includes straight, branched or cyclic, and may include straight and cyclic alkyl moieties as well as branched and cyclic moieties.
The term "alkoxy", as used herein, means "alkyl-O= , wherein "alkyl" is defined as above.
The term "alkylene, as used herein, means an alkyl radical having two available bonding sites i.e., -alkyl-), wherein "alkyl" is defined as above.
SUBSTITUTE PAGE
'. r ' ' ' ' ' '' r '' c ''-7A= ' ' ' ~ '' ' a'' ' ' "' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ', ' ' ' ' a ' ' ' ' ' ' a ' ' a - ' ' "" " '' "< " ~' Unless otherwise indicated, the term "one or more substituents", as used herein, refers to from one to the maximum number of substituents possible based on the number of available bonding sites.
The term "treatment', as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such condition or disorder. The term °treatment", as used herein, refers to the act of treating, as "treating° is defined immediately above.
The compounds of formula I may have optical centers and therefore may occur in different enantiomeric configurations. The invention includes all enantiomers, diastereomers, and SUBSTITUTE PAGE
~~~ s ( f f ( ( f f ( ! ( l f ( 1 ( t « - ~ f (( ( ( ! ( 1 f ! ( 1 -( t < ( f ( f 1 1 ( ( ( ( ( f ( ( ! f f ( I
( f f t ( ( ( f ( l ( t t f ( I (' f ( ( f l f 1 ( ( ( l f other stereoisomers of such compounds of formula I, as well as racemic and other mixtures thereof.
The present invention also relates to all radiolabeled forms of the compounds of the formula I. Preferred radiolabeled compounds of formula I are those wherein the radiolabels are selected from as 3H, "C, '4C, 'BF, '231 and '~I. Such radiolabeled compounds are useful as research and diagnostic tools in metabolism pharmacokinetics studies and in binding assays in both animals and man.
The present invention also relates to a pharmaceutical composition for use in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use and a pharmaceutically acceptable carrier.
The present invention also relates to a method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.
The present invention also relates to a method of treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac spree, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac anythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.~C .,, dependencies on, or addictions to nicotine (andlor tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
SUBSTITUTE PAGE
The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourett's Syndrome in a mammal, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, which comprises (a) an amount of a compound of the formula:
NH
or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use, and (b) a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, which comprises (a) an amount of a compound of the formula:
\
NH
or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and (b) a pharmaceutically acceptable carrier.
This invention also relates to the pharmaceutically acceptable acid addition salts of the compounds of formula I.
- l0a -Examples of pharmaceutically acceptable acid addition salts of the compounds of formula I are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, malate, di-p-toluoyl tartaric acid, and mandelic acid.
As well-known in the art, the pharmaceutical composition mentioned above, may be put in a commercial package. This invention also relates to such a commercial package. The commercial package usually carries a written matter which states that the pharmaceutical composition is to be used for the purpose described in this specification.
Detailed Description of the Invention Except where otherwise stated, R1 through R18, m and P, and structural formula I in the reaction schemes and discussion that follow are defined as above.
Scheme 1 I / ~NH . HCI III
O
I N~CF3 IV
OzN O
I N
O
N
I / ~N CF3 IIB
HZN
Scheme 2 O
\ ~ IIA
N-tBoc VIA
N-tBoc VIB
Scheme 2 continued VIB
H
N
R'~ \ \N-tBoc VII
N
R"
N
R~~~\ I \N-tBoc VII' N
H
N
v R \ / NH IA
N
R"
I
N
R' ~--C\ I \N H
N ~ IB
Scheme 3 ~N-tBoc VIA
R"H N \
~N-tBoc XXIII
R"HN
N-tBoc XXIV
R"
l N \
R'°--C~ \N-tBoc XXV
N
R"
I
N \
v R~°~~ I / NH IB
N ~--' Scheme 4 ~N-tBoc VIB
R N /
~NH IC
R17 wN \
Scheme 5 II
I \N~-CFs XXII
OZN
HO / II
~N--~-CF3 VIII
OZN
O
\NH IE
N U ~--' Scheme 6 Pc~rnB9siolsi3 NH III
O
N-C-CF
O
R~° N O
N--~-CF X
H S
R'° N
-R~° XI
~N
S \
Scheme 6 continued H
R~° N S
N~-R'° XI
S
S
R ~ \ NH IF
N ~ ~-'' Scheme 7 X~
\ \
A I / XZ A I /
{ring A = present or (ring A = present or absent) absent) XI II
XII
OH
A
OH
{ring A = present or absent) XIIIA
\
A N
(ring A = present or absent) XIV
A I NH
IG: (R2 and R3 form ring A) III: (ring A = absent) Scheme 8 R~8 R,s ' R'8 \ .\ I
--' ~ --_ F ~ F
XV XVI XVII
(R~8 = F or (C~-Cs)alkoxy) R'8 Rya OH
N
\ ~C H "
"- 6 5 OH
XIX
XVIII
R'8 R' 8 O
i I \NH \ N CF3 XX
IH
XXI
Scheme 9 NH
R'R8N02S
IJ
O~CF3 N
CI /
~N H
CI
IK
lV
R~3 \ NH
I
O
IL
_22_ Scheme 10 ~NH
\
CI
IM
~NH
OyCF3 NC \
IN
IN
NH2 / , ~NH
IX' H2N
IP
OII / I ~NH
R,s~N \
IQ
c , r , , ~ r , t a c < , r r , , , , , , ~ < < , , , , , r , . - 23 - ,- , a a , , , < , ' , , , a a a , a ~ , , , ".a ~,' a,' ", Scheme 1-10 illustrate methods of synthesizing compounds of the formula 1 .
Referring to Scheme 1, the starting material of formula III is reacted with trifluoroacetic anhydride, in the presence of pyridine, to form the compound of formula IV.
This reaction is typically conducted in methylene chloride at a temperature from about 0°C to about room temperature.
The compound of formula IV is then converted into the dinitro derivative of formula IIA
by the following process. The compound of the formula IV is added to a mixture of 4 or more equivalents of trifluoromethanesulfonic acid (CF3SOZOH) and 2 to 3 equivalents of nitric acid, in a chlorinated hydrocarbon solvent such as chloroform, dichloroethane (DCE) or methylene chloride. The resulting mixture is allowed to react for about 5 to 24 hours.
Both of the foregoing reactions are generally conducted at a temperature ranging from about -78°C to about 0°C for about 2 hours, and then allowed to warm to room temperature for the remaining time.
Reduction of the compound of formula IIA, using methods well known to those of skill in the art, yields the compound of formula I1B. This reduction can be accomplished, for example, using hydrogen and a palladium catalyst such as palladium hydroxide and running the reaction in methanol at about room temperature.
Referring to Scheme 2, the compound of formula IlA is converted into the corresponding compound wherein the trifluoroacetyl protecting group is replaced by a t-Boc protecting group (VIA) by reacting it first with an alkali metal or alkaline earth metal (or ammonium) hydroxide or carbonate, and then reacting the isolated product from the foregoing reaction with di-t-butyldicarbonate. The reaction with the alkali or alkaline earth metal (or ammonium) hydroxide or carbonate is generally carried out in an aqueous alcohol, dioxane or tetrahydrofuran (THF) at a temperature from about room temperature to about 70°C, preferably at about 70°C, for about one to about 24 hours. The reaction of the isolated, unprotected amine or an acid addition salt of such amine, from the above reaction with di-t-butyldicarbonate is preferably carried out in a solvent such as THF, dioxane or methylene chloride at a temperature from about 0°C to about room temperature. This reaction may or may not be conducted in the presence of a base. When the reactant is a salt of the amine, use of a base is preferred. The resulting compound of formula VIA can be converted into the corresponding diamino derivative of formula VIB
using the procedure described above for converting the dinitro compound of formula 11A
into the corresponding diamino compound of formula IIB.
The conversion of the compound of formula VIB into the desired compound of the formula VII can be accomplished by reacting the compound of formula VIB with a compound of the formula SUBSTITUTE PAGE
~,~:-CEO s c r r t , a r c r , r a c a r - ~r~ r r , c c r r r c r r , , r r r , r r r c « r « r r r r- r r r r < r r c c r r c , c r r r « r r r c c r r HsCzOa CZHs XXI IA
i zHs wherein R'° is hydrogen, (C~-C6)alkyl optionally substituted with from one to seven fluorine atoms, aryl-(C°-C3)alkyl wherein said aryl is selected from phenyl and naphthyl, or heteroaryl-(C°
-C3)alkyl wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C~ -C6)alkyl optionally substituted with from one to seven fluorine atoms, (C, -C6)alkoxy optionally substituted with from one to seven fluorine atoms and cyano. The preferred solvent for this reaction is a 10:1 mixture of ethanol:acetic acid. The reaction temperature can range from about 40°C to about 100°C. It is preferably about 60°C. Other appropriate solvents include acetic acid, ethanol and isopropanol.
Alternate methods of preparing compounds of the formula VII the compound of formula VIB are described by Segelstein et al., Tetrahedron Lett., 1993, 34, 1897.
Removal of the t-Boc protecting group from the compound of formula VII yields corresponding compound of formula IA. The protecting group can be removed using methods well known to those of skill in the art. For example, the compound of formula VII can be treated with an anhydrous acid such as hydrochloric acid, hydrobromic acid, methanesulfonic acid, or trifluoroacetic acid, preferably hydrochloric acid in ethyl acetate, at a temperature from about 0°C to about 100°C, preferably from about room temperature to about 70°C, for about one to 24 hours.
The compound of formula VII can be converted into the corresponding compound of formula IB by reacting it with a compound of the formula R"Z, wherein R" is defined as R'° is defined above, and Z is a leaving group such as a halo or sulfonate (e.~Lc ., chloro, bromo, mesylate or tosylate), in the presence of a base such as an alkali metal hydride, hydroxide or carbonate, preferably potassium hydroxide, in a polar solvent such as water, dimethylsulfoxide (DMSO), THF or DMF, preferably a mixture of DMSO and water, and then removing the protecting group as described above. The reaction with R"Z is generally carried out at a temperature from about room temperature to about 100°C, preferably at about 50°C, for about five hours.
SUBSTITUTE PAGE
~,~oEv t. t t t ( 4 ( S < f t 1 f f t t t f ( 4 1 ( ( t ( ~~ t t t f 1 ~7 1 ( t 4 f 1 t < <
f 1 ( ( t l ( f t t t ( t f ( 1 1 4 f t ( ( f 1 f ( ( < ( ( t t ( C f t f ( f C
Scheme 3 illustrates an alternate method of preparing compounds of the formula IB
from the compound of formula VIA. This method is the preferred method of making compounds of the formula IB wherein R" is a bulky group such as an aryl or heteroaryl containing group, or when R" can not be attached, as illustrated in Scheme 2, by alkylation or aryl substitution methods. Referring to Scheme 3, the compound of formula VIA
is reacted with the appropriate compound of formula R"NHZ in a polar solvent such as THF, DMF or DMSO, preferably THF, at a temperature from about room temperature to about 100°C, preferably at the reflux temperature, for about four to eighteen hours. The resulting compound of formula XXIII is then converted into the corresponding compound of the formula XXIV by reducing the vitro group to an amino group using methods well known to those of skill in the art. Such methods are referred to above for the conversion of the compounds of the formula IIA into a compound of the formula IIB in Scheme 1, and exemplified in experimental Examples 12B and 18B. Closure of the imidazole ring to form the corresponding compound of formula XXV can then be accomplished by reacting the compound of formula XXIV from the above reaction with a compound of the formula XXI IA
R'° OC2H5 wherein R'° is defined as above, as described above for converting compounds of the formula VIB into those of the formula VII.
Removal of the protecting group from the compound of formula XXV yields the corresponding compound of formula IB. This can be accomplished using methods well known in the art, for example, as described above for forming compounds of the formula IA
from the corresponding compounds of the formula VII.
Scheme 4 illustrates a method of preparing compounds of the formula IC, wherein R'° and R" are as defined above. Referring to Scheme 4, the compound of formula VIB is reacted with a compound of the formula OH
S03Na Na03S
OH
SUBSTITUTE PAGE
~~~ S~~
(sodium bisulfate ethane dione addition adduct) in water or another polar solvent such as THF, DMF or DMSO, preferably a mixture of water and a water miscible solvent such as THF, for about one to four hours. The reaction temperature can range from about 40°C to about 100°C, and is preferably at about the reflux temperature.
Alternatively, the compound of formula VIB can be reacted with a compound of the formula O
R"
Rio O
(double condensation reaction) in a polar solvent such as THF, water, or acetic acid, preferably a mixture of water and THF. This reaction is typically carried out at a temperature from about 40°C to about 100°C, preferably at the reflux temperature, for about two to four hours.
The desired quinoxoline of formula IC can then be formed by deprotecting the compound formed in either of the foregoing reactions, using the method described above for converting a compound of the formula VII into one of the formula IA.
Scheme 5 illustrates a method of preparing compounds of the formula 1 wherein R2 and R3, together with the benzo ring to which they are attached, form a benzoxazole ring system.
Such a compound, wherein R' is hydrogen, is depicted in Scheme 5 as chemical formula IE.
Referring to Scheme 5, the compound of formula XXII, wherein Y is vitro, halo, trifluoromethanesulfonate or a diazonium salt, is reacted with potassium acetate or another alkali or alkaline earth metal carboxylate in a solvent such as dimethylsulfoxide (DMSO), DMF or acetonitrile, preferably DMSO. This reaction is generally allowed to run for about 12-24 hours.
Appropriate reaction temperatures range from about 70°C to about 140°C. Approximately 100°C
is preferred.
The above reaction yields the compound of formula VIII, which can then be converted into the desired compound having formula IE by the following procedure. First, the compound of formula VIII is reduced by reaction with hydrogen and a palladium or platinum catalyst such as palladium hydroxide in methanol at a temperature from about 0°C to about 70°C, preferably at about room temperature, to form the corresponding amino derivative. The product of this reaction is then reacted with an acid chloride of the formula R'°COCI
or an acid anhydride of the formula (R'°CO)ZO wherein R'° is (C~-C6)alkyl, or a compound of the formula R'°C(OCZHS)3, in an appropriate inert solvent such as decalin, chlorobenzene or xylenes. A
mixture of xylenes is ' « ~' L< <
., , « ' r ~, r , ' ,', _27=,~ , : ~ , a , ' , < < < < < ' < ~ ' a ' < < < a ~ , a a , < «~a « « W «
preferred. This reaction is typically conducted at a temperature from about 120-150°C, preferably at about 140°C. When R'°COCI is used as a reactant, it is preferable to add a stoichiometric amount of triethylamine (TEA) or another organic tertiary amine base and a catalytic amount of pyridinium p-toluenesulfonic acid or pyridinium p-toluenesulfonate (PPTs) to the reaction mixture. When R'°C(OCzH~)3 is used as a reactant, it is preferable to add a catalytic amount of PPTs to the reaction mixture.
Removal of the trifluoroacetyl nitrogen protecting group yields the desired compound of the formula IE. This can be accomplished using methods well known to those of skill in the art, for example, reacting the protected compound with a lower alkanol and an aqueous alkali or alkaline earth metal (or ammonium) hydroxide or carbonate, aqueous sodium carbonate, at a temperature from about 50°C to about 100°C, preferably at about 70 ° C, for about two to six hours.
Scheme 6 illustrates the preparation of compounds of the formula I wherein R' is hydrogen and RZ and R3, together with the benzo ring to which they are attached, form a benzothiazole ring system. Referring to Scheme 6, the compound of formula 111 is reacted with trifluoroacetic anhydride to form the con-esponding compound wherein the ring nitrogen is protected by a trifluoroacetyl group, and the resulting nitrogen protected compound is then reacted with two equivalents of trifluoromethanesulfonic anhydride and one equivalent of nitric acid to form the corresponding compound of formula IX, wherein there is a single vitro substituent on the benzo ring. The reaction with trifluoroacetic acid is typically conducted in the presence of pyridine. Both of the above reactions are typically conducted in a reaction inert solvent such as a chlorinated hydrocarbon solvent, preferably methylene chloride, at a temperature from about 0°C to about room temperature, preferably at about room temperature.
The above transformation can also be accomplished usihg other nitration methods known to those skill in the art.
Reduction of the vitro group to an amine group can be accomplished as described above to provide a compound of the formula IX'.
The compound of formula IX' is then reacted with a carboxylic acid halide or anhydride of the formula R'°COX or (R'°CO)20, wherein X is halo and R'° is hydrogen or (C,-C6)alkyl, and pyridine, TEA or another tertiary amine base, to form a compound of the formula X, which can then be converted to the desired compound having formula XI by reacting it with Lawesson's reagent, which is depicted below.
SUBSTITUTE PAGE
A~~~~ ~CIE~
H3C~0 \ . P~S~P S
S ~ ~S~
\ I ~CH3 O
The reaction with R'°COX, wherein X is halo, or (R'°CO)20 is generally carried out at a temperature from about 0°C to about room temperature, preferably at about room temperature. The reaction with t_awesson's reagent is generally carried out in a reaction inert solvent such as benzene or toluene, preferably toluene, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature.
Closure to the benzothiazole ring and nitrogen deprotection to form the desired compound of formula IF can be accomplished by reacting the compound of formula XI with potassium ferricyanide and sodium hydroxide in a mixture of water and methanol (NaOH/H20/CH30H), at a temperature from about 50°C to about 70°C, preferably at about 60°C for about 1.5 hours.
Scheme 7 illustrates a method of preparing the compound of formula III, which is used as the starting material for the process of Scheme 1, or a compound of the formula IG, wherein R2 and R3 form a ring (labeled "A" in the Scheme), as defined above in the definition of compounds of the formula I. Referring to Scheme 7, the compound of formula XII, wherein X' and Xz are selected, independently, from chloro, fluoro, bromo and iodo, but where at least one of X' and XZ is Br- or I-, reacted with cyclopentadiene, in the presence of magnesium metal, in a THF, dioxane or other ethereal solvent, at a temperature from about 40°C to about 100°C, preferably at about the reflux temperature, to form a compound of the formula XIII.
Reaction of the resulting compound of formula XIII with N-methylmorpholine-N-oxide (NMO) and osmium tetroxide in acetone at about room temperature yields the corresponding compound of the formula XIIIA.
The compound having formula XIIIA is then converted into the corresponding compound of formula XIV using the following procedure. First, the compound of formula XIIIA
is reacted with sodium periodate in a mixture of a chlorinated hydrocarbon, preferably dichloroethane (DCE), and water, or with lead tetraacetate in a chlorinated hydrocarbon solvent, at a temperature from about 0°C to about room temperature, to generate a dialdehyde or glycal intermediate. The product of this reaction is then reacted with benzylamine and sodium triacetoxyborohydride in a chlorinated hydrocarbon solvent at a temperature from about 0°C to about room temperature, preferably at about room temperature, to form the desired compound of formula XIV. Removal of the benzyl group from the compound of formula XIV yields the compound of formula III (when ring A is absent) or IG, (when ring A is present). This can be accomplished using methods well known to those of skill in the art, for example, optionally reacting the free base with one equivalent of acid, e.~c ., hydrochloric acid, (to form the corresponding acid addition salt), followed by hydrogen and palladium hydroxide in methanol at about room temperature.
In the reductive animation step described above and throughout this document, alternatives to benzyl amine, such as ammonia, hydroxylamine, alkoxy amines, methyl amine, allyl amine, and substituted benzyl amines (e.~c ., diphenylmethyl amine and 2-and 4-alkoxy substituted benzyl amines) can also be used. They can be used as free bases, or as their salts, preferably their acetate salts, and can be subsequently removed by methods described for each by T. W. Greene and G.M. Wuts, "Protective Groups in Organic Synthesis", 1991, John Wiley & Sons, New York, NY.
The procedure of Scheme 7 can also be used to prepare compounds of the formula I
wherein R2 and R3 do not form a ring and are not both hydrogen, by replacing the starting material of formula XII with the appropriate compound having the formula R2 X' XII
Scheme 8, 9 and 10 illustrate methods of preparing compounds of the formula I
wherein R' is hydrogen, and Rz and R3 represent a variety of different substituents, as defined above, but do not form a ring.
Scheme 8 illustrates a variation of the process shown in Scheme 7, which can be used to make a compound identical to that of formula III except that the benzo ring is substituted with a fluoro group or an alkoxy group (R'$ in Scheme 8). This compound is depicted in Scheme 8 as chemical structure 1 H. Referring to Scheme 8, where, for example, R'8 is F, 1,3-difluorobenzene is reacted with a strong base such as an alkali metal dialkylamine or an alkali metal alkyl (or aryl) in an ethereal solvent such as ethyl ether or THF, at a temperature below -50°C, followed by quenching with iodine or N-iodosuccinamide, to form 1,3-difluoro-2-iodobenzene. The compound 1,3-difluoro-2-iodobenzene (structural formula XVI
in Scheme 8) is then converted into the compound of formula IH by a series of reactions (represented in Scheme 8 as XVI~XVII->XVIII~XIX-->IH) that are analogous to the series of reactions described above and illustrated in Scheme 7 for converting compounds of the formula XIII into those of the formula IG or II1. Conversion of the compound of formula XVl into the compound of formula XVII can also be accomplished by treating a mixture of the compound of formula XVI
and cyclopentadiene with an alkyl lithium reagent, preferably n-butyl lithium, in an inert hydrocarbon solvent such as petroleum ether or methyl cyclohexane, at a temperature from about -20°C to about room temperature, preferably at about 0°C.
The compound of formula IH can then be converted into the corresponding nitrogen protected derivative of formula XX, using the methods described above for synthesizing the compound of formula IV in Scheme .1. Nitration of the compound of formula XX
using the method described above for preparing the compound of formula IX in Scheme 6, yields the compound of formula XXI wherein the benzo ring is substituted with both a fluoro and nitro group or an alkoxy group and nitro group. The compound of formula XXI can be used to make a variety of compounds of the formula I wherein one of RZ and R3 is fluoro, using methods that are well known to those of skill in the art, for example, by ftrst converting the vitro group to an amino group, converting the amino group to a variety of other substituents, as illustrated in Scheme 10, and then removing the nitrogen protecting group.
The compound of formula XXI acts as a regioisomeric functional equivalent of the compounds having formulas IIA, VIA and XXII, in that the fluorine atom of formula XXI reacts similarly to the vitro and Y groups of formula IIA, VIA, and XXI1, and thus can be subjected to the same series of reactions as those described above for the latter three compounds, providing an alternate means for preparing the products of such reactions. Similarly, the alkoxy group of formula XXI (R'e=alkoxy) may be converted into a hydroxyl group before or after introduction of the vitro group, and then converted to isomeric products as described above.
Also, the trifluoromethanesulfonate salt of such hydroxy derivative can act as a Y-group as described.
Preparation of compounds of formula I where RZ = -O(C~-Cs)alkyl, (C~-Cs) alkyl or aryl wherein aryl is defined as above in the definition of formula I, and R3 is H
or one of the other substituents described above in the definition of formula I, can be prepared as described above and illustrated in Scheme 8 by replacing one of the fluorine atoms of the compound of formula XV with -O-(C~-Cs)alkyl, (C,-Cs)alkyl or aryl, respectively.
Scheme 9 illustrates methods of preparing compounds of the formula I wherein:
(a) R' is hydrogen and RZ is R'R8N02S-; (b) R' and RZ are both chloro; and {c) R' is hydrogen and RZ
is R'3C(=O)-. These compounds are referred to in Scheme 9, respectively, as compounds of formulas IJ, IK and IL.
: ~: : ~, _31'- < <
": ~ . , < < , , ' ~ : : : ' , ' ~ a <
< < ~ , ~ : a < < , ~~ "' ~' Referring to Scheme 9, compounds of the formula IJ can be prepared by reacting the compound of formula 1V with two or more equivalents of a halosulfonic acid, preferably chlorosulfonic acid, at a temperature from about 0°C to about room temperature. Reaction of the chlorosulfonic acid derivative so formed with an amine having the formula R'R$NH, wherein R' and RB are defined as above, followed by removal of the nitrogen protecting group, yields the desired compound having formula IJ.
Compounds of the formula IK can be prepared by reacting the compound of formula IV with iodine trichloride in a chlorinated hydrocarbon solvent, followed by removal of the nitrogen protecting group. The reaction with iodine trichloride is typically carried out at a temperature from about 0°C to about room temperature, and is preferably carried out at about room temperature. In a similar fashion, the analogous mono- or dibrominated or mono- or diiododinated compounds can be prepared by reacting the compound of IV with N-iodosuccinimide or N-bromosuccinimide in a trifluoromethanesulfonic acid solvent, followed by removal of the nitrogen protecting group as described above.
Reaction of the compound of IV with an acid halide of the formula R'3COCI or an acid anhydride of the formula (R'3C0)20, with or without a reaction inert solvent such as a chlorinated hydrocarbon solvent, preferably methylene chloride, in the presence of Lewis acid such as aluminum chloride, at a temperature from about 0°C to about 100°C, followed by nitrogen deprotection, yields the compound of formula IL. The reaction with the acid halide or anhydride can be carried out using other known Lewis acids or other Friedel-Crafts acylation methods that are known in the art.
The reactions described herein in which NOz, -SOzNR'R8, -COR'3, I, Br or CI
are introduced on the compound of formula IV, as depicted in Scheme 9 and described above, can be performed on any analogous compound wherein RZ is hydrogen, (C,-Cs)alkyl, halo, (C,-Cs)alkoxy or -NHCONR'RB, producing compounds of the formula 1 wherein R2 and R3 are defined as in the definition of compounds of the formula I above.
Compounds that are identical to those of the formula IL, but which retain the nitrogen protecting group, can be converted into the corresponding O-acyl substituted compounds, i.e., those wherein the -C(=O)R'3 group of formula IL is replaced with a -O-C(=O)R'3 group, using Baeyer-Villiger processes well known to those skilled in the art. The resulting compounds can be partially hydrolyzed, as described in Example 35, to yield the corresponding hydroxy substituted compounds, and then alkylated to form the corresponding alkoxy substituted compounds. Also, as described in Example 36, such O-acyl substituted compounds can be used to prepare variably substituted benzisoxazoles.
SUBSTITUTE PAGE
l~~t~ SHEET
Scheme 10 illustrates methods of making compounds of the formula I wherein:
(a) R' is hydrogen and RZ is chioro; (b) R' is hydrogen and RZ is cyano; (c) R' is hydrogen and RZ is amino; and (d) R' is hydrogen and Rz is R'3C(=O)N(H)-. These compounds are referred to in Scheme 10, respectively, as compounds of the formula IM, IN, IP and IQ.
Compounds of formula IM can be prepared from compounds of the formula IX' by generation of a diazonium salt with, for instance, an alkali metal nitrite and strong mineral acid (e.~c ., hydrochloric acid, sulfuric acid, hydrobromic acid) in water, followed by reaction with a copper halide salt, such as copper (I) chloride. Nitrogen deprotection by the methods described above yields the desired compound of formula IM. Alternative methods for the generation of diazonium salts, as known and practiced by those of skill in the art, can also be used. The foregoing reaction is generally carried out by temperatures ranging from about 0°C
to about 60°C, preferably about 60°C for about 15 minutes to one hour.
Reaction of the diazodium salt, prepared as described above, with potassium iodide in an aqueous medium provides the analogous iodide derivative. This reaction is generally carried out at a temperature from about 0°C to about room temperature, preferably at about room temperature. The resulting compound, or its analogous N-tert-butylcarbonate protected form, can be used to prepare the corresponding cyano derivative by reaction with copper (I}
cyanide and sodium cyanide in DMF, N,N-dimethylpropylurea (DMPU) or DMSO, preferably DMF, at a temperature from about 50°C to about 180°C, preferably about 150°C. Nitrogen deprotection as described above provides the desired compound of formula IM.
The above described iodide derivative can also be used to access a variety of other substituents such as aryl, acetylene and vinyl substituents, as well as the corresponding carbonyl esters and amides, by palladium and nickel catalyzed processes known to those of skill in the art, such as Heck, Suzuki and Stille couplings and Heck carbonylations.
Nitrogen deprotection of the compound of formula IX' provides the compound of the formula IP.
The compound of formula IX' can be reacted with a acyl group having the formula R"COCI or (R'3C0)ZO using the methods described above, followed by nitrogen deprotection to provide compounds of the formula IQ. In a similar fashion, treatment of the protected amine with a compound having the formula R'3SOzX, when X is chloro or bromo, followed by nitrogen deprotection, provides the corresponding sulfonamide derivative.
Other suitable amine protecting groups that can be used, alternatively, in the procedures described throughout this document include -COCF3, -COCCI3, -COOCH2CCI3, -COO(C,-Cs)alkyl and -COOCHzCsHS. These groups are stable under the conditions described herein, and may be removed by methods described for each in Greene's "Protective Groups in Organic Chemistry", referred to above.
In each of the reactions discussed above, or illustrated in Schemes 1-10, above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, with ambient pressure, i.e., about 1 atmosphere, being preferred as a matter of convenience.
The compounds of the formula I and their pharmaceutically acceptable salts (hereafter "the active compounds") can be administered via either the oral, transdermal (e.~c ., through the use of a patch), intranasal, sublingual, rectal, parenteral or topical routes.
Transdermal and oral administration are preferred. These compounds are, most desirably, administered in dosages ranging from about 0.25 mg up to about 1500 mg per day, preferably from about 0.25 to about 300 mg per day in single or divided doses, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 0.01 mg to about 10 mg per kg of body weight per day is most desirably employed. Variations may nevertheless occur depending upon the weight and condition of the persons being treated and their individual responses to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval during which such administration is carried out.
In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.
The active compounds can be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the several routes previously indicated. More particularly, the active compounds can be administered in a wide variety of different dosage forms, e.~c ., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, transdermal patches, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents. In addition, oral pharmaceutical compositions can be suitably sweetened andlor flavored. In general, the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc can be used for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar] as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration the active ingredient may be combined with various sweetening or flavoring agents, coloring matter and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
For parenteral administration, a solution of an active compound in either sesame or peanut oil or in aqueous propylene glycol can be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8), if necessary, and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
It is also possible to administer the active compounds topically and this can be done by way of creams, a patch, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.
Biological Assay The effectiveness of the active compounds in suppressing nicotine binding to specific receptor sites is determined by the following procedure which is a modification of the methods of Lippiello, P. M. and Fernandes, K. G. (in The Binding of L-['H]Nicotine To A
Single Class of High-Affinity Sites in Rat Brain Membranes, Molecular Pharm., _29, 448-54, (1986)) and Anderson, D. J. and Arneric, S. P. (in Nicotinic Receptor Bindin of 'H-Cystisine_, 3H-Nicotine and 3H-Methylcarmbamylcholine In Rat Brain, European J. Pharm., 253, 261-67 (1994)).
Procedure Male Sprague-Dawley* rats (200-300 g) from Charles River were housed in groups in hanging stainless steel wire cages and were maintained on a 12 hour lightldark cycle (7 a.m.-7 p.m. light period). They received standard Purina Rat Chow and water ad libitum.
The rats were killed by decapitation. Brains were removed immediately following decapitation. Membranes were prepared from brain tissue according to the methods of Lippiello and Femandez (Moles Pharmacol, 29, 448-454, (1986) with some modifications.
Whole brains were removed, rinsed with ice-cold buffer, and homogenized at 0° in 10 volumes of buffer (w/v) using a Brinkmann PolytronT'", setting 6, for 30 seconds. The buffer consisted of 50 mM Tris HCI at a pH of 7.5 at room temperature. The homogenate was sedimented by centrifugation ( 10 minutes; 50,000 x g; 0 to 4°C. The supernatant was poured off and the membranes were gently resuspended with the Polytron and centrifuged again (10 minutes; 50,000 x g; 0 to 4°C. After the second centrifugation, the membranes were resuspended in assay buffer at a concentraYron of l.Og1100mL. The composition of the standard assay buffer was 50 mM Tris HCI, 120 mM
NaCI, 5 mM KCI, 2 mM MgCl2, 2 mM CaCl2 and has a pH of 7.4 at room temperature.
Routine assays were performed in borosilicate glass test tubes. The assay mixture typically consisted of 0.9 mg of membrane protein in a final incubation volume of 1.0 mL. Three sets of tubes were prepared wherein the tubes in each set contained 50~L of vehicle, blank, or test compound solution, respectively. To each tube was added 200 pL of ['HJ-nicotine in assay buffer followed by 750 ~L of the membrane suspension. The final concentration of nicotine in each tube was 0.9 nM. The final concentration of cytisine in the blank was 1 pM. The vehicle consisted of deionized water containing 30 pL of 1 N acetic acid per 50 mL of water. The test compounds and cytisine were dissolved in vehicle. Assays were initiated by vortexing after addition of the membrane suspension to the tube. The samples were incubated at 0 to 4° C in an iced shaking water bath. Incubations were terminated by rapid filtration under vacuum through Whatman GFIBT''" glass fiber filters using a Brandeln'" mule-manifold tissue harvester. Following the initial filtration of the assay mixture, filters were washed two times with ice-cold assay buffer (5 m each). The filters were then placed in counting vials and mixed vigorously with 20 ml of Ready Safe''" (Beckman) before quantification of radioactivity. Samples were counted in a LKB
Wallach RackbetaT''" liquid scintillation counter at 40-50% efficiency. All determinations were in triplicate.
*Trade-mark Calculations Specific binding (C) to the membrane is the difference between total binding in the samples containing vehicle only and membrane (A) and non-specific binding in the samples containing the membrane and cytisine (B), i.e., Specific binding = (C) _ (A) - (B).
Specific binding in the presence of the test compound (E) is the difference between the total binding in the presence of the test compound (D) and non-specific binding (B), i.e. , (E) _ (D) - (B).
Inhibiflon = (1-((E)/(C)) times 100.
The compounds of the invention that were tested in the above assay exhibited ICS
values of less than 10 pM.
The following experimental examples illustrate, but do not limit the scope of, this invention.
10-AZA-TRICYCLO[6.3.1.02'']DODECA-2(7),3,5-TRIENE
A) 1,4-Dihydro-9 ,4-methano-naphthalene (Based wholly or in part on a) Wittig, G.; Knauss, E. Chem. Ber. 1958, 99, 895. b) Muir, D. J.; Stothers, J. B. Can. J. Chem. 1993, 71, 1290.) Magnesium turnings (36.5 g, 1.5 M) were stirred in anhydrous THF (250 mL) in a dried 2 L 3 neck round bottom flask equipped with a 250 mL non-equalizing addition funnel with a nitrogen (NZ) flow adapter, mechanical stirrer and efficient condenser equipped with a N2 flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle.
2-Fluorobromobenzene (2g) was added followed by 1 mL of 3N ethylmagnesium bromide (EtMgBr in THF). The addition funnel was charged with a mixture of cyclopentadiene (94.4 g, 1.43 M, Prepared by the method described in: Org. Syn. Col. Vol. V, 414-418) and bromofluorobenzene (250 g, 1.43 M) which was maintained at 0 °C in a separate flask by an ice bath, and transferred to the addition funnel via cannula. Small portions (~1 mL) of the intimate mixture were introduced to assist initiation (~4x). After ~15 minutes, the reaction initiated (exotherm, and vapor condensation), the heating mantle was removed and the contents of the addition funnel was added dropwise at such rate as to maintain reflux (1.5 hours). The heating mantle was re-applied and a reflux maintained for 1.5 hours. (TLC 100%
hexanes R, 0.67).
The reaction was cooled to room temperature and quenched with HZO (500 mL) and carefully with 1 N HCI (200 mL, produces HZ evolution from unconsumed Mg). To this ~50 mL
concentrated HCI was added to dissolve solids. Total additionlquench time --1 hour.
Saturated aqueous sodium chloride (NaCI) solution (300mL) was added and product hexanes extracted until no potassium permanganate (KMn04) active product is removed.
(4 x 250 mL). The combined organic layer was washed with saturated NaHC03 solution (250 mL), sodium bicarbonate Na2S04 dried and concentrated to an oil 0200 g). The product was distilled at 78-83 °C cLD15mm (131 g, 64%). (An alternative workup is described on p.419 Fieser and Fieser, Vol. I, Reagents for Organic Synthesis, ~ley, NY., NY.;
1967).
B) 1,2,3,4-Tetrahydro-1,4-methano-naphthalene-2,3-diol (Except for the workup method and the quantity of Os04 used, based on VanRheenen, V.; Cha, D.Y.; Hartley, W. M. Org. Syn. 1988, 6, 342.) In a 2 L 3 neck round bottom flask equipped with a Nz flow adapter, mechanical stirrer was placed 1,4-dihydro-1,4-methano-naphthalene (79.5 g, 560 mmol) stirred in acetone (800 mL) and H20 (100 mL) and N-methyl morpholine N-oxide (67.5 g, 576 mmol). To this was added osmium tetroxide (Os04) (15 mL of a 15mo1% t-BuOH solution, 1.48 mmol, 0.26mo1%) and the mixture was stirred vigorously. After 60 hours, the reaction was filtered, and the white product rinsed with acetone and air dried (60.9 g}. The mother liquor was concentrated to an oily solid: acetone trituration, filtration and acetone rinse provided (27.4 g, total 88.3 g, 89%).
(TLC 50% EtOAGhexanes R, ~0.5). mp 176-177.5 °C.
C) 10-Benz~~l-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene (Based on Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.;
Shah, R.
D. J. Org. Chem. 1996, 69, 3849; and Mazzocchi, P. H.; Stahly, B. C. J. Med.
Chem. 1979, 22, 455.) 1,2,3;4-Tetrahydro-1,4-methano-naphthalene-2,3-diol (40 g, 227.3 mmol) was stirred in H20 (1050 mL) and 1,2-dichloroethane (DCE) (420 mL) in a 2 L round bottom flask under nitrogen with cool water bath (~10 °C). To this sodium periodate (Na104) (51 g, 239 mmol) and triethylbenzyl ammonium chloride (Et3BnNCl) (50 mg) were added. The resulting mixture was stirred for 1 hour (slight initial exotherm), then the layers were separated and the aqueous layer was extracted with DCE (200 mL). The organic layer was washed with H20 (4 x 200 mL, or until no reaction to starch iodide is observed in the aqueous wash} then dried through a cotton plug. To this was added benzyl amine (25.5 g, 238.6 mmol) and the mixture was stirred for 2 minutes then immediately transferred into the sodium triacetoxyborohydride NaHB(OAc)31DCE (see below) over 10 minutes.
In a separate 2 L round botton flask flask under nitrogen was magnetically stirred NaHB(OAc)3 (154 g, 0.727 mmol) in DCE (800 mL) at 0 °C (ice bath). To this was added the above mixture over 10 minutes, without delay after the dialdehyde and amine were mixed.
The resulting orange mixture was allowed to warm to room temperature and stirred for 30-60 minutes.
The reaction was quenched by addition of saturated sodium carbonate (NaZC03) solution (-300 mL) carefully at first and the mixture was stirred for 1 hour (pH 9). The layers were separated and the aqueous layer was extracted with CHzCl2 (2 x 300 mL).
The organic layer was washed with saturated aqueous NaCI solution (200 ml), dried through a cotton plug, then evaporated to a red oil. This was dissolved in a minimum of EtzO
and filtered through a Silica pad (3 x 4 inch) eluting with 15% ethyl acetate (EtOAc)/hexanes +1°~ of 37%
aqueous ammonium hydroxide (NH,OH) solution to remove baseline red color.
Concentration affords a light yellow oil (48.5 g, 194.8 mmol, 85.7%). (TLC 10°~6 EtOAGhexanes R~ 0.75). 'H
NMR (400 MHz, CDCI3) 8 7.16 (m, 7H), 6.89 (m, 2H), 3.48 (m, 2H), 3.08 (m, 2H), 2.80 (d, J=9.5 Hz, 2H), 2.42 (d, J=9.5 Hz, 2H), 2.27 (m, 1 H), 1.67 (d, J=10.0 Hz, 1 H). APCI MS m/e 250.3 [(M + 1 )'].
D) 10-Aza-tricyclo[6.3.1.0~--']dodeca-2(7),3,5-triene (For an alternative synthesis, see;
Mazzocchi, P. H.; Stahly, B. C. J. Med. Chem. 1979, 22, 455.) 10-Benzyl-10-aza-tricyclo(6.3.1.0~~')dodeca-2(7),3,5-triene (70.65 g, 2B4 mmol) was stirred in EtOAc (250 mL) and treated with 3N HCI EtOAc (1.03 eq.) slowly with cooling (ice bath). The resulting precipitate was filtered and rinsed with EtOAc. The solids were dissolved in MeOH (250 mL) in a parr bottle. To this was added Pd(OHy~ (7 g of 20°~wUC) and the mixture was shaken under 50-40 psi of H2 for 24 hours or until done by TLC.
The reaction was filtered through a Ceiite pad and concentrated to an oily solid. This was azeotroped with methanol (MeOH) (3x) then triturated with acetone, treated with ethyl ether (EtZO) to precipitate product and filtered. Concentration of the mother liquors and a second treatment provided an off white solid (48.95 g, 251 rnmol, 88°l°). (TLC
10% MeOH/CH~C12 (NH3) R, 0.2).
'H NMR (400 MHz, CDCI3) 5 7.18 (m, 4H), 2.97 (m, 4H), 2.68 (d, J=12.5 Hz, 2H), 2.41 (m, 1H), 1.95 (d, J=11.0 Hz, 1H). APCi MS m/e 160.2 [(M + 1)'].
*Trade-mark 4-FLUORO-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 6-Fluoro-1,4-dihydro-1,4-methano-naphthalene (Eisch, J. J.; Burlinson, N. E. J. Amer. Chem. Soc. 1976, 98, 753-761.
Paquette, L. A.;
Cottrell, D. M.; Snow, R. A. J. Amer. Chem. Soc. 1977, 99, 3723-3733.) Magnesium turnings (0.66 g, 27.2 mmol) were stirred in anhydrous THF (10 mL) in a flame dried 75 mL 3 neck round bottom flask equipped with a non-equalizing addition funnel with a NZ flow adapter, magnetic stirrer and efficient condenser equipped with a NZ flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle. 2,5-Difluorobromobenzene (0.1 g) was added followed by of 3N EtMgBr in THF (0.1 mL). The addition funnel was charged with an intimate mixture of cyclopentadiene (1.71 g, 25.9 mmol) and 2,5-difluorobromobenzene (5.0 g, 25.9 mmol). Small portions (-0.2 mL) of the intimate mixture were introduced to assist initiation (-4x). After -15 minutes, the reaction initiated (exotherm, and vapor condensation) and heating was maintained as necessary during the addition of the contents of the addition funnel. The reaction was then maintained at reflux for 1 hour.
The reaction was cooled to room temperature and quenched with H20 (20 rnL) followed by aqueous 1 N HCI solution (20 mL) to dissolve the solids. Saturated aqueous NaCI
solution (30 mL) was added and product was extracted with hexanes (4 x 25mL).
The combined organic layer was washed with saturated aqueous NaHC03 solution (25 mL), dried (NazSO,), filtered through a Silica plug with hexanes rinse and concentrated to an oil.
Chromatography on Silica gel eluting with hexanes provided an oil (780 mg, 19%). (TLC
hexanes R, 0.38).'H NMR (400 MHz, CDCI~) b 7.10 (m, 1H), 6.97 (d, J=8.0 Hz, 1H), 6.80 (br s, 1H), 6.78 (br s, 1H), 6.59 (m, 1H), 3.87 (br s, 2H), 2.32 (d, J=7.0 Hz, 1 H), 2.25 (d, J=7.0 Hz, 1 H).
B 6-Fluoro-1,2,3,4-tetrahydro-l,4-methano-naphthalene-2,3-diol 6-Fluoro-l,4-dihydro-1,4-methano-naphthalene (680 mg, 4.22 mmol) and N-methyl morpholine N-oxide (599 mg, 4.43 mmol) were stirred in acetone (50 mL) and H20 (5 mL). To this was added a solution of OsO, (0.2 rnL, 2.5%wt. solution in t-BuOH, 0.02 mmol). After 72 hours, Florisil* (5 g) and saturated aqueous NaHS03 solution (3 mL) were added and stirred for 1 hour. The Florisil* was filtered and the filtrate concentrated to produce a crystalline product which was triturated with acetone and filtered (524 mg, 64°h). 'H NMR
(400 MHz, CDCI3) 8 *Trade-mark 7.10 (dd, J=8.0,5.0 Hz, 1 H), 6.90 (dd, J=8.0,2.3 Hz, 1 H), 6.75 (ddd, J=8.0,8Ø2.3 Hz, 1 H), 3.79 (s, 2H), 3.18 (d, J=1.5 Hz, 2H), 2.22 (d, J=10.0 Hz, 1H), 1.92 (dd, J=10.0,1.5 Hz, 1H).
GCMS rn/e 194 (M').
C) 10-Benzyl-4-fluoro-10-aza-tricyclo[6.3.1.Oz-~]dodeca-2(7),3,5-triene 6-1=luoro-1,2,3,4-tetrahydro-l,4-methano-naphthalene-2,3-diol (524 mg, 2.68 mmol) and Et3NBnCl (10 mg) were vigorously stirred in dichloroethane (15 rnL) and HZO (45 mL) then treated with sodium periodate (0.603 mg, 2.82 mmol). After 1.5 hours, the layers were separated and the aqueous layer extracted with DCE (2 x 20 mL). The combined organic layer was washed with Hz0 (4 x 20 mL) until no reaction to starch iodide paper was observed, then with saturated aqueous NaCI solution (20 mL). The organic layer was dried through a cotton plug and treated with benzyl amine (0.308 mL, 2.82 mmol) and stirred for 2 minutes then transferred to an addition funnel. This solution was added over -10 minutes to a vigorously stirred cooled (0 °C) mixture of NaH8(OAc)s (1.82 g, 8.58 mrnol) in DCE (50 mL).
After addition was complete, the mixture was stirred without cooling for 2 hours. The mixture was quenched with saturated aqueous Na~C03 solution (100 mL) and stirred for 1 hour, then the layers were separated and the aqueous layer was extracted with CHZCIz (3 x 30 mL). The combined organic layer was washed with saturated aqueous NaCI solution (50 mL), dried through a cotton plug and concentrated. Chromatography on Silica gel provided an oil (520 mg, 80°~). (TLC 2% acetonelCHZCIz R, 0.40). 'H NMR (400 MHz, CDCIs) 8 7.18 (m, i H), 6.88 (m, 2H), 3.48 (s, 2H), 3.06 (m, 2H), 2.78 (m, 2H), 2.41 (m, 2H), 2.27 (m, 1 H), 1.69 (d, J=10.5 Hz, 1H).
D) 4-Fluoro-10-aza-tricyclo[6.3.1.0'-Ldodeca-2(7),3,5-triene hydrochloride 10-Benzyl-4-fiuoro-l0-aza-tricyclo[6.3.1.0~~']dodeca-2(7).3.5-triene (390 mg, 1.461 mmol), ammonium formate (3.04 g, 48.2 mmol) and 10°l°Pd(OH)~!C
(30 mg) were combined in MeOH (50 mL) and brought to reflux under N2 for 1.5 hours. Ammonium formate (1.0 g) was added and reflux continued for 0.5 hour. The reaction mixture was filtered through a Celite pad which was rinsed with MeOH. The filtrate was concentrated. The residues were treated with saturated aqueous NazCO' solution (30 mL) and product extracted with methylene chloride (CHzCIz) (3 x 25 mL). The organic layer was washed with saturated aqueous NaCI
solution (50 mL), dried through a cotton plug and concentrated. The residue was treated with 2N HCI MeOH (5 mL) and concentrated then taken up in minimum of MeOH and saturated with EtzO. After stirring 18h, the white crystals were collected by filtration (86 mg, 28%). (TLC
''Trade-mark 5% MeOH/CH2CIz (NH3) R, 0.27). (data for free base) 'H NMR (400 MHz, CDCI3) 8 7.06 (m, 1 H), 6.83 (m, 2H), 2.89 (m, 4H), 2.61 (dd, J=12.0 Hz, 2H), 2.37 (m, 1 H), 1.87 (d, J=11.5 Hz, 1H). APCI MS m/e 178.2 ((M + 1)*], (HCI salt) mp 260-262 °C.
4-METHYL-10-AZA-TRICYCLO[6.3.1.02--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-5-methylbromobenzene. (data for free base) 'H NMR (400 MHz, CDCI3) S 7.04 (d, J=7.5 Hz, 1 H), 6.99 (s, 1 H), 6.98 (d, J=7.5 Hz, 1 H), 2.98-2.90 (m, 4H), 2.63 (m, 2H), 2.35 (m, 1 H), 2.32 (s, 3H), 1.87 (d, J=11.5 Hz, 1 H). APCI MS m/e 174.2 [(M +
1 ) *]. (HCI salt) mp 254-255 °C. Anal. Calcd. for C,ZH~ZF3N.HCL1/3H20: C, 53.44; H, 5.11;
N, 5.19. Found C, 53.73; H, 4.82; N, 5.15.
4-TRIFLUOROMETHYL-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE (See Grunewald, G. L.; Paradkar, V. M.; Pazhenchevsky, B.;
Pleiss, M.
A.; Sall, D. J.; Seibel, W. L.; Reitz, T. J. J. Org. Chem. 1983, 48, 2321-2327. Grunewald, G.
L.; Markovich, K. M.; Sall, D. J. J. Med. Chem. 1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-5-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) 8 7.71 (s, 1 H), 7.64 (d, J=8.0 Hz, 1 H), 7.57 (d, J=8.0 Hz, 1 H), 3.46 (m, 4H), 3.21 (d, J=12.5 Hz, 2H), 2.41 (m, 1 H), 2.16 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )*]. (HCI
salt) mp 244-246 °C. Anal. Calcd. for C,ZH,ZF3N.HCL1/3HZ0: C, 53.44; H, 5.11; N, 5.19.
Found C, 53.77; H, 4.82; N, 5.18.
3-TRIFLUOROMETHYL-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIE_N_E
HYDROCHLORIDE (Grunewald, G. L.; Markovich, K. M.; Sall, D. J. J. Med. Chem.
1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-6-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) 8 7.65 (s, 2H), 7.52 (m, 1H), 3.65 (br s, 1H), 3.49-3.43 (m, 3H), 3.20 (m, 2H), 2.42 (m, 1H), 2.18 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )*J. (HCI salt) mp 275-277 °C.
3-FLUORO-10-AZA-TRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 2,6-Difluoroiodobenzene (Roe, A. M.; Burton, R. A.; Willey, G. L.; Baines, M. W.;
Rasmussen, A. C. J. Med. Chem. 1968, 11, 814-819. Tamborski, C.; Soloski, E.
J. Org.
Chem. 1966, 31, 746-749. Grunewald, G. L.; Arrington, H. S.; Bartlett, W. J.;
Reitz, T. J.; Sall, D. J. J. Med. Chem. 1986, 29, 1972-1982.) 1,3-Difluorobenzene (57.05 g, 0.5 M) in THF (75 mL) was added to a -78 °C stirred solution of n-butyllithium (n-BuLi) (200 mL, 2.5 M/hexanes, 0.5 M) and THF (500 mL) under Nz. By controlling the addition rate the internal temperature was maintained below -70 °C. The total addition time was ~1/2 hour. The resulting slurry was stirred an additional 1/2 hour, then the dispersion was treated with a solution of iodine (126.9 g, 0.5 M) in THF (300 mL) at a rate that maintained an internal temperature below -70 °C.
After complete addition the mixture was allowed to warm to room temperature, and was treated with H20 (100 mL) and 10% aqueous NaZS203 solution (100 mL) and stirred. The layers were separated and the aqueous layer extracted with hexanes (2 x 250 mL). The combined organic layer was washed with 10% aqueous NazS203 solution (100 mL), H20 {100 mL), saturated aqueous NaCI solution (100 mL), dried (Na2S04} filtered and concentrated to give a yellow oil (106.5 g). Distillation at ~1-5 mm at ~80 °C provided a light yellow oil (89.5 g, 75%). 'H NMR (400 MHz, CDC13) 8 7.30 (m, 1 H), 6.87 (m, 2H). GCMS m/e 240 (M'').
B) 5-Fluoro-1,4-dihydro-1,4-methano-naphthalene A solution of 2,6-difluoroiodobenzene (5.0 g, 20.8 mmol) and cyclopentadiene (2.07 g, 31.3 mmol) was stirred at 0 °C in P. ether (70 mL, 40-60 °C) under NZ and treated with n-BuLi (8.74 mL, 2.5M in hexanes, 21.8 mmol) dropwise over 10 minutes. The reaction was quenched after 15 minutes by addition of aqueous 1 N HCi solution and the product was extracted with hexanes (3 x 50 mL). The combined organic layer was washed with Hz0 (50 mL), saturated aqueous NaCI solution (50 mL), dried (MgS04), filtered and evaporated.
Chromatography on Silica gel provided product as an oil (1.5 g, 45%). (TLC
hexanes R, 0.55).'H NMR {400 MHz, CDCI3) 8 7.08 (ddd, J=7.0,1.0,0.8 Hz, 1H), 6.96 (ddd, J=8.5,8.3,7.0 Hz, 1 H), 6.86 (br s, 2H), 6.72 (ddd, J=8.5,8.3,0.8 Hz, 1 H), 4.25 (br s, 1 H), 3.98 (br s, 1 H), 2.36 (ddd, J=7.2,1.7,1.7 Hz, 1 H), 2.30 (ddd, J=7.2,1.7,1.5 Hz, 1 H). GCMS m/e 160 (M+).
C) 3-Fluoro-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene hydrochloride The title compound was prepared by the methods described in Example 2B,C,D
starting with 5-fluoro-1,4-dihydro-1,4-methano-naphthalene. 'H NMR (400 MHz, CD30D) 8 7.36 (ddd, J=8.3,7:3,5.0 Hz, 1 H), 7.21 (d, J=7.3 Hz, 1 H), 7.07 (t, J=8.3 Hz, 1 H), 3.62 (br s, 1 H), 3.42-3.30 (m, 3H), 3.21 (m, 2H), 2.38 (m, 1 H), 2.12 (d, J=11.5 Hz, 1 H). APCI MS m/e 178.4 [(M + 1 )']. mp 269-271 °C.
4-NITRO-10-AZATRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A~ 1-(10-Aza-tricyclo[6.3.1.OZ--']dodeca-2(7),3,5-men-10-yl)-2 2 2-trifluoro-ethanone 10-Aza-tricyclo[6.3.1.02']dodeca-2(7),3,5-triene hydrochloride salt (12.4 g, 63.9 mmol) was stirred in CHZCIZ (200 mL). This was cooled (ice bath) and treated with pyridine (12.65 g, 160 mmol) followed by trifluoroacetic anhydride (TFAA) (16.8 g, 11.3 mL, 80 mmol) from an addition funnel over 10 minutes. After ~3 hours, the solution was poured into 0.5N
aqueous HCI (200 mL) and the layers separated. The aqueous layer was extracted with CHzCl2 (3 x 50 mL) and the combined organic layer was washed with 0.5N aqueous HCI (50 mL), HZO (2 x 50 mL) and saturated aqueous NaHC03 solution (50 mL). This solution was dried through a cotton plug, then diluted with ~3% EtOAc and filtered through a 2 inch Silica pad eluted with ~3% EtOAcICH2C12. Concentration afforded a clear oil which crystallized to give white needles {15.35 g, 60.2 mmol, 94%). (TLC 30% EtOAclhexanes Rf 0.53).
'H NMR
(400 MHz, CDCI3) 8 7.18 (m, 4H), 4.29 (br d, J=12.6 Hz, 1 H), 3.84 (br d, J=12.6 Hz, 1 H), 3.51 (dd, J=12.6,1.5 Hz, 1 H), 3.21 (br s, 1 H), 3.10 (br s, 1 H), 3.10 (br d, J=12.6 Hz, 1 H), 2.37 (m, 1 H), 1.92 (d, J=10.8 Hz, 1 H). GCMS m/e 255 (M+). mp 67-68 °C.
B) 1-(4-Nitro-10-aza-tricyclo[6.3.1.0~]dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro ethanone (Based on the method described by Coon, C. L.; Blucher, W.G.; Hill, M. E. J. Org.
Chem. 1973, 25, 4243.) To a solution of trifluoromethanesulfonic acid (2.4 ml, 13.7 mmol) in CHZCIZ
(10 ml) stirred at 0 °C was slowly added nitric acid (0.58 ml, 27.4 mmol) generating a white precipitate. After 10 minutes the resulting mixture was cooled to -78 °C and treated with 1-(10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (3.5 g, 13.7 mmol) in CH2CI2 (15 ml) dropwise from an addition funnel over 5 minutes. The reaction was stirred at -78 °C for 30 minutes then warmed to 0 °C for 1 hour.
The reaction mixture was poured into a vigorously stirred ice (100 g). The layers were separated and the aqueous layer extracted with CHzCIz (3 x 30 rnl), The organic layer was combined and washed with H20 (3 x 30 ml). The combined organic layer was washed with saturated aqueous NaHC03 solution (20 mL) and Hz0 (20 mL) then dried through a cotton plug and concentrated to give an orange oil that solidified on standing (4.2 g). Chromatography yielded pure product as a crystalline solid (3.2 g, 78%). (TLC 30% EtOAc/hexanes R, 0.23). 'H NMR (400 MHz, CDCl3) 8 8.12 (br d, J=8.0 Hz, 1 H), 8.08 (br s, 1 H), 7.37 (br d, J=8.0 Hz, 1 H), 4.38 (br d, J=12.6 Hz, 1 H), 3.94 (br d, J=12.6 Hz, 1 H), 3.59 (br d, J=12.6 Hz, 1 H), 3.43-3.35 (m, 2H), 3.18 (br d, J=12.6 Hz, 1 H), 2.48 (m, 1H), 2.07 (d, J=10.8 Hz, 1H). GCMS m!e 300 (M').
C) 4-Nitro-l0-azatricyclo[6.3.1.0j'-Ldodeca-2(7),3,5-triene hydrochloride 1-(4-Nitro-10-aza-tricyclo(6,3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (182 mg, 0.61 mmol) was stirred with NaZC03 (160 mg, 1.21 mmol) in MeOH (3 mL) and HZO (1 mL) at 70 °C for 18 hours. The mixture was concentrated, water was added and the product was extracted with CHZCI2. The organic layer was extracted with 1N
aqueous HCI
(3 x 20 mL) and the acidic layer washed with CHZCIZ (2 x 20 mL). The aqueous layer was basified to pH -10 with Na~C03(s) and product was extracted with CH2CIz (3 x 30 mL). The organic layer was dried through a cotton plug and concentrated to an oil. This was dissolved in MeOH and treated with 1 N HCI MeOH, concentrated to solids which were recrystallized from MeOH/Et20 to afford product as a white solid (73 mg, 50%). (TLC 5%
MeOH/CHzCl2 (NH3) Rt 0.38). 'H NMR (400 MHz, DMSO-d6) & 8.21 (s, 1H), 8.18 (dd, J=8.0,2.0 Hz, 1 H), 7.59 (d, J=8.0 Hz, 1H), 3.43 (br s, 2H), 3.28 (m, 2H), 3.07 (dd, J= 13.0,13.0 Hz, 2H), 2.24 (m, 1H), 2.08 (d, J=11.5 Hz, 1H). APC1 MS mle 205.1 J(M + 1 )'] mp 265-270 °C.
FXAMPI F R
4-AMINO-10-AZATR1CYCL0[6.3.1.0]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
4-Nitro-l0-azatricyclo[6.3.1.0=~'Jdodeca-2(7),3,5-triene (500 mg, 2.08 mmol) was stirred in 1,4-dioxane (40 mL) and treated with saturated aqueous Na2C03 solution (15 mL).
To this was added di-t-butyldicarbonate (1.8 g, 8.31 mmol). After stirring 18 hours the reaction was treated with Hz0 (50 mL), extracted with CH2CIz (4 x 30 mL), dried through a cotton plug and concentrated to provide an oil (500 mg, 91%).
This oil (500 mg, 1.64 mmol) was dissolved in MeOH (30 mL), treated with 10%Pd/C
(~50 mg) and hydrogenated under a HZ atmosphere (45 psi) for 1 hour. The mixture was filtered through a Celite pad and concentrated to a clear oil (397 mg, 88%).
*Trade-mark This oil (50 mg, 0.18 mmol) was stirred in 3N HCI EtOAc (3 mL) for 2 hours then concentrated to a white solid (25 mg, 56°l°). 'H NMR (400 MHz, DMSO-d6) b 7.38-7.10 (3H), 3.60 (br s, 2H), 3.25 (m, 2H), 2.98 (m, 2H), 2.18 (m, 1H), 1.98 (d, J=11.5 Hz, 1H). APCI MS
Me 175.1 [(M + 1 )'] mp 9 89-192 °C.
N'--j10-AZATRICYCLOI6.3.1.OyLDODECA-2(7),3,5-TRIEN-4-YL]ACETAMIDE
HYDROCHLORIDE
A) 1-(4-Arnino-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-men-10-yl)-2,2.2-trifluoro-ethanone Hydrogenation of 1-(4-vitro-10-aza-tricyclo(6.3.1.0~~']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (2.0 g, 6.66 mmol) under a H~ atmosphere (40 psi) and 10°~PdIC (200 mg) in MeOH over 1.5 hours, filtration through Celiteiand concentration affords a yellow oil (1.7 g). (TLC 50°l° EtOAclhexanes R, 0.27). 'H NMR (400 MHz, CDCI3) b 6.99 (m, 1H), 6.64 (br s, 1 H), 6.57 (rn, 1 H), 4.25 (m, 1 H), 3.82 (m, 1 H), 3.50 (m. 1 H), 3.17-3.07 (m, 3H), 2.35 (m, 1H), 1.90 (d, J=10.8 Hz, 1H). GCMS m/e 270 (M').
g) N-(10-Trifluoroacetyl-10-aza-tricyclo(6.3.1.Oz-']dodeca-2(7),3,5-men-4-yl)-acetamide 1-(4-Amino-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2.2,2-mfluoro-ethanone (850 mg, 3.14 mmol) was stirred in CHICIz (5 mL) and treated with methyl amine (0.53 mL, 3.76 mmol) and acetyl chloride (0.23 mL, 3.2 mmol) then stirred 18 hours. Standard NaHC03 workup yielded an oil which was chromatographed to provide a clear oil (850 mg, 87°J°). (50°J° EtOAclhexanes R, 0.28).
CAN'-110-Azatricyclo(6.3.1.Oj-']dodeca-2(7),3,5-men-4-yl]acetamide hydrochloride N-(10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.Oz~']dodeca-2(7),3,5-men-4-yl)-acetamide (100 mg, 0.32 rnmol) was stirred with NazC03 (70 mg, 0.64 mmol) in MeOH (10 mL) and Hi0 (2 mL) at 70 °C for 18 hours. The mixture was concentrated, water was added and the product was extracted with EtOAc. The organic layer was extracted with 1 N
aqueous HCI (3 x 20 mL) and the acidic layer washed with EtOAc (2 x 20 mL). The aqueous layer was basif~ed to pH ~10 with NazC03 (s) and product was extracted with EtOAc (3 x 20 mL).
The organic layer was dried (sodium sulfate (NaZSO,)) and concentrated to an oil. This material was dissolved in MeOH and treated with 3N HCI EtOAc (3 mL), concentrated and recrystaliized *Trade-mark from MeOH/EtzO to provide a solid (40 mg, 50%). 'H NMR (400 MHz, DMSO-ds) S
9.98 (s, 1 H), 9.02 (br m, NH), 7.65 (s, 1 H), 7.55 (br s, NH), 7.38 (d, J=8.0 Hz, 1 H), 7.20 (d, J=8.0 Hz, 1 H), 3.33 (m, 4H), 2.96 (m, 2H), 2.13 (m, 1 H), 2.00 (s, 3H), 1.96 (d, J=10.5 Hz, 1 H). APCI MS
m/e 217.2 [(M + 1 )''], mp 225-230 °C.
FXAMPI F 1n 6-METHYL-5-THIA-7,13-DIAZATETRACYCLO[9 3 1 02''-°._O~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) N-(10-Trifluorothioacetyl-10-aza-tricyclo[6.3101]dodeca-2(7),3,5 -trien-4-yl)-lhin'r~cf~mirlc N-(10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-men-4-yl)-acetamide (850 mg, 2.72 mmol) and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent) (1.1 g, 2.72 mmol) were combined in toluene (10 mL) and brought to reflux for 1.5 hours. After cooling the reaction was worked up with EtOAclsaturated aqueous NaHC03 solution. The organic layer was dried (NazS04), filtered, concentrated and chromatographed on Silica gel to produce product (410 mg, 44%). (50%
EtOAc/hexanes R, 0.38) B~ 6-Methyl-5-this-7,13-diazatetracyclo[9.3.1.0~'-°.Oy]pentadeca-2(10),3,6,8-tetraene hydrochloride The above oil, 2,2,2-trifluoro-N-(10-trifluorothioacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-4-yl)-thioacetamide, (360 mg, 1.05 mmol) was dissolved in MeOH (10 mL) and 1N NaOH (5 mL) and added to potassium ferricyanide (K3Fe(CN)s)(1.72 g, 5.23 mmol) in H20 (10 mL). This mixture was warmed to 60 °C for 1.5 hours, cooled, concentrated and worked up with EtOAc/H20. This material was stirred in dioxane (20 mL) and treated with H20 (50 mL) and Na2C03 to achieve pH 10. To this was added di-t-butyldicarbonate (436 mg, 2.0 mmol) and the mixture was stirred for 18 hours. The reaction was concentrated, treated with H20 and extracted with CHzCl2. The product was chromatographed (Silica 30% EtOAc/hexanes R, 0.41) to yield an oil (100 mg).
The above product was treated with 3N HCI/EtOAc (3 mL) and warmed to reflux for ~15 minutes then concentrated to a solid which was azeotroped with CH2CI2 (2x). These solids were dissolved in a minimum amount of MeOH then saturated with Et20 and stirred.
The resulting white crystalline powder was collected by filtration (40 mg, 14%).
'H NMR (400 MHz, DMSO-ds) 8 9.46 (s, NH), 7.65 (s, 1H), 7.82 (s, 1H), 7.65 (br m, NH), 3.36 (m, 2H), 3.24 (m, 2H), 3.02 (m, 2H), 2.76 (s, 3H), 2.23 (m, 1H), 2.06 (d, J=10.8 Hz, 1 H). APCI MS m/e 231.1 [(M + 1 )']. mp 183-184 °C.
FXAMPI F ~ 1 4,5-DINITRO-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
A) 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ-']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (Based on the method described in Coon, C. L.; Blucher, W. G.; Hill, M. E. J. Org.
Chem. 1973, 25, 4243. For an additional related example of dinitration see:
Tanida, H.;
Ishitobi, H.; Irie, T.; Tsushima, T. J. Am. Chem. Soc. 19fi9, 91, 4512.) To a solution of trifluoromethanesulfonic acid (79.8 ml, 902.1 mmol) in CHZCIZ
(550 ml) stirred at 0 °C was slowly added nitric acid (19.1 ml, 450.9 mmol) generating a white precipitate. After 10 minutes, 1-(10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (50 g, 196 mmol) in CHZCIZ (300 ml) was added dropwise from an addition funnel over 30 minutes. The reaction was stirred at 0 °C for 2.5 hours and then stirred at room temperature for 24 hours. The reaction mixture was poured into a vigorously stirred mixture of Hz0 (500 ml) and ice (400 g). The layers were separated and the aqueous layer back extracted with CHZCIZ (3 x 300 ml). The organic layer was combined and washed with H20 (3 x 300 ml). The combined aqueous layers were re-extracted with CHZCl2 (2 x 100 ml).
The organic layer was combined and washed with saturated aqueous NaHC03 solution (200 mL) and Hz0 (200 mL) then dried through a cotton plug and concentrated to solids.
Trituration with EtOAc/hexanes produced off white solids which were filtered and dried (52 g, 151 mmol, 77%. The mother liquor was chromatographed to give an additional 4.0 g for a total of 56.0 g (82.8%). (TLC 50% EtOAc/hexanes R, 0.29) 'H NMR (400 MHz, CDC13) 8 7.77 (s, 1 H), 7.75 (s, 1 H), 4.39 (br d, J=13.0 Hz, 1 H), 3.98 (br d, J=13.0 Hz, 1 H), 3.65 (d, J=13.0 Hz, 1 H), 3.49 (br s, 1 H), 3.44 (br s, 1 H), 3.24 (br d, J=12.6 Hz, 1 H), 2.53 (m, 1 H), 2.14 (d, J=11.5 Hz, 1 H). GCMS m/e 345 (M').
B) 4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ=']dodeca-2(7),3,5-triene 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (3.7 g, 10.7 mmol) and Na2C03 (2.3 g, 21.4 mmol) were combined in MeOH (50 mL) and H20 (20 mL) then warmed to reflux for 18 hours. The reaction was cooled, concentrated, treated with H20 and extracted with CHZCI2 (3 x 50 mL) then dried through a cotton plug.
After concentration, tile residue was chromatographed to provide brown solids.
(1.9 g, 71%).
(TLC 5°!° MeOH/CHzCIz (NH3) R, 0.36). 'H NMR (400 MHz, CDCI3) b 7.69 (s, 2H), 3.17 (br s, 2H), 3.11 (d, J=12.6 Hz, 2H), 2.53 (m, 1H), 2.07 (d, J=11.0 Hz, 1H). GCMS m/e 249 (M').
6-METHYL-7-PROPYL-5,7,13-TRIA2ATETRACYClO[9.3.1.02''-°.O,~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
AL 4,5-Dinitro-10-aza-tricyclo[6.3.1.0~=']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester 4,5-Dinitro-10-aza-tricyclo(6.3.1.0~~']dodeca-2(7),3,5-triene, (1.9 g, 7.6 mmol) was stirred in 1,4-dioxane (75 mL) and treated with saturated aqueous NazC03 solution (10 mL).
To this was added di-t-butyldicarbonate (3.31 g, 15.2 mmol). After stirring 6 hours the reaction was treated with Hz0 ( 50 mL) and extracted with EtOAc (4 x 25 mL), dried (NazSO,), filtered, concentrated and chromatographed to provide product (1.9 g, 71°~). (TLC 30%
EtOAc/hexanes (NHS) R, 0.58). 'H NMR (400 MHz, CDCI3) b 7.77 (br s, 1H), 7.72 (br s, 1H), 4.08 (m, 1 H), 3.92 (m, 1 H), 3.39 (br s, 1 H), 3.27 (br s, 1 H), 3.25 (m, 1 H), 3.18 (m, 1 H), 2.46 (rn, 1H), 2.02 (d, J=11.0 Hz, 1H).
B) 4,5-Diamino-10-aza-tricyclo[6.3.i.0z-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 4,5-Dinitro-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester (1.9 g, 5.44 mmol) was hydrogenated in MeOH under a H~ atmosphere (45 psi) over 10%Pd/C (100 mg) for 1.5 hours then filtered through a Celite pad and concentrated to white solids (1.57 g, 100%). (TLC 5°~ MeOH/CHzCh (NH3) R,0.14).
C) 6-Methyl-5,7,13-triazatetracyclo[9.3.1.Oz-'°.0'~8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tent-butyl ester (For conditions, see; Segelstein, 8. E.;
Chenard, B. L.; Macor, J. E.; Post, R. J. Tetrahedron Lett 1993, 34, 1897.) 4,5-Diamino-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyi ester (700 mg, 2.42 mmol) was dissolved in EtOH (10 rnL) and acetic acid (HOAc) (1 mL) and treated with 1-ethoxyethylenemalononitrile (329 mg, 2.42 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated treated with H20 and saturated aqueous NaxC03 solution and extracted with EtOAc (3 x 50 mL), then dried (Na~SO,). After filtration and concentration, the residue was *Trade-mark chromatographed to provide brown solids (247 mg, 36%). (TLC 5% MeOH/CHZCIZ
(NH3) R, 0.28).
D) 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.OZ'-'°.04=8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tent-butyl ester (For conditions, see; Pilarski, B. Liebigs Ann.
Chem. 1983, 1078.) 6-Methyl-5,7,13-triazatetracyclo[9.3.1.0z''°.0°'e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester (80 mg, 0.267 mmol) was stirred in 50%
aqueous NaOH
solution (3 mL) and DMSO (1 mL) then treated with 1-iodopropane (0.03 mL, 0.321 mmol}.
This mixture was warmed to 40 °C for 2 hours then cooled, treated with Hz0 and extracted with EtOAc. The organic layer was washed with Hz0 (3x) then dried (Na2S04), filtered and concentrated to an oil (90 mg, 0.253 mmol). (TLC 5% MeOH/CHzCIz (NH3) Rf 0.15).
E) 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.02-L.04=8]pentadeca-2(10),3,5,8-tetraene hydrochloride 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.02''°, pa,e]pentadeca-2( 10),3, 5, 8-tetraene-13-carboxylic acid tert-butyl ester (90 mg, 0.253 mmol) was dissolved in 3N HCI
EtOAc (5 mL) and warmed to 100 °C for 112 hour. The mixture was cooled, concentrated, slurried in EtOAc, and filtered to provide a white solid (25 mg, 34%). 'H NMR
(400 MHz, DMSO-ds) 8 9.56 (s, NH), 7.91 (s, 1 H), 7.83 (br m, NH), 7.74 (s, 1 H), 4.38 (m, 2H), 3.48 (m, 2H}, 3.32 (m, 2H), 3.10 (m, 2H), 2.87 (s, 3H), 2.28 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H) 1.85 (m, 2H), 0.97 (m, 3H). mp 147-150 °C.
FX~~/IDI G ~ ~
5,7,13-TRIAZATETRACYCLO[9.3.1.02'-'°.0°~]PENTADECA-2(10),3,5,8-TETRAENE
HYDROCHLORIDE
A} 5,7,13-Triazatetracyclo[9.3.1.OZW°.0"-e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester (For conditions, see; Segelstein, B. E.;
Chenard, B. f_.; Macor, J. E.; Post, R. J. Tetrahedron Lett. 1993, 34, 1897.) 4,5-Diamino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester (1.0 g, 3.45 mmol) was dissolved in EtOH (10 mL) and HOAc (1 mL) and treated with ethoxymethylenemalononitrile (421 mg, 3.45 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated treated with H20 and saturated aqueous Na2C03 solution and extracted with EtOAc (3 x 50 mL), then dried (NaZS04). After filtration and concentration, the residue was chromatographed to provide brown solids (580 mg, 56%). (TLC 5% MeOH/CHzCIz (NH3) R, 0.28) ~- 5,7,13-triazatetracyclo[9.3.1.02-°'-°.04-6]pentadeca-2(10),3,5,8-tetraene hydrochloride 5,7,13-Triazatetracyclo[9.3.1.02''°.04~eJpentadeca-2( 10), 3,5, 8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DZO) 8 8.95 (s, 1 H), 7.67 (s, 2H), 3.45 (br s, 2H), 3.31 {d, J=12.5 Hz, 2H), 3.13 (d, J=12.5 Hz, 2H), 2.30 (m, 1 H), 1.99 (d, J=11.5 Hz, 1 H). APCI MS m/e 200.1 [(M + 1 )+]. mp >250 °C.
7-METHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.04- a]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 5,7,13 triazatetracyclo[9.3.1.02''°.0''~BJpentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodomethane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, Dz0) 8 8.97 (s, 1H), 7.71 (s, 1 H), 7.67 (s, 1 H), 3.94 (s, 3H), 3.48 (m, 2H), 3.33 (d, J=12.2 Hz, 2H), 3.14 (d, J=12.2 Hz, 2H), 2.34 (m, 1 H), 2.03 (d, J=11.5 Hz, 1 H). APCI MS m/e 214.2 [(M + 1 )+].
6-METHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.048]PENTADECA-2( 10), 3,5,8-TETRAENE HYDROCHLORIDE
6-Methyl-5,7,13-triazatetracyclo[9.3.1.02''°.pa,eJpentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.40 (br m, NH), 7.77 (br m, NH), 7.70 (s, 1 H), 3.44 (m, 2H), 3.30 (m, 2H), 3.05 (br d, J=11.0 Hz, 2H), 2.79 (s, 3H), 2.23 {m, 1 H), 2.10 (d, J=10.8 Hz, 1 H). GCMS m/e 213.5 (M').
FXD~/IPI F 1~
6,7-DIMETHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.0°~JPENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 6-methyl-5,7,13-triazatetracyclo[9.3.1.02''°.04'8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodomethane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.52 (s, NH), 7.84 (s, 1 H), 7.82 (br m, NH), 7.72 {s, 1 H}, 3.90 (s, 3H), 3.45 (m, 2H), 3.28 (m, 2H), 3.04 (m, 2H), 2.82 (s, 3H), 2.23 (m, 1 H), 2.12 (d, J=11.0 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )+]. mp 225-230 °C.
FXAAADI ~ 17 7-PROPYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.0'-8]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 5,7,13 triazatetracyclo[9.3.1.0z''°.04'e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodopropane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.52 (s, 1H), 9.45 (br s, NH), 7.97 (s, 1H), 7.85 (s, 1H), 7.83 (br m, NH), 4.43 (m, 2H), 3.49 (m, 2H), 3.33 (m, 2H), 3.08 (m, 2H), 2.28 (m, 1H), 2.15 (d, J=11.0 Hz, 1H), 1.92 (m, 2H), 0.93 (m, 3H). APCI
MS m/e 242.2 [(M + 1 )+j. mp 170-171 °C (subl.).
7-BUTYL-5,7,13-TRIAZATETRACYCLO[9.3.1.OZ-~'-°.04=8]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
A) 4-Butylamino-5-vitro-10-aza-tricyclo[6.3.1.0~'-]dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (For conditions, see; Senskey, M. D.; Bradshaw, J. D.;
Tessier, C. A.;
Youngs, W. J. Tetrahedron Lett. 1995, 36, 6217.}
4,5-Dinitro-10-aza-tricyclo[6.3.1.02v]dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester {500 mg, 1.43 mmol) and 1-butylamine (1.42 mL, 14.3 mmol) were combined in THF (5 mL) and stirred 4 hours. The mixture was diluted with EtOAc (50 mL) and washed with H20 (3 x 30 mL) then dried (Na2S04), filtered and concentrated to an oil.
This oil was passed through a Silica gel filter column to remove baseline impurities eluting with 30%
EtOAGhexanes (510 mg, 1.41 mmol, 99%).
B) 4-Butyfamino-5-amino-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 4-Butylamino-5-vitro-10-aza-tricycfo[6.3.1.OZ'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (460 mg, 1.27 mmol) was treated with ammonium formate (850 mg, 12.7 mmol) and 10%Pd(OH)zIC (50 mg) in MeOH (20 mL) and brought to reflux for 1 hour then filtered through a Celite pad and concentrated. The solids were treated with saturated aqueous Na~CO~ solution, extracted with CHzCIZ (3 x 30 mL) and dried by filtration through a cotton plug to give an oil (440 mg, 100%).
~ 7-Butyl-5,7,13-triazatetracyclo[9.3.1.02'-'°.0'-°]pentadeca-2(10),3,5,8-tetraene-13-c_ arboxylic acid tert-butyl ester 4-Butylamino-5-amino-l0-aza-tricyclo[6.3.1.Oz~')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (440 mg, 1.27 mmol) was dissolved in EtOH (20 mL) and HOAc (2 mL) and treated with ethoxymethylenemalononitrile (186 mg, 1.52 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated, treated with HZO and saturated aqueous NaZC03 solution then extracted with EtOAc (3 x 50 mL) and dried (NaZSO,). After filtration and concentration, the residue was chromatographed to provide a yellow oil. (400 mg, 89%). (TLC 5% MeOHlCH2CIz (NH3) R, 0.70).
D) 7-Butyl-5.7,13-triazatetracyclo[9.3.1.0z'-'°.0'-°~pentadeca-2(10),3,5,8-tetraene hydrochloride 7-Butyl-5,7,13-triazatetracyclo[9.3.1.Oz~'°.0'ypentadeca-2( 10),3, 5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DMSO-d°) S 9.93 (brs, NH), 9.68 (s, 1H), 7.99 (s, 1H), 7.92 (br m, NH), 7.87 (s, 1H), 4.50 (m, 2H), 3.49 (m, 2H), 3.30 (m, 2H), 3.08 (m, 2H), 2.26 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H), 1.88 (m, 2H), 1.32 (m, 2H), 0.82 (t, J=7.0 Hz, 3H). APCI MS m/e 256.2 j(M + 1)']. mp 204-208 °C.
7-lsobutyl-5,7,13-triazatetracyclo[9.3.1.0~~-'°.0'-°]eentadeca-2(10).3,5,8-tetraene hydroch loride 4,5-Dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and isobutylamine were converted to the title compound utilizing the methods described in Example 18A-D. 'H NMR (400 MHz, CDCI3) b 7.74 (s, 1H), 7.52 (s, 1H), 7.14 (s, 1H), 3.90 (dd, J=7.5,2.0 Hz, 2H), 3.04-2.97 (m, 4H), 2.70 (dd, J=12.8,2.3 Hz, 2H), 2.42 (m, 1 H), 2.19 (m, 1 H), 1.98 (d. J=10.5 Hz, 1 H), 0.93 (m, 6H). APCI MS rrVe 256.2 [(M + 1 )']. mp 147-150 °C (subl.).
*Trade-mark 6-METHYL-7-ISOBUTYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02.'-°.0"~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
A) 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.OZw'-°.0°=8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tart-butt'! ester 4-Amino-5-isobutylamino-10-aza-tricyclo(6. 3.1.02~']dodeca-2(7), 3, 5-triene-carboxylic acid tart-butyl ester (250 mg, 0.74 mmol) from Example 19B was dissolved in EtOH
(10 mL) and HOAc (2 mL) and treated with 1-ethoxyethylenemalononitrile (118 mg, 0.87 mmol). The reaction proceeded as in Example 18C (18h) and was worked up similarly to provide product (TLC 3% MeOH/CHZCIZ (NH3) R, 0.57).
B) 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.02'-'°.04=8]pentadeca-2(10),3,5,8-tetraene hydrochloride 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.02''°.04'8]pentadeca-2( 10),3, 5,8-tetraene-13-carboxylic acid tart-butyl ester was converted to the title compound by the methods described in Example 12E. APCI MS m/e 270.3 [(M + 1 )']. mp 129-130 °C (subl.).
7-PHENYL-5,7,13-TRIAZATETRACYCLO[9.3.1.OZ''-°.0~]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 18A, 4,5-dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl ester and aniline were converted to 4-phenylamino-5-nitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl at 75 °C for 4 hours in the coupling step.
This was then converted to the title compound utilizing the methods described in Example 18B,C,D. 'H NMR
(400 MHz, DMSO-ds) 8 9.08 (1 H), 7.78-7.57 (m, 7H), 3.47-3.00 (m, 6H), 2.23 (m, 1 H), 2.09 (d, J=11.5 Hz, 1 H). APCI MS m/e 276.2 [(M + 1 )+). mp 210-213 °C.
6-METHYL-7-PHENYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.°.04=B;~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 21 and Example 20, 4,5-dinitro-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl ester and aniline were converted to the title compound. 'H NMR (400 MHz, DMSO-ds) 8 7.79 (s, 1H), 7.73-7.56 (m, 5H), 7.32 (s, 1 H), 3.46-2.99 (m, 6H), 2.66 (s, 3H), 2.23 (m, 1 H), 2.08 (d, J=11.0 Hz, 1 H). APCI
MS m/e 290.2 [(M + 1 )''). mp >250 °C.
FXAMPI F ~~
2,10 4,8 7-NEOPENTYL-5,7,13-TRIAZATETRACYCLO[9.3.1 0-.0-~PENTADECA-2~10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 18A-D, 4,5-dinitro-10-aza tricyclo[6.3.1.02'')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and neopentylamine were converted to the title compound. t-Boc precursor GCMS m/e 369 (M+).
(HCI salt) mp >250 °C.
FXA~IIPI G 7d 6-METrIYL 7-NEOPENM-5,7,13-TRIAZA1FTRACYCLO[9.3.1.0_.04-~PENTADECA.2(10),3,5,8-TErRAENE HYDROCHLORIDE
Utilizing the methods described in Example 21 and 20, 4,5-dinitro-10-aza tricyclo[6.3.1.02'')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and neopentylamine were converted to the title compound. 'H NMR (400 MHz, DMSO-ds) s 7.31 (s ,1H), 7.27 (s ,1H), 7.02 (br s, , NH), 4.41 (t, J=13.0 Hz, 2H), 3.90 (s, 3H), 3.47-3.26 (m, 6H), 2.20 (m, 1 H), 2.00 (d, J=11.5 Hz, 1 H), 0.90 (s, 9H). t-Boc precursor APCI MS
m/e 384.2 [(M +
1)''). mp >250 °C.
6,7-DIMETHYL-6,8,14-TRIAZATETRA~CYCLO[10.3.1.0'-'-0~1-ID(ADECA.2(11 ),3,5,7,9~PENTAENE
HYDROCHLORIDE (Based on the following procedure: Jones, R. G.; McLaughlin, K.
C. Org.
Syn. 1963, 4, 824. b) Ehrlich, J., Bobert, M. T. J. Org. Chem. 1947, 522.) 4,5-Diamino-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (100 mg, 0.35 mmol) was warmed to 80 °C in H20 (5 mL). To this butane 2,3-dione (0.034 mL, 0.38 mmol) was added under Nz for 2 hours. The reaction was cooled to room temperature and extracted with EtOAc (3 x 40 ml). The combined organic layer was washed with H20 (2 x 30 ml), dried (Na2S04), filtered, concentrated and chromatographed on Silica gel to provide an oil (120 mg, 100%). The oil was dissolved in 2N HCI
MeOH (5 mL) and warmed to reflux for 30 minutes, then concentrated. Recrystallization from MeOH/Et20 provided a white powder (50 mg, 43%). (TLC EtOAc RI 0.14). 'H NMR (400 MHz, DMSO-ds) 8 7.85 (s, 2H), 3.50 (br s, 2H), 3.32 (d, J=12.5 Hz, 2H), 3.10 (d, J=12.5 Hz, 2H), 2.64 (s, 6H), 2.24 (m, 1H), 2.13 (d, J=11.0 Hz, 1H). t-Boc precursor APCI MS m/e 340.3 [(M +
1)'].
FXAMPI F ~~
5,8,14-TRIAZATETRACYCLO[10.3.1.0~~-".0'--~jHEXADECA-2(11 ),3.5,7,9-PENTAENE
HYDROCHLORIDE
A) 1-(4,5-Diamino-10-aza-tricyclo[6.3.1.0~=']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7).3,5-men-10-yl)-2,2.2-trifluoro-ethanone (3.0 g, 8.70 mmol) was hydrogenated in MeOH (30 ml) under H2 (45 psi) over Pd(OH)z (300 rrig of 20 wt%IC, 10%wt). After 2.5 hours the reaction was filtered through a Celite*pad and rinsed with MeOH (30 ml). The solution was concentrated to a light brown oil which crystallized (2.42 g, 96%). (TLC 10% MeOHICHZCI= R, 0.56). APCI MS m/e 286.2 [(M +
1 )']. mp 129-131 °C.
. B) 1 ~5,8,14-Triazatetracyclo[10.3.1.OZV'.0''-~lhexadeca-2(11),3,5,7,9-pentaene)-2,2,2-trifluoro-ethanone 1-(4,5-Diamino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (500 mg, 1.75 mmol) was stirred in THF (2 ml). This mixture was treated with Hs0 (2 mL) and glyoxal sodium bisulfite addition compound hydrate (931 mg, 3.50 mmol) then stirred at 55 °C for 2.5 hours. The reaction was cooled to room temperature and extracted with EtOAc (3 x 40 ml). The combined organic layer was washed with HZO (2 x 30 ml), dried (NaiSO,), filtered, concentrated and chromatographed on Silica gel to provide an off whtte powder (329 mg, 60%). (TLC 25% EtOAGhexanes R, 0.40). mp 164-166 °C.
C) 5,8,14-Triazatetracyclo[10.3.1.0~'-'.0'=-~]hexadeca-2(11),3,5,7,9-pentaene hydrochloride 1-(5,8,14-Triaiatetracyclo[10.3.1.02'".0''°jhexadeca-2( 11 ),3,5,7,9-pentaene)~2,2,2-trifluoro-ethanone (320 mg, 1.04 mmol) was scurried in MeOH (2.0 ml) and treated with Na2C03 (221 mg, 2.08 mmol) in H20 (2.0 ml). The mixture was warmed to 70 °C for 2 hours, then concentrated, treated with Hz0 (20 mL) and extracted with CH2CIz (3 x 10 ml). The organic layer was dried through a cotton plug and concentrated to give a light yellow oil (183 rng, 83%) which solidfied upon standing (mp 138-140 °C). This material was dissolved in MeOH (10 mL), treated with 3M HCUEtOAc (3 ml), concentrated and azeotroped with MeOH
*Trade-mark (2 x 20 mL) to give solids which were recrystallized from MeOH/Et20 to afford product as a white solid (208 mg, 97%). (TLC 5% MeOH/CHZCIz (NH3) R, 0.26). 'H NMR (400 MHz, CD30D) 8 8.94 (s, 2H), 8.12 (s, 2H), 3.70 (m, 2H), 3.54 (d, J=12.5 Hz, 2H), 3.35 (d, J=12.5 Hz, 2H), 2.49 (m, 1 H), 2.08 (d, J=11.0 Hz, 1 H). GCMS m/e 211 (M+). mp 225-230 °C.
14~1AETHYL-5,8,14TRIAZATETRACYCLO[10.3.1.0~-'-'.(x'-~HEXADECA-2(11),3,5,7,9-PEN'fAENE
HYDROCHLORIDE
5,8,14-Triazatetracyclo[10.3.1.02'".04'9]hexadeca-2(11),3,5,7,9-pentaene (207 mg, 0.98 mmol) was treated with 37% aqueous formalise solution (1 mL) and formic acid (1 mL) then warmed to 80 °C for 1 hour. The reaction was poured into water, made basic (NaOH, pH
~11) and extracted with EtOAc. The organic layer was dried (Na2S04), concentrated and chromatographed on Silica gel to provide a yellow solid. This was stirred in MeOH (2 mL) and treated with 3N HCI EtOAc (2 mL). After concentration the solids were recrystallized from MeOH/Et20 to afford product as a white solid (70 mg, 27%). (2% MeOH/CH2Clz (NH3) R, 0.47). 'H NMR (400 MHz, CDCI3) 8 8.71 (s, 2H), 7.80 (s, 2H), 3.37 (br s, 2H), 3.03 (m, 2H), 2.47 (m, 2H), 2.32 (m, 1 H), 2.18 (br s, 3H), 1.84 (d, J=11.0 Hz, 1 H). APCI
MS m/e 226.2 [(M +
1 )+]. mp >250 °C.
5-OXA-7,13-DIAZATETRACYCLO[9.3.1.02-~'-°.04'8]PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) 2,2,2-Trifluoro-1-(4-hydroxy-5-vitro-10-aza-tricyclo[6.3.1.0'-]dodeca-2(7),3,5-trien-10-yl)-ethanone 1-(4, 5-Dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-tries-10-yl)-2,2,2-trifluoro-ethanone (900 mg, 2.61 mmol) and potassium acetate (KOAc) (2.6 g, 26.1 mmol) were dissolved in DMSO (10 mL) and warmed with stirring to 100 °C for 16 hours. The mixture was cooled and diluted with H20 ( 50 mL) then extracted with 80% EtOAGhexanes (6 x 25 mL).
The organic layer was washed with Hz0 (3 x 20 mL), dried (NaZS04), filtered and concentrated and purified by chromatography to give an oil (575 mg, 70%). (TLC
50%
EtOAGhexanes (NH3) R, 0.56) B~ 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.0=]dodeca-2(7),3,5-trien-10-yl)-ethanone 2,2,2-Trifluoro-1-(4-hydroxy-5-vitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trim-10 yl)-ethanone (575 mg, 1.82 mmol) was hydrogenated in MeOH under a H2 atmosphere at (45 *.
psi) over 10%Pd/C (80 mg) for 1.5 hours then filtered through a Celite pad and concentrated to white solids (450 mg. 86%). (TLC 5% MeOH/CH2Clz (NH3) R, 0.6). 'H NMR (400 MHz, CD30D) b 6.67-6.59 (m, 2H), 4.12 (m, 1H), 3.73 (m, 1H), 3.73 (m, 1H), 3.51 (m, 1H), 3.07 (m, 2H), 2.24 (m, 1H), 1.94 (d, J=10.5 Hz. 1H). GCMS m/e 286 (M').
C~ 2,2,2-Trifluoro-1-(5-oxa-7,13-diazatetracyclo[9.3.1.02'-'°.0'=B]pentadeca-2(10),3,6,8-tetraene)-ethanone (Goldstein, S. W.; Darnbek, P. J. J. Het. Chern. 1990, 27, 335.) 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-ethanone (150 mg, 0.524 mmol), trimethyl orthoformate (0.19 mL, 1.73 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 18 mg, 0.07 mmol) and xylenes (10 mL) were combined under nitrogen and stirred at 135 °C for 18 hours. The mixture was cooled, treated with Hz0 and extracted with EtOAc. The extracts were dried (Na2S0,), filtered, concentrated and purified by chromatography to give an oil (110 mg, 71°~). (TLC
20°~ EtOAGhexanes R, 0.40) 5-Oxa-7,13-diazatetracyclo[9.3.1.OZ'-'°.0~=°]pentadeca-2( 10),3.6, 8-tetraene hydrochloride 2,2,2-Trifluoro-1-(5-oxa-7,13-diazatetracyclo[9.3.1.OZ''°.0''°jpentadeca-2( 10),3,6, 8-tetraene}-ethanone (110 mg, 0.37 mmol) was stirred in MeOH (5 mL) and treated with Na2C03 (78 mg, 0.74 mmol) in HZO (2 mL). The stirred mixture was warmed to 80 °C for 2 hours, concentrated to solids, diluted with H20 and extracted with EtOAc (3 x 40 mL).
The product was extracted into aqueous 1 N HCI solution (2 x 40 mL) which was washed with EtOAc then neutralized with saturated aqueous Na2C0~ solution to pH-10. The product was extracted with EtOAc (3 x 40 mL), dried (Na2S0,), concentrated and chromatographed on Silica gel to produce an oil. (TLC 5% MeOH/CHzCIZ (NH3) R, 0.19).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) then concentrated, stirred in a minimum of CHZCIz and saturated with hexanes: After 18 hours, the product was collected by filtration (55 mg, 63%). 'H NMR (400 MHz, CD30D) b 8.47 (s, 1 H), 7.70 (s, 1 H), 7.65 (s, 1 H), 3.41 (m, 2H), 3.30 (m, 2H), 3.10 (d, J=12.5 Hz, 2H), 2.47 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H). APCI MS rNe 201.03 [(M + 1 )'].
*Trade-mark 6-METHYL-5-OXA-7,13-DIAZATETRACYCLO[9.3.1.02''-°.04~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) 2,2,2-Trifluoro-1-(6-methyl 5-oxa-7,13-diazatetracyclo[9.3.1.02-'°.04=a entadeca-2(10),3,6,8-tetraene)-ethanone 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02']dodeca-2(7),3,5-trien-10-yl)-ethanone (150 mg, 0.524 mmol), methyl orthoacetate (0.34 mL, 1.83 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 20 mg, 0.08 mmol) and xylenes (10 mL) were combined under nitrogen and stirred at 135 °C for 18 hours. Workup, isolation and purification as in Example 28C provided the title compound (90 mg, 55%).
B) 6-Methyl-5-oxa-7,13-diazatetracyclo[9.3.1.02Wo.0~]pentadeca-2(10),3,6,8-tetraene hydrochloride 2,2,2-Trifluoro-1-(6-methyl 5-oxa-7,13-diazatetracyclo[9.3.1.02''°.0'''e]pentadeca 2(10),3,6,8-tetraene)-ethanone (90 mg, 0.30 mmol) was stirred in MeOH (5 mL) and treated with Na2C03 (61 mg, 0.58 mmol) in H20 (2 mL). The stirred mixture was warmed to 80 °C for 2 hours, concentrated to solids, diluted with H20 and extracted with EtOAc (3 x 40 mL). The solution was dried (Na2S04), concentrated, and chromatographed on Silica gel to produce an oil. (TLC 10% MeOH/CHZCIZ (NH3) Rf 0.18). 'H NMR (free base) (400 MHz, CDC13) 8 7.40 (s, 1H), 7.26 (s, 1H), 3.05-2.98 (m, 4H), 2.72 (d, J=12.8 Hz, 2H), 2.59 (s, 3H), 2.46 (m, 1H), 1.98 (d, J=10.5 Hz, 1 H).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) then concentrated, stirred in a minimum of CHzCIz and saturated with hexanes. After 18 hours, the product was collected by filtration (10 mg, 13%). APCI MS m/e 215.2 [(M + 1 )+], mp >250 °C.
2-FLUORO-N-(5-HYDROXY-10-AZA-TRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIEN-4-YL)-BENZAMiDE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2{7),3,5-trien-10-yl)-ethanone {150 mg, 0.524 mmol), 2-fluorobenzoyl chloride (0.07 mL, 0.576 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 20 mg, 0.08 mmol), pyridine (0.046 mL, 0.576 mmol) and xylenes (5 mL) were combined under nitrogen and stirred at 135 °C
for 18 hours. After 24 hours, additional PPTS (50 mg) was added and the material stirred at 135 °C for an additional 24 hours. Workup as above provided crude product {145 mg, 0.375 mmol) which was combined with Na2C03(s) (80 mg, 0.75 mmol) in MeOH (5 mL) and HZO (2 mL) and heated to reflux. After 3 hours, the reaction was cooled and diluted with water then extracted with CHZCI2 (4 x 40 mL), dried through a cotton plug then chromatographed to remove baseline impurity (5% MeOH/CH2C12 (NH3)). The crude material was treated with excess 3N
HCI
EtOAc and concentrated, then dissolved in a minimum of MeOH and the solution was saturated with Et20 and stirred. After stirring 4 hours the product was collected by filtration (85 mg, 68%). 'H NMR (400 MHz, CD30D) b 7.99 (m, 2H), 7.59 (m, 1H), 7.36-7.23 (m, 2H}, 6.82 (s, 1 H), 2.99 (m, 4H), 2.78 (m, 2H), 2.35 (m, 1 H), 1.96 (d, J=10.5 Hz, 1 H). APCI MS m/e 313.1 [(M + 1 )+], mp 125-130 °C (subl.).
4~CHLORO-10,AZATRICYCLO(6.3.1.~2(>),3,5-1RIENE HYDROCHLORIDE
A) 1-(4-Chloro-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone Copper(I)chloride (CuCI) was prepared as follows: CuS04 (4.3 g) and NaCI (1.2 g) were dissolved in hot H20 (14 mL). sodium bisulfite (NaHS03) (1 g) and sodium hydroxide (NaOH) (690 mg) were dissolved in H20 {7 mL) and added to the hot acidic solution over 5 minutes. The precipitated white solids were filtered and washed with water.
1-(4-Amino-10-aza-tricyclo[6.3.1.OZ~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (460 mg, 1.7 mmol) was dissolved in H20 (2 rnL) and concentrated HCI
solution{1 mL) then cooled to 0 °C and treated with a solution of sodium nitrite (NaN02) (275 mg) in H20 (1 mL) dropwise. To the resulting solution was added a CuCI (202 mg, prepared as described above, 2.04 mmol) in concentrated HCI solution (2 mL) over 10 minutes (gas evolution observed). The resulting solution was warmed to 60 °C for 15 minutes, then was cooled to room temperature and extracted with EtOAc (4 x 30 mL). After drying over NaZS04, the solution was filtered and concentrated to an oil which was filtered through a Silica pad to remove baseline material eluting with 50% EtOAc/hexanes to give an oil {470 mg, 95%).
B) 4-Chloro-10-azatricyclo(6.3.1.Oj'-]dodeca-2(7),3,5-triene hydrochloride 1-(4-Chloro-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (470 mg, 1.62 mmol) and NazC03 (344 mg, 3.24 mmol) in MeOH (30 mL) and H20 (10 mL) were heated to reflux. After 2 hours, the reaction was cooled and diluted with water then extracted with EtOAc {4 x 40 mL), dried (Na2S04), filtered and concentrated to a yellow oil. The crude material was treated with excess 3N HCI EtOAc and concentrated, then dissolved in a minimum of CHZCIZ and the solution was saturated with hexanes and stirred.
After stirring 4 hours the product was collected by filtration {155 mg, 42%).
'H NMR (free base) (400 MHz, CDCI3) 8 7.15 (m, 2H), 7.09 (d, J=8.0 Hz, 1 H), 3.00-2.94 (m, 4H), 2.68, (m, 2H), 2.38 (m, 1H), 1.92 (d, J=10.5 Hz, 1H).'H NMR (HCI salt) (400 MHz, DMSO-ds) 8 7.30 7.20 (m, 3H), 3.30-3.15 (m, 6H), 2.37 (m, 1 H), 1.89 (d, J=11.0 Hz, 1 H). APCI
MS m/e 194.1 [(M + 1 )+).
FXAMPI F ~~
10-AZATRICYCLO[6.3.1.0~2,7~]DODECA-2(7),3,5-TRIEN-4-YL CYANIDE
HYDROCHLORIDE
A) 1-(4-lodo-10-aza-tricyclo[6.3.1.Oz-']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone 1-(4-Amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-trien-10-yl)-2,2,2-trifluoro-ethanone (500 mg, 1.85 mmol) was dissolved in H20 (5 mL) and concentrated HZS04 solution (0.5 mL) then cooled to 0 °C and treated with a solution of sodium nitrite (NaNOz) (140 mg, 2.04 mmol) in HZO (2 mL) dropwise. Potassium iodide (460 mg, 2.78 mmol) in 1 N
solution (0.5 mL) was added over 10 minutes (reaction becomes dark red). The resulting solution was warmed to room temperature and stirred 18 hours. The reaction was quenched with NaHS03 and water (pH 2.5) then extracted with EtOAc (4 x 30 mL). After drying (NaZS04), the solution was filtered and concentrated to a yellow oil which was chromatographed on Silica gel to provide a yellow oil. (260 mg, 37%). (TLC 30%
EtOAc/hexanes R, 0.70). (A 5.4 g scale performed as above yielded 5 g, 67%).
B) 4-lodo-10-aza-tricyclo[6.3.1.OZ-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 1-(4-lodo-10-aza-tricyclo[6.3.1.OZ'')dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (5 g, 13.1 mmol) and 37% saturated aqueous NH40H solution (50 mL) were stirred in MeOH (250 ml) for 2 hours then concentrated and azeotroped with MeOH (2 x 50 mL). The resulting product was stirred in 1,4-dioxane (75 mL) and treated with saturated NaZC03 solution (15 mL). To this was added di-t-butyldicarbonate (5.71 g, 26.2 mmol).
After stirring 18 hours the reaction was treated with H20 ( 50 mL) and extracted with CHZCIZ
(4 x 30 mL), dried (Na2S04), filtered, concentrated and chromatographed on Silica gel (TLC
20%
EtOAc/hexanes) to provide product as an oil (4.9 g, 98%).
C) 4-Cyano-10-aza-tricycio(6.3.1.0~']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester (Utilizing the methods described in: House, H. O.; Fischer, W. F.
J. Org. Chem.
1969, 3626. ) CuCN (108 mg, 1.21 mmol) and NaCN (59 mg, 1.21 mmol) were combined in dry DMF (6 mL) and warmed to 150 °C under NZ. Solution occurs in 20 minutes. To this was added 4-iodo-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (232 mg, 0.6 mmol) in DMF (3.5 mL) and the mixture was stirred for 18 hours at 150 °C.
The reaction was cooled and diluted with 50% saturated aqueous NaCI solution and extracted with 50% EtOAc/hexanes (3 x 30 mL). After drying (NazS04), filtration and concentration the product was isolated by chromatography (86 mg, 50%). (TLC 20% EtOAc/hexanes R~
0.28).
D) 10-Azatricyclo[6.3.1.0--2,7~]dodeca-2(7),3,5-men-4-vl cyanide hydrochloride 4-Cyano-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester was treated with 3N HCI EtOAc (6 mL) and warmed to reflux for 2 hours, then concentrated, dissolved in a minimum of MeOH which was saturated with Et20 and stirred 18 hours. The product was collected by filtration (49 mg, 73%). 'H NMR (400 MHz, DMSO-ds) b 9.66 (br s, NH), 7.86 (br s, NH), 7.74-7.70 (m, 2H), 7.49 (d, J=7.5 Hz, 1 H), 3.33-2.97 (m, 6H), 2.17 (m, 1 H), 2.01 (d, J=11.0 Hz, 1 H). GCMS m/e 184 (M'). mp 268-273 °C.
FX~~ADI G Q0.
3-(10-AZATRICYCLO(6.3.1.02-']DODECA-2(7),3,5-TRIEN-4-YL)-5-METHYL-1 2 4-OXADIAZOLE HYDROCHLORIDE
4-Cyano-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (300 mg, 1.1 mmol) was stirred in EtOH (10 mL). To this hydroxyl amine hydrochloride (382 mg, 5.5 mmol) and NaOH (242 mg, 6.05 mmol) were added and the mixture was warmed to reflux. After 45 minutes, the reaction was cooled, diluted with H20 and extracted with EtOAc. The organic layer was dried (NaZS04) and concentrated to afford a yellow solid (110 mg, 0.35 mmol). This solid was dissolved in pyridine (1 mL) and treated with acetyl chloride (0.03 mL, 0.415 mmol) and warmed to 100°C for 18 hours. The reaction was cooled, treated with Hz0 and extracted with EtOAc. The organic extracts were washed with water and saturated aqueous NaCI solution, dried (Na2S04) and concentrated.
Chromatography on Silica gel afforded product (50 mg, 0.15 mmol). (25% EtOAclhexanes R, 0.18).
This product was treated with 2N HCI MeOH (10 mL), heated to 70 °C for 1 hour, cooled, concentrated and recrystallized from MeOH/Et20 to provide product (15 mg). APCI MS m/e 242.2 [(M + 1 )'].
EXAMPI F ~d 1-( 10-AZATRICYCLO[6.3.1.02--']DODECA-2(7),3, 5-TRIEN-4-YL)-1-ETHANONE
HYDROCHLORIDE
A) 1-(4-Acetyl-10-aza-tricyclo[6.3.1.Oz-']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (253 mg, 1.0 mmol) and AcCI (0.68 mL, 10 mmol) were dissolved in DCE (3 mL) and treated with aluminum chloride (AICI3) (667 mg, 5.0 mmol). The resulting yellow mixture was stirred for 30 minutes then poured over ice and saturated aqueous NaHC03 solution. After stirring 20 minutes the mixture was extracted with CHzCl2 (3 x 30 mL). The organic layer was dried through a cotton plug then concentrated to a orange-yellow oil (255 mg, 86%).
B) 4-Acetyl-10-aza-tricyclo[6.3.1.02-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester 1-{4-Acetyl-10-aza-tricycio[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (1.3 g, 4.37 mmol) and 37% aqueous NH40H solution (10 mL) were stirred in MeOH
(30 ml) for 3 hours, then concentrated and azeotroped with MeOH (2 x 50 mL).
(This product could be converted to an HCI salt directly: see the next example.) The resulting product was stirred in 1,4-dioxane (20 mL) and treated with saturated aqueous Na2C03 solution (5 mL). To this was added di-t-butyldicarbonate (1.91 g, 8.74 mmol). After stirring 2 hours, the reaction was treated with H20 (50 mL), extracted with CHzCIZ (4 x 30 mL), dried (Na2S04), filtered, concentrated and chromatographed to provide an oil (1.3 g, 100%). (TLC 40%
EtOAc/hexanes Rt 0.56).
C) 1-(10-Azatricyclo[6.3.1.OJ'-]dodeca-2(7},3,5-men-4-yl)-1-ethanone hydrochloride 4-Acetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tent-butyl ester (190 mg, 0.63 mmol) was treated with excess 3N HCI EtOAc and warmed to 70°C for 1 hour then concentrated and dissolved in a minimum of MeOH. The resulting solution was saturated with EtzO and stirred. After 18 hours the white crystalline product was collected by filtration (81 mg, 54%). 'H NMR (400 MHz, DMSO-ds) b 9.75 (br s, NH), 7.89 (s, 1H), 7.88 (d, J=8.0 Hz, 1 H), 7.74 (br s, NH), 7.44 (d, J=8.0 Hz, 1 H), 3.33 (br s, 2H), 3.22 (br s, 2H), 3.00 (br m, 2H), 2.54 (s, 3H), 2.17 (m, 1 H), 2.02 (d, J=11.0 Hz, 1 H). GCMS m/e 201 (M+). mp 198-202 °C.
R~° N O
N--~-CF X
H S
R'° N
-R~° XI
~N
S \
Scheme 6 continued H
R~° N S
N~-R'° XI
S
S
R ~ \ NH IF
N ~ ~-'' Scheme 7 X~
\ \
A I / XZ A I /
{ring A = present or (ring A = present or absent) absent) XI II
XII
OH
A
OH
{ring A = present or absent) XIIIA
\
A N
(ring A = present or absent) XIV
A I NH
IG: (R2 and R3 form ring A) III: (ring A = absent) Scheme 8 R~8 R,s ' R'8 \ .\ I
--' ~ --_ F ~ F
XV XVI XVII
(R~8 = F or (C~-Cs)alkoxy) R'8 Rya OH
N
\ ~C H "
"- 6 5 OH
XIX
XVIII
R'8 R' 8 O
i I \NH \ N CF3 XX
IH
XXI
Scheme 9 NH
R'R8N02S
IJ
O~CF3 N
CI /
~N H
CI
IK
lV
R~3 \ NH
I
O
IL
_22_ Scheme 10 ~NH
\
CI
IM
~NH
OyCF3 NC \
IN
IN
NH2 / , ~NH
IX' H2N
IP
OII / I ~NH
R,s~N \
IQ
c , r , , ~ r , t a c < , r r , , , , , , ~ < < , , , , , r , . - 23 - ,- , a a , , , < , ' , , , a a a , a ~ , , , ".a ~,' a,' ", Scheme 1-10 illustrate methods of synthesizing compounds of the formula 1 .
Referring to Scheme 1, the starting material of formula III is reacted with trifluoroacetic anhydride, in the presence of pyridine, to form the compound of formula IV.
This reaction is typically conducted in methylene chloride at a temperature from about 0°C to about room temperature.
The compound of formula IV is then converted into the dinitro derivative of formula IIA
by the following process. The compound of the formula IV is added to a mixture of 4 or more equivalents of trifluoromethanesulfonic acid (CF3SOZOH) and 2 to 3 equivalents of nitric acid, in a chlorinated hydrocarbon solvent such as chloroform, dichloroethane (DCE) or methylene chloride. The resulting mixture is allowed to react for about 5 to 24 hours.
Both of the foregoing reactions are generally conducted at a temperature ranging from about -78°C to about 0°C for about 2 hours, and then allowed to warm to room temperature for the remaining time.
Reduction of the compound of formula IIA, using methods well known to those of skill in the art, yields the compound of formula I1B. This reduction can be accomplished, for example, using hydrogen and a palladium catalyst such as palladium hydroxide and running the reaction in methanol at about room temperature.
Referring to Scheme 2, the compound of formula IlA is converted into the corresponding compound wherein the trifluoroacetyl protecting group is replaced by a t-Boc protecting group (VIA) by reacting it first with an alkali metal or alkaline earth metal (or ammonium) hydroxide or carbonate, and then reacting the isolated product from the foregoing reaction with di-t-butyldicarbonate. The reaction with the alkali or alkaline earth metal (or ammonium) hydroxide or carbonate is generally carried out in an aqueous alcohol, dioxane or tetrahydrofuran (THF) at a temperature from about room temperature to about 70°C, preferably at about 70°C, for about one to about 24 hours. The reaction of the isolated, unprotected amine or an acid addition salt of such amine, from the above reaction with di-t-butyldicarbonate is preferably carried out in a solvent such as THF, dioxane or methylene chloride at a temperature from about 0°C to about room temperature. This reaction may or may not be conducted in the presence of a base. When the reactant is a salt of the amine, use of a base is preferred. The resulting compound of formula VIA can be converted into the corresponding diamino derivative of formula VIB
using the procedure described above for converting the dinitro compound of formula 11A
into the corresponding diamino compound of formula IIB.
The conversion of the compound of formula VIB into the desired compound of the formula VII can be accomplished by reacting the compound of formula VIB with a compound of the formula SUBSTITUTE PAGE
~,~:-CEO s c r r t , a r c r , r a c a r - ~r~ r r , c c r r r c r r , , r r r , r r r c « r « r r r r- r r r r < r r c c r r c , c r r r « r r r c c r r HsCzOa CZHs XXI IA
i zHs wherein R'° is hydrogen, (C~-C6)alkyl optionally substituted with from one to seven fluorine atoms, aryl-(C°-C3)alkyl wherein said aryl is selected from phenyl and naphthyl, or heteroaryl-(C°
-C3)alkyl wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C~ -C6)alkyl optionally substituted with from one to seven fluorine atoms, (C, -C6)alkoxy optionally substituted with from one to seven fluorine atoms and cyano. The preferred solvent for this reaction is a 10:1 mixture of ethanol:acetic acid. The reaction temperature can range from about 40°C to about 100°C. It is preferably about 60°C. Other appropriate solvents include acetic acid, ethanol and isopropanol.
Alternate methods of preparing compounds of the formula VII the compound of formula VIB are described by Segelstein et al., Tetrahedron Lett., 1993, 34, 1897.
Removal of the t-Boc protecting group from the compound of formula VII yields corresponding compound of formula IA. The protecting group can be removed using methods well known to those of skill in the art. For example, the compound of formula VII can be treated with an anhydrous acid such as hydrochloric acid, hydrobromic acid, methanesulfonic acid, or trifluoroacetic acid, preferably hydrochloric acid in ethyl acetate, at a temperature from about 0°C to about 100°C, preferably from about room temperature to about 70°C, for about one to 24 hours.
The compound of formula VII can be converted into the corresponding compound of formula IB by reacting it with a compound of the formula R"Z, wherein R" is defined as R'° is defined above, and Z is a leaving group such as a halo or sulfonate (e.~Lc ., chloro, bromo, mesylate or tosylate), in the presence of a base such as an alkali metal hydride, hydroxide or carbonate, preferably potassium hydroxide, in a polar solvent such as water, dimethylsulfoxide (DMSO), THF or DMF, preferably a mixture of DMSO and water, and then removing the protecting group as described above. The reaction with R"Z is generally carried out at a temperature from about room temperature to about 100°C, preferably at about 50°C, for about five hours.
SUBSTITUTE PAGE
~,~oEv t. t t t ( 4 ( S < f t 1 f f t t t f ( 4 1 ( ( t ( ~~ t t t f 1 ~7 1 ( t 4 f 1 t < <
f 1 ( ( t l ( f t t t ( t f ( 1 1 4 f t ( ( f 1 f ( ( < ( ( t t ( C f t f ( f C
Scheme 3 illustrates an alternate method of preparing compounds of the formula IB
from the compound of formula VIA. This method is the preferred method of making compounds of the formula IB wherein R" is a bulky group such as an aryl or heteroaryl containing group, or when R" can not be attached, as illustrated in Scheme 2, by alkylation or aryl substitution methods. Referring to Scheme 3, the compound of formula VIA
is reacted with the appropriate compound of formula R"NHZ in a polar solvent such as THF, DMF or DMSO, preferably THF, at a temperature from about room temperature to about 100°C, preferably at the reflux temperature, for about four to eighteen hours. The resulting compound of formula XXIII is then converted into the corresponding compound of the formula XXIV by reducing the vitro group to an amino group using methods well known to those of skill in the art. Such methods are referred to above for the conversion of the compounds of the formula IIA into a compound of the formula IIB in Scheme 1, and exemplified in experimental Examples 12B and 18B. Closure of the imidazole ring to form the corresponding compound of formula XXV can then be accomplished by reacting the compound of formula XXIV from the above reaction with a compound of the formula XXI IA
R'° OC2H5 wherein R'° is defined as above, as described above for converting compounds of the formula VIB into those of the formula VII.
Removal of the protecting group from the compound of formula XXV yields the corresponding compound of formula IB. This can be accomplished using methods well known in the art, for example, as described above for forming compounds of the formula IA
from the corresponding compounds of the formula VII.
Scheme 4 illustrates a method of preparing compounds of the formula IC, wherein R'° and R" are as defined above. Referring to Scheme 4, the compound of formula VIB is reacted with a compound of the formula OH
S03Na Na03S
OH
SUBSTITUTE PAGE
~~~ S~~
(sodium bisulfate ethane dione addition adduct) in water or another polar solvent such as THF, DMF or DMSO, preferably a mixture of water and a water miscible solvent such as THF, for about one to four hours. The reaction temperature can range from about 40°C to about 100°C, and is preferably at about the reflux temperature.
Alternatively, the compound of formula VIB can be reacted with a compound of the formula O
R"
Rio O
(double condensation reaction) in a polar solvent such as THF, water, or acetic acid, preferably a mixture of water and THF. This reaction is typically carried out at a temperature from about 40°C to about 100°C, preferably at the reflux temperature, for about two to four hours.
The desired quinoxoline of formula IC can then be formed by deprotecting the compound formed in either of the foregoing reactions, using the method described above for converting a compound of the formula VII into one of the formula IA.
Scheme 5 illustrates a method of preparing compounds of the formula 1 wherein R2 and R3, together with the benzo ring to which they are attached, form a benzoxazole ring system.
Such a compound, wherein R' is hydrogen, is depicted in Scheme 5 as chemical formula IE.
Referring to Scheme 5, the compound of formula XXII, wherein Y is vitro, halo, trifluoromethanesulfonate or a diazonium salt, is reacted with potassium acetate or another alkali or alkaline earth metal carboxylate in a solvent such as dimethylsulfoxide (DMSO), DMF or acetonitrile, preferably DMSO. This reaction is generally allowed to run for about 12-24 hours.
Appropriate reaction temperatures range from about 70°C to about 140°C. Approximately 100°C
is preferred.
The above reaction yields the compound of formula VIII, which can then be converted into the desired compound having formula IE by the following procedure. First, the compound of formula VIII is reduced by reaction with hydrogen and a palladium or platinum catalyst such as palladium hydroxide in methanol at a temperature from about 0°C to about 70°C, preferably at about room temperature, to form the corresponding amino derivative. The product of this reaction is then reacted with an acid chloride of the formula R'°COCI
or an acid anhydride of the formula (R'°CO)ZO wherein R'° is (C~-C6)alkyl, or a compound of the formula R'°C(OCZHS)3, in an appropriate inert solvent such as decalin, chlorobenzene or xylenes. A
mixture of xylenes is ' « ~' L< <
., , « ' r ~, r , ' ,', _27=,~ , : ~ , a , ' , < < < < < ' < ~ ' a ' < < < a ~ , a a , < «~a « « W «
preferred. This reaction is typically conducted at a temperature from about 120-150°C, preferably at about 140°C. When R'°COCI is used as a reactant, it is preferable to add a stoichiometric amount of triethylamine (TEA) or another organic tertiary amine base and a catalytic amount of pyridinium p-toluenesulfonic acid or pyridinium p-toluenesulfonate (PPTs) to the reaction mixture. When R'°C(OCzH~)3 is used as a reactant, it is preferable to add a catalytic amount of PPTs to the reaction mixture.
Removal of the trifluoroacetyl nitrogen protecting group yields the desired compound of the formula IE. This can be accomplished using methods well known to those of skill in the art, for example, reacting the protected compound with a lower alkanol and an aqueous alkali or alkaline earth metal (or ammonium) hydroxide or carbonate, aqueous sodium carbonate, at a temperature from about 50°C to about 100°C, preferably at about 70 ° C, for about two to six hours.
Scheme 6 illustrates the preparation of compounds of the formula I wherein R' is hydrogen and RZ and R3, together with the benzo ring to which they are attached, form a benzothiazole ring system. Referring to Scheme 6, the compound of formula 111 is reacted with trifluoroacetic anhydride to form the con-esponding compound wherein the ring nitrogen is protected by a trifluoroacetyl group, and the resulting nitrogen protected compound is then reacted with two equivalents of trifluoromethanesulfonic anhydride and one equivalent of nitric acid to form the corresponding compound of formula IX, wherein there is a single vitro substituent on the benzo ring. The reaction with trifluoroacetic acid is typically conducted in the presence of pyridine. Both of the above reactions are typically conducted in a reaction inert solvent such as a chlorinated hydrocarbon solvent, preferably methylene chloride, at a temperature from about 0°C to about room temperature, preferably at about room temperature.
The above transformation can also be accomplished usihg other nitration methods known to those skill in the art.
Reduction of the vitro group to an amine group can be accomplished as described above to provide a compound of the formula IX'.
The compound of formula IX' is then reacted with a carboxylic acid halide or anhydride of the formula R'°COX or (R'°CO)20, wherein X is halo and R'° is hydrogen or (C,-C6)alkyl, and pyridine, TEA or another tertiary amine base, to form a compound of the formula X, which can then be converted to the desired compound having formula XI by reacting it with Lawesson's reagent, which is depicted below.
SUBSTITUTE PAGE
A~~~~ ~CIE~
H3C~0 \ . P~S~P S
S ~ ~S~
\ I ~CH3 O
The reaction with R'°COX, wherein X is halo, or (R'°CO)20 is generally carried out at a temperature from about 0°C to about room temperature, preferably at about room temperature. The reaction with t_awesson's reagent is generally carried out in a reaction inert solvent such as benzene or toluene, preferably toluene, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature.
Closure to the benzothiazole ring and nitrogen deprotection to form the desired compound of formula IF can be accomplished by reacting the compound of formula XI with potassium ferricyanide and sodium hydroxide in a mixture of water and methanol (NaOH/H20/CH30H), at a temperature from about 50°C to about 70°C, preferably at about 60°C for about 1.5 hours.
Scheme 7 illustrates a method of preparing the compound of formula III, which is used as the starting material for the process of Scheme 1, or a compound of the formula IG, wherein R2 and R3 form a ring (labeled "A" in the Scheme), as defined above in the definition of compounds of the formula I. Referring to Scheme 7, the compound of formula XII, wherein X' and Xz are selected, independently, from chloro, fluoro, bromo and iodo, but where at least one of X' and XZ is Br- or I-, reacted with cyclopentadiene, in the presence of magnesium metal, in a THF, dioxane or other ethereal solvent, at a temperature from about 40°C to about 100°C, preferably at about the reflux temperature, to form a compound of the formula XIII.
Reaction of the resulting compound of formula XIII with N-methylmorpholine-N-oxide (NMO) and osmium tetroxide in acetone at about room temperature yields the corresponding compound of the formula XIIIA.
The compound having formula XIIIA is then converted into the corresponding compound of formula XIV using the following procedure. First, the compound of formula XIIIA
is reacted with sodium periodate in a mixture of a chlorinated hydrocarbon, preferably dichloroethane (DCE), and water, or with lead tetraacetate in a chlorinated hydrocarbon solvent, at a temperature from about 0°C to about room temperature, to generate a dialdehyde or glycal intermediate. The product of this reaction is then reacted with benzylamine and sodium triacetoxyborohydride in a chlorinated hydrocarbon solvent at a temperature from about 0°C to about room temperature, preferably at about room temperature, to form the desired compound of formula XIV. Removal of the benzyl group from the compound of formula XIV yields the compound of formula III (when ring A is absent) or IG, (when ring A is present). This can be accomplished using methods well known to those of skill in the art, for example, optionally reacting the free base with one equivalent of acid, e.~c ., hydrochloric acid, (to form the corresponding acid addition salt), followed by hydrogen and palladium hydroxide in methanol at about room temperature.
In the reductive animation step described above and throughout this document, alternatives to benzyl amine, such as ammonia, hydroxylamine, alkoxy amines, methyl amine, allyl amine, and substituted benzyl amines (e.~c ., diphenylmethyl amine and 2-and 4-alkoxy substituted benzyl amines) can also be used. They can be used as free bases, or as their salts, preferably their acetate salts, and can be subsequently removed by methods described for each by T. W. Greene and G.M. Wuts, "Protective Groups in Organic Synthesis", 1991, John Wiley & Sons, New York, NY.
The procedure of Scheme 7 can also be used to prepare compounds of the formula I
wherein R2 and R3 do not form a ring and are not both hydrogen, by replacing the starting material of formula XII with the appropriate compound having the formula R2 X' XII
Scheme 8, 9 and 10 illustrate methods of preparing compounds of the formula I
wherein R' is hydrogen, and Rz and R3 represent a variety of different substituents, as defined above, but do not form a ring.
Scheme 8 illustrates a variation of the process shown in Scheme 7, which can be used to make a compound identical to that of formula III except that the benzo ring is substituted with a fluoro group or an alkoxy group (R'$ in Scheme 8). This compound is depicted in Scheme 8 as chemical structure 1 H. Referring to Scheme 8, where, for example, R'8 is F, 1,3-difluorobenzene is reacted with a strong base such as an alkali metal dialkylamine or an alkali metal alkyl (or aryl) in an ethereal solvent such as ethyl ether or THF, at a temperature below -50°C, followed by quenching with iodine or N-iodosuccinamide, to form 1,3-difluoro-2-iodobenzene. The compound 1,3-difluoro-2-iodobenzene (structural formula XVI
in Scheme 8) is then converted into the compound of formula IH by a series of reactions (represented in Scheme 8 as XVI~XVII->XVIII~XIX-->IH) that are analogous to the series of reactions described above and illustrated in Scheme 7 for converting compounds of the formula XIII into those of the formula IG or II1. Conversion of the compound of formula XVl into the compound of formula XVII can also be accomplished by treating a mixture of the compound of formula XVI
and cyclopentadiene with an alkyl lithium reagent, preferably n-butyl lithium, in an inert hydrocarbon solvent such as petroleum ether or methyl cyclohexane, at a temperature from about -20°C to about room temperature, preferably at about 0°C.
The compound of formula IH can then be converted into the corresponding nitrogen protected derivative of formula XX, using the methods described above for synthesizing the compound of formula IV in Scheme .1. Nitration of the compound of formula XX
using the method described above for preparing the compound of formula IX in Scheme 6, yields the compound of formula XXI wherein the benzo ring is substituted with both a fluoro and nitro group or an alkoxy group and nitro group. The compound of formula XXI can be used to make a variety of compounds of the formula I wherein one of RZ and R3 is fluoro, using methods that are well known to those of skill in the art, for example, by ftrst converting the vitro group to an amino group, converting the amino group to a variety of other substituents, as illustrated in Scheme 10, and then removing the nitrogen protecting group.
The compound of formula XXI acts as a regioisomeric functional equivalent of the compounds having formulas IIA, VIA and XXII, in that the fluorine atom of formula XXI reacts similarly to the vitro and Y groups of formula IIA, VIA, and XXI1, and thus can be subjected to the same series of reactions as those described above for the latter three compounds, providing an alternate means for preparing the products of such reactions. Similarly, the alkoxy group of formula XXI (R'e=alkoxy) may be converted into a hydroxyl group before or after introduction of the vitro group, and then converted to isomeric products as described above.
Also, the trifluoromethanesulfonate salt of such hydroxy derivative can act as a Y-group as described.
Preparation of compounds of formula I where RZ = -O(C~-Cs)alkyl, (C~-Cs) alkyl or aryl wherein aryl is defined as above in the definition of formula I, and R3 is H
or one of the other substituents described above in the definition of formula I, can be prepared as described above and illustrated in Scheme 8 by replacing one of the fluorine atoms of the compound of formula XV with -O-(C~-Cs)alkyl, (C,-Cs)alkyl or aryl, respectively.
Scheme 9 illustrates methods of preparing compounds of the formula I wherein:
(a) R' is hydrogen and RZ is R'R8N02S-; (b) R' and RZ are both chloro; and {c) R' is hydrogen and RZ
is R'3C(=O)-. These compounds are referred to in Scheme 9, respectively, as compounds of formulas IJ, IK and IL.
: ~: : ~, _31'- < <
": ~ . , < < , , ' ~ : : : ' , ' ~ a <
< < ~ , ~ : a < < , ~~ "' ~' Referring to Scheme 9, compounds of the formula IJ can be prepared by reacting the compound of formula 1V with two or more equivalents of a halosulfonic acid, preferably chlorosulfonic acid, at a temperature from about 0°C to about room temperature. Reaction of the chlorosulfonic acid derivative so formed with an amine having the formula R'R$NH, wherein R' and RB are defined as above, followed by removal of the nitrogen protecting group, yields the desired compound having formula IJ.
Compounds of the formula IK can be prepared by reacting the compound of formula IV with iodine trichloride in a chlorinated hydrocarbon solvent, followed by removal of the nitrogen protecting group. The reaction with iodine trichloride is typically carried out at a temperature from about 0°C to about room temperature, and is preferably carried out at about room temperature. In a similar fashion, the analogous mono- or dibrominated or mono- or diiododinated compounds can be prepared by reacting the compound of IV with N-iodosuccinimide or N-bromosuccinimide in a trifluoromethanesulfonic acid solvent, followed by removal of the nitrogen protecting group as described above.
Reaction of the compound of IV with an acid halide of the formula R'3COCI or an acid anhydride of the formula (R'3C0)20, with or without a reaction inert solvent such as a chlorinated hydrocarbon solvent, preferably methylene chloride, in the presence of Lewis acid such as aluminum chloride, at a temperature from about 0°C to about 100°C, followed by nitrogen deprotection, yields the compound of formula IL. The reaction with the acid halide or anhydride can be carried out using other known Lewis acids or other Friedel-Crafts acylation methods that are known in the art.
The reactions described herein in which NOz, -SOzNR'R8, -COR'3, I, Br or CI
are introduced on the compound of formula IV, as depicted in Scheme 9 and described above, can be performed on any analogous compound wherein RZ is hydrogen, (C,-Cs)alkyl, halo, (C,-Cs)alkoxy or -NHCONR'RB, producing compounds of the formula 1 wherein R2 and R3 are defined as in the definition of compounds of the formula I above.
Compounds that are identical to those of the formula IL, but which retain the nitrogen protecting group, can be converted into the corresponding O-acyl substituted compounds, i.e., those wherein the -C(=O)R'3 group of formula IL is replaced with a -O-C(=O)R'3 group, using Baeyer-Villiger processes well known to those skilled in the art. The resulting compounds can be partially hydrolyzed, as described in Example 35, to yield the corresponding hydroxy substituted compounds, and then alkylated to form the corresponding alkoxy substituted compounds. Also, as described in Example 36, such O-acyl substituted compounds can be used to prepare variably substituted benzisoxazoles.
SUBSTITUTE PAGE
l~~t~ SHEET
Scheme 10 illustrates methods of making compounds of the formula I wherein:
(a) R' is hydrogen and RZ is chioro; (b) R' is hydrogen and RZ is cyano; (c) R' is hydrogen and RZ is amino; and (d) R' is hydrogen and Rz is R'3C(=O)N(H)-. These compounds are referred to in Scheme 10, respectively, as compounds of the formula IM, IN, IP and IQ.
Compounds of formula IM can be prepared from compounds of the formula IX' by generation of a diazonium salt with, for instance, an alkali metal nitrite and strong mineral acid (e.~c ., hydrochloric acid, sulfuric acid, hydrobromic acid) in water, followed by reaction with a copper halide salt, such as copper (I) chloride. Nitrogen deprotection by the methods described above yields the desired compound of formula IM. Alternative methods for the generation of diazonium salts, as known and practiced by those of skill in the art, can also be used. The foregoing reaction is generally carried out by temperatures ranging from about 0°C
to about 60°C, preferably about 60°C for about 15 minutes to one hour.
Reaction of the diazodium salt, prepared as described above, with potassium iodide in an aqueous medium provides the analogous iodide derivative. This reaction is generally carried out at a temperature from about 0°C to about room temperature, preferably at about room temperature. The resulting compound, or its analogous N-tert-butylcarbonate protected form, can be used to prepare the corresponding cyano derivative by reaction with copper (I}
cyanide and sodium cyanide in DMF, N,N-dimethylpropylurea (DMPU) or DMSO, preferably DMF, at a temperature from about 50°C to about 180°C, preferably about 150°C. Nitrogen deprotection as described above provides the desired compound of formula IM.
The above described iodide derivative can also be used to access a variety of other substituents such as aryl, acetylene and vinyl substituents, as well as the corresponding carbonyl esters and amides, by palladium and nickel catalyzed processes known to those of skill in the art, such as Heck, Suzuki and Stille couplings and Heck carbonylations.
Nitrogen deprotection of the compound of formula IX' provides the compound of the formula IP.
The compound of formula IX' can be reacted with a acyl group having the formula R"COCI or (R'3C0)ZO using the methods described above, followed by nitrogen deprotection to provide compounds of the formula IQ. In a similar fashion, treatment of the protected amine with a compound having the formula R'3SOzX, when X is chloro or bromo, followed by nitrogen deprotection, provides the corresponding sulfonamide derivative.
Other suitable amine protecting groups that can be used, alternatively, in the procedures described throughout this document include -COCF3, -COCCI3, -COOCH2CCI3, -COO(C,-Cs)alkyl and -COOCHzCsHS. These groups are stable under the conditions described herein, and may be removed by methods described for each in Greene's "Protective Groups in Organic Chemistry", referred to above.
In each of the reactions discussed above, or illustrated in Schemes 1-10, above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, with ambient pressure, i.e., about 1 atmosphere, being preferred as a matter of convenience.
The compounds of the formula I and their pharmaceutically acceptable salts (hereafter "the active compounds") can be administered via either the oral, transdermal (e.~c ., through the use of a patch), intranasal, sublingual, rectal, parenteral or topical routes.
Transdermal and oral administration are preferred. These compounds are, most desirably, administered in dosages ranging from about 0.25 mg up to about 1500 mg per day, preferably from about 0.25 to about 300 mg per day in single or divided doses, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 0.01 mg to about 10 mg per kg of body weight per day is most desirably employed. Variations may nevertheless occur depending upon the weight and condition of the persons being treated and their individual responses to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval during which such administration is carried out.
In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.
The active compounds can be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the several routes previously indicated. More particularly, the active compounds can be administered in a wide variety of different dosage forms, e.~c ., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, transdermal patches, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents. In addition, oral pharmaceutical compositions can be suitably sweetened andlor flavored. In general, the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc can be used for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar] as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration the active ingredient may be combined with various sweetening or flavoring agents, coloring matter and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
For parenteral administration, a solution of an active compound in either sesame or peanut oil or in aqueous propylene glycol can be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8), if necessary, and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
It is also possible to administer the active compounds topically and this can be done by way of creams, a patch, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.
Biological Assay The effectiveness of the active compounds in suppressing nicotine binding to specific receptor sites is determined by the following procedure which is a modification of the methods of Lippiello, P. M. and Fernandes, K. G. (in The Binding of L-['H]Nicotine To A
Single Class of High-Affinity Sites in Rat Brain Membranes, Molecular Pharm., _29, 448-54, (1986)) and Anderson, D. J. and Arneric, S. P. (in Nicotinic Receptor Bindin of 'H-Cystisine_, 3H-Nicotine and 3H-Methylcarmbamylcholine In Rat Brain, European J. Pharm., 253, 261-67 (1994)).
Procedure Male Sprague-Dawley* rats (200-300 g) from Charles River were housed in groups in hanging stainless steel wire cages and were maintained on a 12 hour lightldark cycle (7 a.m.-7 p.m. light period). They received standard Purina Rat Chow and water ad libitum.
The rats were killed by decapitation. Brains were removed immediately following decapitation. Membranes were prepared from brain tissue according to the methods of Lippiello and Femandez (Moles Pharmacol, 29, 448-454, (1986) with some modifications.
Whole brains were removed, rinsed with ice-cold buffer, and homogenized at 0° in 10 volumes of buffer (w/v) using a Brinkmann PolytronT'", setting 6, for 30 seconds. The buffer consisted of 50 mM Tris HCI at a pH of 7.5 at room temperature. The homogenate was sedimented by centrifugation ( 10 minutes; 50,000 x g; 0 to 4°C. The supernatant was poured off and the membranes were gently resuspended with the Polytron and centrifuged again (10 minutes; 50,000 x g; 0 to 4°C. After the second centrifugation, the membranes were resuspended in assay buffer at a concentraYron of l.Og1100mL. The composition of the standard assay buffer was 50 mM Tris HCI, 120 mM
NaCI, 5 mM KCI, 2 mM MgCl2, 2 mM CaCl2 and has a pH of 7.4 at room temperature.
Routine assays were performed in borosilicate glass test tubes. The assay mixture typically consisted of 0.9 mg of membrane protein in a final incubation volume of 1.0 mL. Three sets of tubes were prepared wherein the tubes in each set contained 50~L of vehicle, blank, or test compound solution, respectively. To each tube was added 200 pL of ['HJ-nicotine in assay buffer followed by 750 ~L of the membrane suspension. The final concentration of nicotine in each tube was 0.9 nM. The final concentration of cytisine in the blank was 1 pM. The vehicle consisted of deionized water containing 30 pL of 1 N acetic acid per 50 mL of water. The test compounds and cytisine were dissolved in vehicle. Assays were initiated by vortexing after addition of the membrane suspension to the tube. The samples were incubated at 0 to 4° C in an iced shaking water bath. Incubations were terminated by rapid filtration under vacuum through Whatman GFIBT''" glass fiber filters using a Brandeln'" mule-manifold tissue harvester. Following the initial filtration of the assay mixture, filters were washed two times with ice-cold assay buffer (5 m each). The filters were then placed in counting vials and mixed vigorously with 20 ml of Ready Safe''" (Beckman) before quantification of radioactivity. Samples were counted in a LKB
Wallach RackbetaT''" liquid scintillation counter at 40-50% efficiency. All determinations were in triplicate.
*Trade-mark Calculations Specific binding (C) to the membrane is the difference between total binding in the samples containing vehicle only and membrane (A) and non-specific binding in the samples containing the membrane and cytisine (B), i.e., Specific binding = (C) _ (A) - (B).
Specific binding in the presence of the test compound (E) is the difference between the total binding in the presence of the test compound (D) and non-specific binding (B), i.e. , (E) _ (D) - (B).
Inhibiflon = (1-((E)/(C)) times 100.
The compounds of the invention that were tested in the above assay exhibited ICS
values of less than 10 pM.
The following experimental examples illustrate, but do not limit the scope of, this invention.
10-AZA-TRICYCLO[6.3.1.02'']DODECA-2(7),3,5-TRIENE
A) 1,4-Dihydro-9 ,4-methano-naphthalene (Based wholly or in part on a) Wittig, G.; Knauss, E. Chem. Ber. 1958, 99, 895. b) Muir, D. J.; Stothers, J. B. Can. J. Chem. 1993, 71, 1290.) Magnesium turnings (36.5 g, 1.5 M) were stirred in anhydrous THF (250 mL) in a dried 2 L 3 neck round bottom flask equipped with a 250 mL non-equalizing addition funnel with a nitrogen (NZ) flow adapter, mechanical stirrer and efficient condenser equipped with a N2 flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle.
2-Fluorobromobenzene (2g) was added followed by 1 mL of 3N ethylmagnesium bromide (EtMgBr in THF). The addition funnel was charged with a mixture of cyclopentadiene (94.4 g, 1.43 M, Prepared by the method described in: Org. Syn. Col. Vol. V, 414-418) and bromofluorobenzene (250 g, 1.43 M) which was maintained at 0 °C in a separate flask by an ice bath, and transferred to the addition funnel via cannula. Small portions (~1 mL) of the intimate mixture were introduced to assist initiation (~4x). After ~15 minutes, the reaction initiated (exotherm, and vapor condensation), the heating mantle was removed and the contents of the addition funnel was added dropwise at such rate as to maintain reflux (1.5 hours). The heating mantle was re-applied and a reflux maintained for 1.5 hours. (TLC 100%
hexanes R, 0.67).
The reaction was cooled to room temperature and quenched with HZO (500 mL) and carefully with 1 N HCI (200 mL, produces HZ evolution from unconsumed Mg). To this ~50 mL
concentrated HCI was added to dissolve solids. Total additionlquench time --1 hour.
Saturated aqueous sodium chloride (NaCI) solution (300mL) was added and product hexanes extracted until no potassium permanganate (KMn04) active product is removed.
(4 x 250 mL). The combined organic layer was washed with saturated NaHC03 solution (250 mL), sodium bicarbonate Na2S04 dried and concentrated to an oil 0200 g). The product was distilled at 78-83 °C cLD15mm (131 g, 64%). (An alternative workup is described on p.419 Fieser and Fieser, Vol. I, Reagents for Organic Synthesis, ~ley, NY., NY.;
1967).
B) 1,2,3,4-Tetrahydro-1,4-methano-naphthalene-2,3-diol (Except for the workup method and the quantity of Os04 used, based on VanRheenen, V.; Cha, D.Y.; Hartley, W. M. Org. Syn. 1988, 6, 342.) In a 2 L 3 neck round bottom flask equipped with a Nz flow adapter, mechanical stirrer was placed 1,4-dihydro-1,4-methano-naphthalene (79.5 g, 560 mmol) stirred in acetone (800 mL) and H20 (100 mL) and N-methyl morpholine N-oxide (67.5 g, 576 mmol). To this was added osmium tetroxide (Os04) (15 mL of a 15mo1% t-BuOH solution, 1.48 mmol, 0.26mo1%) and the mixture was stirred vigorously. After 60 hours, the reaction was filtered, and the white product rinsed with acetone and air dried (60.9 g}. The mother liquor was concentrated to an oily solid: acetone trituration, filtration and acetone rinse provided (27.4 g, total 88.3 g, 89%).
(TLC 50% EtOAGhexanes R, ~0.5). mp 176-177.5 °C.
C) 10-Benz~~l-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene (Based on Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.;
Shah, R.
D. J. Org. Chem. 1996, 69, 3849; and Mazzocchi, P. H.; Stahly, B. C. J. Med.
Chem. 1979, 22, 455.) 1,2,3;4-Tetrahydro-1,4-methano-naphthalene-2,3-diol (40 g, 227.3 mmol) was stirred in H20 (1050 mL) and 1,2-dichloroethane (DCE) (420 mL) in a 2 L round bottom flask under nitrogen with cool water bath (~10 °C). To this sodium periodate (Na104) (51 g, 239 mmol) and triethylbenzyl ammonium chloride (Et3BnNCl) (50 mg) were added. The resulting mixture was stirred for 1 hour (slight initial exotherm), then the layers were separated and the aqueous layer was extracted with DCE (200 mL). The organic layer was washed with H20 (4 x 200 mL, or until no reaction to starch iodide is observed in the aqueous wash} then dried through a cotton plug. To this was added benzyl amine (25.5 g, 238.6 mmol) and the mixture was stirred for 2 minutes then immediately transferred into the sodium triacetoxyborohydride NaHB(OAc)31DCE (see below) over 10 minutes.
In a separate 2 L round botton flask flask under nitrogen was magnetically stirred NaHB(OAc)3 (154 g, 0.727 mmol) in DCE (800 mL) at 0 °C (ice bath). To this was added the above mixture over 10 minutes, without delay after the dialdehyde and amine were mixed.
The resulting orange mixture was allowed to warm to room temperature and stirred for 30-60 minutes.
The reaction was quenched by addition of saturated sodium carbonate (NaZC03) solution (-300 mL) carefully at first and the mixture was stirred for 1 hour (pH 9). The layers were separated and the aqueous layer was extracted with CHzCl2 (2 x 300 mL).
The organic layer was washed with saturated aqueous NaCI solution (200 ml), dried through a cotton plug, then evaporated to a red oil. This was dissolved in a minimum of EtzO
and filtered through a Silica pad (3 x 4 inch) eluting with 15% ethyl acetate (EtOAc)/hexanes +1°~ of 37%
aqueous ammonium hydroxide (NH,OH) solution to remove baseline red color.
Concentration affords a light yellow oil (48.5 g, 194.8 mmol, 85.7%). (TLC 10°~6 EtOAGhexanes R~ 0.75). 'H
NMR (400 MHz, CDCI3) 8 7.16 (m, 7H), 6.89 (m, 2H), 3.48 (m, 2H), 3.08 (m, 2H), 2.80 (d, J=9.5 Hz, 2H), 2.42 (d, J=9.5 Hz, 2H), 2.27 (m, 1 H), 1.67 (d, J=10.0 Hz, 1 H). APCI MS m/e 250.3 [(M + 1 )'].
D) 10-Aza-tricyclo[6.3.1.0~--']dodeca-2(7),3,5-triene (For an alternative synthesis, see;
Mazzocchi, P. H.; Stahly, B. C. J. Med. Chem. 1979, 22, 455.) 10-Benzyl-10-aza-tricyclo(6.3.1.0~~')dodeca-2(7),3,5-triene (70.65 g, 2B4 mmol) was stirred in EtOAc (250 mL) and treated with 3N HCI EtOAc (1.03 eq.) slowly with cooling (ice bath). The resulting precipitate was filtered and rinsed with EtOAc. The solids were dissolved in MeOH (250 mL) in a parr bottle. To this was added Pd(OHy~ (7 g of 20°~wUC) and the mixture was shaken under 50-40 psi of H2 for 24 hours or until done by TLC.
The reaction was filtered through a Ceiite pad and concentrated to an oily solid. This was azeotroped with methanol (MeOH) (3x) then triturated with acetone, treated with ethyl ether (EtZO) to precipitate product and filtered. Concentration of the mother liquors and a second treatment provided an off white solid (48.95 g, 251 rnmol, 88°l°). (TLC
10% MeOH/CH~C12 (NH3) R, 0.2).
'H NMR (400 MHz, CDCI3) 5 7.18 (m, 4H), 2.97 (m, 4H), 2.68 (d, J=12.5 Hz, 2H), 2.41 (m, 1H), 1.95 (d, J=11.0 Hz, 1H). APCi MS m/e 160.2 [(M + 1)'].
*Trade-mark 4-FLUORO-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 6-Fluoro-1,4-dihydro-1,4-methano-naphthalene (Eisch, J. J.; Burlinson, N. E. J. Amer. Chem. Soc. 1976, 98, 753-761.
Paquette, L. A.;
Cottrell, D. M.; Snow, R. A. J. Amer. Chem. Soc. 1977, 99, 3723-3733.) Magnesium turnings (0.66 g, 27.2 mmol) were stirred in anhydrous THF (10 mL) in a flame dried 75 mL 3 neck round bottom flask equipped with a non-equalizing addition funnel with a NZ flow adapter, magnetic stirrer and efficient condenser equipped with a NZ flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle. 2,5-Difluorobromobenzene (0.1 g) was added followed by of 3N EtMgBr in THF (0.1 mL). The addition funnel was charged with an intimate mixture of cyclopentadiene (1.71 g, 25.9 mmol) and 2,5-difluorobromobenzene (5.0 g, 25.9 mmol). Small portions (-0.2 mL) of the intimate mixture were introduced to assist initiation (-4x). After -15 minutes, the reaction initiated (exotherm, and vapor condensation) and heating was maintained as necessary during the addition of the contents of the addition funnel. The reaction was then maintained at reflux for 1 hour.
The reaction was cooled to room temperature and quenched with H20 (20 rnL) followed by aqueous 1 N HCI solution (20 mL) to dissolve the solids. Saturated aqueous NaCI
solution (30 mL) was added and product was extracted with hexanes (4 x 25mL).
The combined organic layer was washed with saturated aqueous NaHC03 solution (25 mL), dried (NazSO,), filtered through a Silica plug with hexanes rinse and concentrated to an oil.
Chromatography on Silica gel eluting with hexanes provided an oil (780 mg, 19%). (TLC
hexanes R, 0.38).'H NMR (400 MHz, CDCI~) b 7.10 (m, 1H), 6.97 (d, J=8.0 Hz, 1H), 6.80 (br s, 1H), 6.78 (br s, 1H), 6.59 (m, 1H), 3.87 (br s, 2H), 2.32 (d, J=7.0 Hz, 1 H), 2.25 (d, J=7.0 Hz, 1 H).
B 6-Fluoro-1,2,3,4-tetrahydro-l,4-methano-naphthalene-2,3-diol 6-Fluoro-l,4-dihydro-1,4-methano-naphthalene (680 mg, 4.22 mmol) and N-methyl morpholine N-oxide (599 mg, 4.43 mmol) were stirred in acetone (50 mL) and H20 (5 mL). To this was added a solution of OsO, (0.2 rnL, 2.5%wt. solution in t-BuOH, 0.02 mmol). After 72 hours, Florisil* (5 g) and saturated aqueous NaHS03 solution (3 mL) were added and stirred for 1 hour. The Florisil* was filtered and the filtrate concentrated to produce a crystalline product which was triturated with acetone and filtered (524 mg, 64°h). 'H NMR
(400 MHz, CDCI3) 8 *Trade-mark 7.10 (dd, J=8.0,5.0 Hz, 1 H), 6.90 (dd, J=8.0,2.3 Hz, 1 H), 6.75 (ddd, J=8.0,8Ø2.3 Hz, 1 H), 3.79 (s, 2H), 3.18 (d, J=1.5 Hz, 2H), 2.22 (d, J=10.0 Hz, 1H), 1.92 (dd, J=10.0,1.5 Hz, 1H).
GCMS rn/e 194 (M').
C) 10-Benzyl-4-fluoro-10-aza-tricyclo[6.3.1.Oz-~]dodeca-2(7),3,5-triene 6-1=luoro-1,2,3,4-tetrahydro-l,4-methano-naphthalene-2,3-diol (524 mg, 2.68 mmol) and Et3NBnCl (10 mg) were vigorously stirred in dichloroethane (15 rnL) and HZO (45 mL) then treated with sodium periodate (0.603 mg, 2.82 mmol). After 1.5 hours, the layers were separated and the aqueous layer extracted with DCE (2 x 20 mL). The combined organic layer was washed with Hz0 (4 x 20 mL) until no reaction to starch iodide paper was observed, then with saturated aqueous NaCI solution (20 mL). The organic layer was dried through a cotton plug and treated with benzyl amine (0.308 mL, 2.82 mmol) and stirred for 2 minutes then transferred to an addition funnel. This solution was added over -10 minutes to a vigorously stirred cooled (0 °C) mixture of NaH8(OAc)s (1.82 g, 8.58 mrnol) in DCE (50 mL).
After addition was complete, the mixture was stirred without cooling for 2 hours. The mixture was quenched with saturated aqueous Na~C03 solution (100 mL) and stirred for 1 hour, then the layers were separated and the aqueous layer was extracted with CHZCIz (3 x 30 mL). The combined organic layer was washed with saturated aqueous NaCI solution (50 mL), dried through a cotton plug and concentrated. Chromatography on Silica gel provided an oil (520 mg, 80°~). (TLC 2% acetonelCHZCIz R, 0.40). 'H NMR (400 MHz, CDCIs) 8 7.18 (m, i H), 6.88 (m, 2H), 3.48 (s, 2H), 3.06 (m, 2H), 2.78 (m, 2H), 2.41 (m, 2H), 2.27 (m, 1 H), 1.69 (d, J=10.5 Hz, 1H).
D) 4-Fluoro-10-aza-tricyclo[6.3.1.0'-Ldodeca-2(7),3,5-triene hydrochloride 10-Benzyl-4-fiuoro-l0-aza-tricyclo[6.3.1.0~~']dodeca-2(7).3.5-triene (390 mg, 1.461 mmol), ammonium formate (3.04 g, 48.2 mmol) and 10°l°Pd(OH)~!C
(30 mg) were combined in MeOH (50 mL) and brought to reflux under N2 for 1.5 hours. Ammonium formate (1.0 g) was added and reflux continued for 0.5 hour. The reaction mixture was filtered through a Celite pad which was rinsed with MeOH. The filtrate was concentrated. The residues were treated with saturated aqueous NazCO' solution (30 mL) and product extracted with methylene chloride (CHzCIz) (3 x 25 mL). The organic layer was washed with saturated aqueous NaCI
solution (50 mL), dried through a cotton plug and concentrated. The residue was treated with 2N HCI MeOH (5 mL) and concentrated then taken up in minimum of MeOH and saturated with EtzO. After stirring 18h, the white crystals were collected by filtration (86 mg, 28%). (TLC
''Trade-mark 5% MeOH/CH2CIz (NH3) R, 0.27). (data for free base) 'H NMR (400 MHz, CDCI3) 8 7.06 (m, 1 H), 6.83 (m, 2H), 2.89 (m, 4H), 2.61 (dd, J=12.0 Hz, 2H), 2.37 (m, 1 H), 1.87 (d, J=11.5 Hz, 1H). APCI MS m/e 178.2 ((M + 1)*], (HCI salt) mp 260-262 °C.
4-METHYL-10-AZA-TRICYCLO[6.3.1.02--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-5-methylbromobenzene. (data for free base) 'H NMR (400 MHz, CDCI3) S 7.04 (d, J=7.5 Hz, 1 H), 6.99 (s, 1 H), 6.98 (d, J=7.5 Hz, 1 H), 2.98-2.90 (m, 4H), 2.63 (m, 2H), 2.35 (m, 1 H), 2.32 (s, 3H), 1.87 (d, J=11.5 Hz, 1 H). APCI MS m/e 174.2 [(M +
1 ) *]. (HCI salt) mp 254-255 °C. Anal. Calcd. for C,ZH~ZF3N.HCL1/3H20: C, 53.44; H, 5.11;
N, 5.19. Found C, 53.73; H, 4.82; N, 5.15.
4-TRIFLUOROMETHYL-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE (See Grunewald, G. L.; Paradkar, V. M.; Pazhenchevsky, B.;
Pleiss, M.
A.; Sall, D. J.; Seibel, W. L.; Reitz, T. J. J. Org. Chem. 1983, 48, 2321-2327. Grunewald, G.
L.; Markovich, K. M.; Sall, D. J. J. Med. Chem. 1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-5-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) 8 7.71 (s, 1 H), 7.64 (d, J=8.0 Hz, 1 H), 7.57 (d, J=8.0 Hz, 1 H), 3.46 (m, 4H), 3.21 (d, J=12.5 Hz, 2H), 2.41 (m, 1 H), 2.16 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )*]. (HCI
salt) mp 244-246 °C. Anal. Calcd. for C,ZH,ZF3N.HCL1/3HZ0: C, 53.44; H, 5.11; N, 5.19.
Found C, 53.77; H, 4.82; N, 5.18.
3-TRIFLUOROMETHYL-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIE_N_E
HYDROCHLORIDE (Grunewald, G. L.; Markovich, K. M.; Sall, D. J. J. Med. Chem.
1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-6-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) 8 7.65 (s, 2H), 7.52 (m, 1H), 3.65 (br s, 1H), 3.49-3.43 (m, 3H), 3.20 (m, 2H), 2.42 (m, 1H), 2.18 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )*J. (HCI salt) mp 275-277 °C.
3-FLUORO-10-AZA-TRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 2,6-Difluoroiodobenzene (Roe, A. M.; Burton, R. A.; Willey, G. L.; Baines, M. W.;
Rasmussen, A. C. J. Med. Chem. 1968, 11, 814-819. Tamborski, C.; Soloski, E.
J. Org.
Chem. 1966, 31, 746-749. Grunewald, G. L.; Arrington, H. S.; Bartlett, W. J.;
Reitz, T. J.; Sall, D. J. J. Med. Chem. 1986, 29, 1972-1982.) 1,3-Difluorobenzene (57.05 g, 0.5 M) in THF (75 mL) was added to a -78 °C stirred solution of n-butyllithium (n-BuLi) (200 mL, 2.5 M/hexanes, 0.5 M) and THF (500 mL) under Nz. By controlling the addition rate the internal temperature was maintained below -70 °C. The total addition time was ~1/2 hour. The resulting slurry was stirred an additional 1/2 hour, then the dispersion was treated with a solution of iodine (126.9 g, 0.5 M) in THF (300 mL) at a rate that maintained an internal temperature below -70 °C.
After complete addition the mixture was allowed to warm to room temperature, and was treated with H20 (100 mL) and 10% aqueous NaZS203 solution (100 mL) and stirred. The layers were separated and the aqueous layer extracted with hexanes (2 x 250 mL). The combined organic layer was washed with 10% aqueous NazS203 solution (100 mL), H20 {100 mL), saturated aqueous NaCI solution (100 mL), dried (Na2S04} filtered and concentrated to give a yellow oil (106.5 g). Distillation at ~1-5 mm at ~80 °C provided a light yellow oil (89.5 g, 75%). 'H NMR (400 MHz, CDC13) 8 7.30 (m, 1 H), 6.87 (m, 2H). GCMS m/e 240 (M'').
B) 5-Fluoro-1,4-dihydro-1,4-methano-naphthalene A solution of 2,6-difluoroiodobenzene (5.0 g, 20.8 mmol) and cyclopentadiene (2.07 g, 31.3 mmol) was stirred at 0 °C in P. ether (70 mL, 40-60 °C) under NZ and treated with n-BuLi (8.74 mL, 2.5M in hexanes, 21.8 mmol) dropwise over 10 minutes. The reaction was quenched after 15 minutes by addition of aqueous 1 N HCi solution and the product was extracted with hexanes (3 x 50 mL). The combined organic layer was washed with Hz0 (50 mL), saturated aqueous NaCI solution (50 mL), dried (MgS04), filtered and evaporated.
Chromatography on Silica gel provided product as an oil (1.5 g, 45%). (TLC
hexanes R, 0.55).'H NMR {400 MHz, CDCI3) 8 7.08 (ddd, J=7.0,1.0,0.8 Hz, 1H), 6.96 (ddd, J=8.5,8.3,7.0 Hz, 1 H), 6.86 (br s, 2H), 6.72 (ddd, J=8.5,8.3,0.8 Hz, 1 H), 4.25 (br s, 1 H), 3.98 (br s, 1 H), 2.36 (ddd, J=7.2,1.7,1.7 Hz, 1 H), 2.30 (ddd, J=7.2,1.7,1.5 Hz, 1 H). GCMS m/e 160 (M+).
C) 3-Fluoro-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene hydrochloride The title compound was prepared by the methods described in Example 2B,C,D
starting with 5-fluoro-1,4-dihydro-1,4-methano-naphthalene. 'H NMR (400 MHz, CD30D) 8 7.36 (ddd, J=8.3,7:3,5.0 Hz, 1 H), 7.21 (d, J=7.3 Hz, 1 H), 7.07 (t, J=8.3 Hz, 1 H), 3.62 (br s, 1 H), 3.42-3.30 (m, 3H), 3.21 (m, 2H), 2.38 (m, 1 H), 2.12 (d, J=11.5 Hz, 1 H). APCI MS m/e 178.4 [(M + 1 )']. mp 269-271 °C.
4-NITRO-10-AZATRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A~ 1-(10-Aza-tricyclo[6.3.1.OZ--']dodeca-2(7),3,5-men-10-yl)-2 2 2-trifluoro-ethanone 10-Aza-tricyclo[6.3.1.02']dodeca-2(7),3,5-triene hydrochloride salt (12.4 g, 63.9 mmol) was stirred in CHZCIZ (200 mL). This was cooled (ice bath) and treated with pyridine (12.65 g, 160 mmol) followed by trifluoroacetic anhydride (TFAA) (16.8 g, 11.3 mL, 80 mmol) from an addition funnel over 10 minutes. After ~3 hours, the solution was poured into 0.5N
aqueous HCI (200 mL) and the layers separated. The aqueous layer was extracted with CHzCl2 (3 x 50 mL) and the combined organic layer was washed with 0.5N aqueous HCI (50 mL), HZO (2 x 50 mL) and saturated aqueous NaHC03 solution (50 mL). This solution was dried through a cotton plug, then diluted with ~3% EtOAc and filtered through a 2 inch Silica pad eluted with ~3% EtOAcICH2C12. Concentration afforded a clear oil which crystallized to give white needles {15.35 g, 60.2 mmol, 94%). (TLC 30% EtOAclhexanes Rf 0.53).
'H NMR
(400 MHz, CDCI3) 8 7.18 (m, 4H), 4.29 (br d, J=12.6 Hz, 1 H), 3.84 (br d, J=12.6 Hz, 1 H), 3.51 (dd, J=12.6,1.5 Hz, 1 H), 3.21 (br s, 1 H), 3.10 (br s, 1 H), 3.10 (br d, J=12.6 Hz, 1 H), 2.37 (m, 1 H), 1.92 (d, J=10.8 Hz, 1 H). GCMS m/e 255 (M+). mp 67-68 °C.
B) 1-(4-Nitro-10-aza-tricyclo[6.3.1.0~]dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro ethanone (Based on the method described by Coon, C. L.; Blucher, W.G.; Hill, M. E. J. Org.
Chem. 1973, 25, 4243.) To a solution of trifluoromethanesulfonic acid (2.4 ml, 13.7 mmol) in CHZCIZ
(10 ml) stirred at 0 °C was slowly added nitric acid (0.58 ml, 27.4 mmol) generating a white precipitate. After 10 minutes the resulting mixture was cooled to -78 °C and treated with 1-(10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (3.5 g, 13.7 mmol) in CH2CI2 (15 ml) dropwise from an addition funnel over 5 minutes. The reaction was stirred at -78 °C for 30 minutes then warmed to 0 °C for 1 hour.
The reaction mixture was poured into a vigorously stirred ice (100 g). The layers were separated and the aqueous layer extracted with CHzCIz (3 x 30 rnl), The organic layer was combined and washed with H20 (3 x 30 ml). The combined organic layer was washed with saturated aqueous NaHC03 solution (20 mL) and Hz0 (20 mL) then dried through a cotton plug and concentrated to give an orange oil that solidified on standing (4.2 g). Chromatography yielded pure product as a crystalline solid (3.2 g, 78%). (TLC 30% EtOAc/hexanes R, 0.23). 'H NMR (400 MHz, CDCl3) 8 8.12 (br d, J=8.0 Hz, 1 H), 8.08 (br s, 1 H), 7.37 (br d, J=8.0 Hz, 1 H), 4.38 (br d, J=12.6 Hz, 1 H), 3.94 (br d, J=12.6 Hz, 1 H), 3.59 (br d, J=12.6 Hz, 1 H), 3.43-3.35 (m, 2H), 3.18 (br d, J=12.6 Hz, 1 H), 2.48 (m, 1H), 2.07 (d, J=10.8 Hz, 1H). GCMS m!e 300 (M').
C) 4-Nitro-l0-azatricyclo[6.3.1.0j'-Ldodeca-2(7),3,5-triene hydrochloride 1-(4-Nitro-10-aza-tricyclo(6,3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (182 mg, 0.61 mmol) was stirred with NaZC03 (160 mg, 1.21 mmol) in MeOH (3 mL) and HZO (1 mL) at 70 °C for 18 hours. The mixture was concentrated, water was added and the product was extracted with CHZCI2. The organic layer was extracted with 1N
aqueous HCI
(3 x 20 mL) and the acidic layer washed with CHZCIZ (2 x 20 mL). The aqueous layer was basified to pH -10 with Na~C03(s) and product was extracted with CH2CIz (3 x 30 mL). The organic layer was dried through a cotton plug and concentrated to an oil. This was dissolved in MeOH and treated with 1 N HCI MeOH, concentrated to solids which were recrystallized from MeOH/Et20 to afford product as a white solid (73 mg, 50%). (TLC 5%
MeOH/CHzCl2 (NH3) Rt 0.38). 'H NMR (400 MHz, DMSO-d6) & 8.21 (s, 1H), 8.18 (dd, J=8.0,2.0 Hz, 1 H), 7.59 (d, J=8.0 Hz, 1H), 3.43 (br s, 2H), 3.28 (m, 2H), 3.07 (dd, J= 13.0,13.0 Hz, 2H), 2.24 (m, 1H), 2.08 (d, J=11.5 Hz, 1H). APC1 MS mle 205.1 J(M + 1 )'] mp 265-270 °C.
FXAMPI F R
4-AMINO-10-AZATR1CYCL0[6.3.1.0]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
4-Nitro-l0-azatricyclo[6.3.1.0=~'Jdodeca-2(7),3,5-triene (500 mg, 2.08 mmol) was stirred in 1,4-dioxane (40 mL) and treated with saturated aqueous Na2C03 solution (15 mL).
To this was added di-t-butyldicarbonate (1.8 g, 8.31 mmol). After stirring 18 hours the reaction was treated with Hz0 (50 mL), extracted with CH2CIz (4 x 30 mL), dried through a cotton plug and concentrated to provide an oil (500 mg, 91%).
This oil (500 mg, 1.64 mmol) was dissolved in MeOH (30 mL), treated with 10%Pd/C
(~50 mg) and hydrogenated under a HZ atmosphere (45 psi) for 1 hour. The mixture was filtered through a Celite pad and concentrated to a clear oil (397 mg, 88%).
*Trade-mark This oil (50 mg, 0.18 mmol) was stirred in 3N HCI EtOAc (3 mL) for 2 hours then concentrated to a white solid (25 mg, 56°l°). 'H NMR (400 MHz, DMSO-d6) b 7.38-7.10 (3H), 3.60 (br s, 2H), 3.25 (m, 2H), 2.98 (m, 2H), 2.18 (m, 1H), 1.98 (d, J=11.5 Hz, 1H). APCI MS
Me 175.1 [(M + 1 )'] mp 9 89-192 °C.
N'--j10-AZATRICYCLOI6.3.1.OyLDODECA-2(7),3,5-TRIEN-4-YL]ACETAMIDE
HYDROCHLORIDE
A) 1-(4-Arnino-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-men-10-yl)-2,2.2-trifluoro-ethanone Hydrogenation of 1-(4-vitro-10-aza-tricyclo(6.3.1.0~~']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (2.0 g, 6.66 mmol) under a H~ atmosphere (40 psi) and 10°~PdIC (200 mg) in MeOH over 1.5 hours, filtration through Celiteiand concentration affords a yellow oil (1.7 g). (TLC 50°l° EtOAclhexanes R, 0.27). 'H NMR (400 MHz, CDCI3) b 6.99 (m, 1H), 6.64 (br s, 1 H), 6.57 (rn, 1 H), 4.25 (m, 1 H), 3.82 (m, 1 H), 3.50 (m. 1 H), 3.17-3.07 (m, 3H), 2.35 (m, 1H), 1.90 (d, J=10.8 Hz, 1H). GCMS m/e 270 (M').
g) N-(10-Trifluoroacetyl-10-aza-tricyclo(6.3.1.Oz-']dodeca-2(7),3,5-men-4-yl)-acetamide 1-(4-Amino-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-men-10-yl)-2.2,2-mfluoro-ethanone (850 mg, 3.14 mmol) was stirred in CHICIz (5 mL) and treated with methyl amine (0.53 mL, 3.76 mmol) and acetyl chloride (0.23 mL, 3.2 mmol) then stirred 18 hours. Standard NaHC03 workup yielded an oil which was chromatographed to provide a clear oil (850 mg, 87°J°). (50°J° EtOAclhexanes R, 0.28).
CAN'-110-Azatricyclo(6.3.1.Oj-']dodeca-2(7),3,5-men-4-yl]acetamide hydrochloride N-(10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.Oz~']dodeca-2(7),3,5-men-4-yl)-acetamide (100 mg, 0.32 rnmol) was stirred with NazC03 (70 mg, 0.64 mmol) in MeOH (10 mL) and Hi0 (2 mL) at 70 °C for 18 hours. The mixture was concentrated, water was added and the product was extracted with EtOAc. The organic layer was extracted with 1 N
aqueous HCI (3 x 20 mL) and the acidic layer washed with EtOAc (2 x 20 mL). The aqueous layer was basif~ed to pH ~10 with NazC03 (s) and product was extracted with EtOAc (3 x 20 mL).
The organic layer was dried (sodium sulfate (NaZSO,)) and concentrated to an oil. This material was dissolved in MeOH and treated with 3N HCI EtOAc (3 mL), concentrated and recrystaliized *Trade-mark from MeOH/EtzO to provide a solid (40 mg, 50%). 'H NMR (400 MHz, DMSO-ds) S
9.98 (s, 1 H), 9.02 (br m, NH), 7.65 (s, 1 H), 7.55 (br s, NH), 7.38 (d, J=8.0 Hz, 1 H), 7.20 (d, J=8.0 Hz, 1 H), 3.33 (m, 4H), 2.96 (m, 2H), 2.13 (m, 1 H), 2.00 (s, 3H), 1.96 (d, J=10.5 Hz, 1 H). APCI MS
m/e 217.2 [(M + 1 )''], mp 225-230 °C.
FXAMPI F 1n 6-METHYL-5-THIA-7,13-DIAZATETRACYCLO[9 3 1 02''-°._O~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) N-(10-Trifluorothioacetyl-10-aza-tricyclo[6.3101]dodeca-2(7),3,5 -trien-4-yl)-lhin'r~cf~mirlc N-(10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-men-4-yl)-acetamide (850 mg, 2.72 mmol) and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent) (1.1 g, 2.72 mmol) were combined in toluene (10 mL) and brought to reflux for 1.5 hours. After cooling the reaction was worked up with EtOAclsaturated aqueous NaHC03 solution. The organic layer was dried (NazS04), filtered, concentrated and chromatographed on Silica gel to produce product (410 mg, 44%). (50%
EtOAc/hexanes R, 0.38) B~ 6-Methyl-5-this-7,13-diazatetracyclo[9.3.1.0~'-°.Oy]pentadeca-2(10),3,6,8-tetraene hydrochloride The above oil, 2,2,2-trifluoro-N-(10-trifluorothioacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-4-yl)-thioacetamide, (360 mg, 1.05 mmol) was dissolved in MeOH (10 mL) and 1N NaOH (5 mL) and added to potassium ferricyanide (K3Fe(CN)s)(1.72 g, 5.23 mmol) in H20 (10 mL). This mixture was warmed to 60 °C for 1.5 hours, cooled, concentrated and worked up with EtOAc/H20. This material was stirred in dioxane (20 mL) and treated with H20 (50 mL) and Na2C03 to achieve pH 10. To this was added di-t-butyldicarbonate (436 mg, 2.0 mmol) and the mixture was stirred for 18 hours. The reaction was concentrated, treated with H20 and extracted with CHzCl2. The product was chromatographed (Silica 30% EtOAc/hexanes R, 0.41) to yield an oil (100 mg).
The above product was treated with 3N HCI/EtOAc (3 mL) and warmed to reflux for ~15 minutes then concentrated to a solid which was azeotroped with CH2CI2 (2x). These solids were dissolved in a minimum amount of MeOH then saturated with Et20 and stirred.
The resulting white crystalline powder was collected by filtration (40 mg, 14%).
'H NMR (400 MHz, DMSO-ds) 8 9.46 (s, NH), 7.65 (s, 1H), 7.82 (s, 1H), 7.65 (br m, NH), 3.36 (m, 2H), 3.24 (m, 2H), 3.02 (m, 2H), 2.76 (s, 3H), 2.23 (m, 1H), 2.06 (d, J=10.8 Hz, 1 H). APCI MS m/e 231.1 [(M + 1 )']. mp 183-184 °C.
FXAMPI F ~ 1 4,5-DINITRO-10-AZA-TRICYCLO[6.3.1.02=']DODECA-2(7),3,5-TRIENE
A) 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ-']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (Based on the method described in Coon, C. L.; Blucher, W. G.; Hill, M. E. J. Org.
Chem. 1973, 25, 4243. For an additional related example of dinitration see:
Tanida, H.;
Ishitobi, H.; Irie, T.; Tsushima, T. J. Am. Chem. Soc. 19fi9, 91, 4512.) To a solution of trifluoromethanesulfonic acid (79.8 ml, 902.1 mmol) in CHZCIZ
(550 ml) stirred at 0 °C was slowly added nitric acid (19.1 ml, 450.9 mmol) generating a white precipitate. After 10 minutes, 1-(10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (50 g, 196 mmol) in CHZCIZ (300 ml) was added dropwise from an addition funnel over 30 minutes. The reaction was stirred at 0 °C for 2.5 hours and then stirred at room temperature for 24 hours. The reaction mixture was poured into a vigorously stirred mixture of Hz0 (500 ml) and ice (400 g). The layers were separated and the aqueous layer back extracted with CHZCIZ (3 x 300 ml). The organic layer was combined and washed with H20 (3 x 300 ml). The combined aqueous layers were re-extracted with CHZCl2 (2 x 100 ml).
The organic layer was combined and washed with saturated aqueous NaHC03 solution (200 mL) and Hz0 (200 mL) then dried through a cotton plug and concentrated to solids.
Trituration with EtOAc/hexanes produced off white solids which were filtered and dried (52 g, 151 mmol, 77%. The mother liquor was chromatographed to give an additional 4.0 g for a total of 56.0 g (82.8%). (TLC 50% EtOAc/hexanes R, 0.29) 'H NMR (400 MHz, CDC13) 8 7.77 (s, 1 H), 7.75 (s, 1 H), 4.39 (br d, J=13.0 Hz, 1 H), 3.98 (br d, J=13.0 Hz, 1 H), 3.65 (d, J=13.0 Hz, 1 H), 3.49 (br s, 1 H), 3.44 (br s, 1 H), 3.24 (br d, J=12.6 Hz, 1 H), 2.53 (m, 1 H), 2.14 (d, J=11.5 Hz, 1 H). GCMS m/e 345 (M').
B) 4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ=']dodeca-2(7),3,5-triene 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (3.7 g, 10.7 mmol) and Na2C03 (2.3 g, 21.4 mmol) were combined in MeOH (50 mL) and H20 (20 mL) then warmed to reflux for 18 hours. The reaction was cooled, concentrated, treated with H20 and extracted with CHZCI2 (3 x 50 mL) then dried through a cotton plug.
After concentration, tile residue was chromatographed to provide brown solids.
(1.9 g, 71%).
(TLC 5°!° MeOH/CHzCIz (NH3) R, 0.36). 'H NMR (400 MHz, CDCI3) b 7.69 (s, 2H), 3.17 (br s, 2H), 3.11 (d, J=12.6 Hz, 2H), 2.53 (m, 1H), 2.07 (d, J=11.0 Hz, 1H). GCMS m/e 249 (M').
6-METHYL-7-PROPYL-5,7,13-TRIA2ATETRACYClO[9.3.1.02''-°.O,~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
AL 4,5-Dinitro-10-aza-tricyclo[6.3.1.0~=']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester 4,5-Dinitro-10-aza-tricyclo(6.3.1.0~~']dodeca-2(7),3,5-triene, (1.9 g, 7.6 mmol) was stirred in 1,4-dioxane (75 mL) and treated with saturated aqueous NazC03 solution (10 mL).
To this was added di-t-butyldicarbonate (3.31 g, 15.2 mmol). After stirring 6 hours the reaction was treated with Hz0 ( 50 mL) and extracted with EtOAc (4 x 25 mL), dried (NazSO,), filtered, concentrated and chromatographed to provide product (1.9 g, 71°~). (TLC 30%
EtOAc/hexanes (NHS) R, 0.58). 'H NMR (400 MHz, CDCI3) b 7.77 (br s, 1H), 7.72 (br s, 1H), 4.08 (m, 1 H), 3.92 (m, 1 H), 3.39 (br s, 1 H), 3.27 (br s, 1 H), 3.25 (m, 1 H), 3.18 (m, 1 H), 2.46 (rn, 1H), 2.02 (d, J=11.0 Hz, 1H).
B) 4,5-Diamino-10-aza-tricyclo[6.3.i.0z-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 4,5-Dinitro-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester (1.9 g, 5.44 mmol) was hydrogenated in MeOH under a H~ atmosphere (45 psi) over 10%Pd/C (100 mg) for 1.5 hours then filtered through a Celite pad and concentrated to white solids (1.57 g, 100%). (TLC 5°~ MeOH/CHzCh (NH3) R,0.14).
C) 6-Methyl-5,7,13-triazatetracyclo[9.3.1.Oz-'°.0'~8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tent-butyl ester (For conditions, see; Segelstein, 8. E.;
Chenard, B. L.; Macor, J. E.; Post, R. J. Tetrahedron Lett 1993, 34, 1897.) 4,5-Diamino-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyi ester (700 mg, 2.42 mmol) was dissolved in EtOH (10 rnL) and acetic acid (HOAc) (1 mL) and treated with 1-ethoxyethylenemalononitrile (329 mg, 2.42 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated treated with H20 and saturated aqueous NaxC03 solution and extracted with EtOAc (3 x 50 mL), then dried (Na~SO,). After filtration and concentration, the residue was *Trade-mark chromatographed to provide brown solids (247 mg, 36%). (TLC 5% MeOH/CHZCIZ
(NH3) R, 0.28).
D) 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.OZ'-'°.04=8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tent-butyl ester (For conditions, see; Pilarski, B. Liebigs Ann.
Chem. 1983, 1078.) 6-Methyl-5,7,13-triazatetracyclo[9.3.1.0z''°.0°'e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester (80 mg, 0.267 mmol) was stirred in 50%
aqueous NaOH
solution (3 mL) and DMSO (1 mL) then treated with 1-iodopropane (0.03 mL, 0.321 mmol}.
This mixture was warmed to 40 °C for 2 hours then cooled, treated with Hz0 and extracted with EtOAc. The organic layer was washed with Hz0 (3x) then dried (Na2S04), filtered and concentrated to an oil (90 mg, 0.253 mmol). (TLC 5% MeOH/CHzCIz (NH3) Rf 0.15).
E) 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.02-L.04=8]pentadeca-2(10),3,5,8-tetraene hydrochloride 6-Methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.02''°, pa,e]pentadeca-2( 10),3, 5, 8-tetraene-13-carboxylic acid tert-butyl ester (90 mg, 0.253 mmol) was dissolved in 3N HCI
EtOAc (5 mL) and warmed to 100 °C for 112 hour. The mixture was cooled, concentrated, slurried in EtOAc, and filtered to provide a white solid (25 mg, 34%). 'H NMR
(400 MHz, DMSO-ds) 8 9.56 (s, NH), 7.91 (s, 1 H), 7.83 (br m, NH), 7.74 (s, 1 H), 4.38 (m, 2H), 3.48 (m, 2H}, 3.32 (m, 2H), 3.10 (m, 2H), 2.87 (s, 3H), 2.28 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H) 1.85 (m, 2H), 0.97 (m, 3H). mp 147-150 °C.
FX~~/IDI G ~ ~
5,7,13-TRIAZATETRACYCLO[9.3.1.02'-'°.0°~]PENTADECA-2(10),3,5,8-TETRAENE
HYDROCHLORIDE
A} 5,7,13-Triazatetracyclo[9.3.1.OZW°.0"-e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester (For conditions, see; Segelstein, B. E.;
Chenard, B. f_.; Macor, J. E.; Post, R. J. Tetrahedron Lett. 1993, 34, 1897.) 4,5-Diamino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester (1.0 g, 3.45 mmol) was dissolved in EtOH (10 mL) and HOAc (1 mL) and treated with ethoxymethylenemalononitrile (421 mg, 3.45 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated treated with H20 and saturated aqueous Na2C03 solution and extracted with EtOAc (3 x 50 mL), then dried (NaZS04). After filtration and concentration, the residue was chromatographed to provide brown solids (580 mg, 56%). (TLC 5% MeOH/CHzCIz (NH3) R, 0.28) ~- 5,7,13-triazatetracyclo[9.3.1.02-°'-°.04-6]pentadeca-2(10),3,5,8-tetraene hydrochloride 5,7,13-Triazatetracyclo[9.3.1.02''°.04~eJpentadeca-2( 10), 3,5, 8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DZO) 8 8.95 (s, 1 H), 7.67 (s, 2H), 3.45 (br s, 2H), 3.31 {d, J=12.5 Hz, 2H), 3.13 (d, J=12.5 Hz, 2H), 2.30 (m, 1 H), 1.99 (d, J=11.5 Hz, 1 H). APCI MS m/e 200.1 [(M + 1 )+]. mp >250 °C.
7-METHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.04- a]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 5,7,13 triazatetracyclo[9.3.1.02''°.0''~BJpentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodomethane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, Dz0) 8 8.97 (s, 1H), 7.71 (s, 1 H), 7.67 (s, 1 H), 3.94 (s, 3H), 3.48 (m, 2H), 3.33 (d, J=12.2 Hz, 2H), 3.14 (d, J=12.2 Hz, 2H), 2.34 (m, 1 H), 2.03 (d, J=11.5 Hz, 1 H). APCI MS m/e 214.2 [(M + 1 )+].
6-METHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.048]PENTADECA-2( 10), 3,5,8-TETRAENE HYDROCHLORIDE
6-Methyl-5,7,13-triazatetracyclo[9.3.1.02''°.pa,eJpentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.40 (br m, NH), 7.77 (br m, NH), 7.70 (s, 1 H), 3.44 (m, 2H), 3.30 (m, 2H), 3.05 (br d, J=11.0 Hz, 2H), 2.79 (s, 3H), 2.23 {m, 1 H), 2.10 (d, J=10.8 Hz, 1 H). GCMS m/e 213.5 (M').
FXD~/IPI F 1~
6,7-DIMETHYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.0°~JPENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 6-methyl-5,7,13-triazatetracyclo[9.3.1.02''°.04'8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodomethane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.52 (s, NH), 7.84 (s, 1 H), 7.82 (br m, NH), 7.72 {s, 1 H}, 3.90 (s, 3H), 3.45 (m, 2H), 3.28 (m, 2H), 3.04 (m, 2H), 2.82 (s, 3H), 2.23 (m, 1 H), 2.12 (d, J=11.0 Hz, 1 H). APCI MS m/e 228.2 [(M + 1 )+]. mp 225-230 °C.
FXAAADI ~ 17 7-PROPYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.0'-8]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 12D, 5,7,13 triazatetracyclo[9.3.1.0z''°.04'e]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by reaction with iodopropane followed by deprotection as described in Example 12E. 'H NMR (400 MHz, DMSO-ds) 8 9.52 (s, 1H), 9.45 (br s, NH), 7.97 (s, 1H), 7.85 (s, 1H), 7.83 (br m, NH), 4.43 (m, 2H), 3.49 (m, 2H), 3.33 (m, 2H), 3.08 (m, 2H), 2.28 (m, 1H), 2.15 (d, J=11.0 Hz, 1H), 1.92 (m, 2H), 0.93 (m, 3H). APCI
MS m/e 242.2 [(M + 1 )+j. mp 170-171 °C (subl.).
7-BUTYL-5,7,13-TRIAZATETRACYCLO[9.3.1.OZ-~'-°.04=8]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
A) 4-Butylamino-5-vitro-10-aza-tricyclo[6.3.1.0~'-]dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (For conditions, see; Senskey, M. D.; Bradshaw, J. D.;
Tessier, C. A.;
Youngs, W. J. Tetrahedron Lett. 1995, 36, 6217.}
4,5-Dinitro-10-aza-tricyclo[6.3.1.02v]dodeca-2(7),3,5-triene-10-carboxylic acid tert butyl ester {500 mg, 1.43 mmol) and 1-butylamine (1.42 mL, 14.3 mmol) were combined in THF (5 mL) and stirred 4 hours. The mixture was diluted with EtOAc (50 mL) and washed with H20 (3 x 30 mL) then dried (Na2S04), filtered and concentrated to an oil.
This oil was passed through a Silica gel filter column to remove baseline impurities eluting with 30%
EtOAGhexanes (510 mg, 1.41 mmol, 99%).
B) 4-Butyfamino-5-amino-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 4-Butylamino-5-vitro-10-aza-tricycfo[6.3.1.OZ'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (460 mg, 1.27 mmol) was treated with ammonium formate (850 mg, 12.7 mmol) and 10%Pd(OH)zIC (50 mg) in MeOH (20 mL) and brought to reflux for 1 hour then filtered through a Celite pad and concentrated. The solids were treated with saturated aqueous Na~CO~ solution, extracted with CHzCIZ (3 x 30 mL) and dried by filtration through a cotton plug to give an oil (440 mg, 100%).
~ 7-Butyl-5,7,13-triazatetracyclo[9.3.1.02'-'°.0'-°]pentadeca-2(10),3,5,8-tetraene-13-c_ arboxylic acid tert-butyl ester 4-Butylamino-5-amino-l0-aza-tricyclo[6.3.1.Oz~')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (440 mg, 1.27 mmol) was dissolved in EtOH (20 mL) and HOAc (2 mL) and treated with ethoxymethylenemalononitrile (186 mg, 1.52 mmol). The resulting mixture was warmed to 60 °C and stirred 18 hours. The reaction was cooled, concentrated, treated with HZO and saturated aqueous NaZC03 solution then extracted with EtOAc (3 x 50 mL) and dried (NaZSO,). After filtration and concentration, the residue was chromatographed to provide a yellow oil. (400 mg, 89%). (TLC 5% MeOHlCH2CIz (NH3) R, 0.70).
D) 7-Butyl-5.7,13-triazatetracyclo[9.3.1.0z'-'°.0'-°~pentadeca-2(10),3,5,8-tetraene hydrochloride 7-Butyl-5,7,13-triazatetracyclo[9.3.1.Oz~'°.0'ypentadeca-2( 10),3, 5,8-tetraene-13-carboxylic acid tert-butyl ester was converted to the title compound by the methods described in Example 12E. 'H NMR (400 MHz, DMSO-d°) S 9.93 (brs, NH), 9.68 (s, 1H), 7.99 (s, 1H), 7.92 (br m, NH), 7.87 (s, 1H), 4.50 (m, 2H), 3.49 (m, 2H), 3.30 (m, 2H), 3.08 (m, 2H), 2.26 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H), 1.88 (m, 2H), 1.32 (m, 2H), 0.82 (t, J=7.0 Hz, 3H). APCI MS m/e 256.2 j(M + 1)']. mp 204-208 °C.
7-lsobutyl-5,7,13-triazatetracyclo[9.3.1.0~~-'°.0'-°]eentadeca-2(10).3,5,8-tetraene hydroch loride 4,5-Dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and isobutylamine were converted to the title compound utilizing the methods described in Example 18A-D. 'H NMR (400 MHz, CDCI3) b 7.74 (s, 1H), 7.52 (s, 1H), 7.14 (s, 1H), 3.90 (dd, J=7.5,2.0 Hz, 2H), 3.04-2.97 (m, 4H), 2.70 (dd, J=12.8,2.3 Hz, 2H), 2.42 (m, 1 H), 2.19 (m, 1 H), 1.98 (d. J=10.5 Hz, 1 H), 0.93 (m, 6H). APCI MS rrVe 256.2 [(M + 1 )']. mp 147-150 °C (subl.).
*Trade-mark 6-METHYL-7-ISOBUTYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02.'-°.0"~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
A) 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.OZw'-°.0°=8]pentadeca-2(10),3,5,8-tetraene-13-carboxylic acid tart-butt'! ester 4-Amino-5-isobutylamino-10-aza-tricyclo(6. 3.1.02~']dodeca-2(7), 3, 5-triene-carboxylic acid tart-butyl ester (250 mg, 0.74 mmol) from Example 19B was dissolved in EtOH
(10 mL) and HOAc (2 mL) and treated with 1-ethoxyethylenemalononitrile (118 mg, 0.87 mmol). The reaction proceeded as in Example 18C (18h) and was worked up similarly to provide product (TLC 3% MeOH/CHZCIZ (NH3) R, 0.57).
B) 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.02'-'°.04=8]pentadeca-2(10),3,5,8-tetraene hydrochloride 6-Methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.02''°.04'8]pentadeca-2( 10),3, 5,8-tetraene-13-carboxylic acid tart-butyl ester was converted to the title compound by the methods described in Example 12E. APCI MS m/e 270.3 [(M + 1 )']. mp 129-130 °C (subl.).
7-PHENYL-5,7,13-TRIAZATETRACYCLO[9.3.1.OZ''-°.0~]PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 18A, 4,5-dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl ester and aniline were converted to 4-phenylamino-5-nitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl at 75 °C for 4 hours in the coupling step.
This was then converted to the title compound utilizing the methods described in Example 18B,C,D. 'H NMR
(400 MHz, DMSO-ds) 8 9.08 (1 H), 7.78-7.57 (m, 7H), 3.47-3.00 (m, 6H), 2.23 (m, 1 H), 2.09 (d, J=11.5 Hz, 1 H). APCI MS m/e 276.2 [(M + 1 )+). mp 210-213 °C.
6-METHYL-7-PHENYL-5,7,13-TRIAZATETRACYCLO[9.3.1.02''-°.°.04=B;~PENTADECA-2(10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 21 and Example 20, 4,5-dinitro-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tart-butyl ester and aniline were converted to the title compound. 'H NMR (400 MHz, DMSO-ds) 8 7.79 (s, 1H), 7.73-7.56 (m, 5H), 7.32 (s, 1 H), 3.46-2.99 (m, 6H), 2.66 (s, 3H), 2.23 (m, 1 H), 2.08 (d, J=11.0 Hz, 1 H). APCI
MS m/e 290.2 [(M + 1 )''). mp >250 °C.
FXAMPI F ~~
2,10 4,8 7-NEOPENTYL-5,7,13-TRIAZATETRACYCLO[9.3.1 0-.0-~PENTADECA-2~10),3,5,8-TETRAENE HYDROCHLORIDE
Utilizing the methods described in Example 18A-D, 4,5-dinitro-10-aza tricyclo[6.3.1.02'')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and neopentylamine were converted to the title compound. t-Boc precursor GCMS m/e 369 (M+).
(HCI salt) mp >250 °C.
FXA~IIPI G 7d 6-METrIYL 7-NEOPENM-5,7,13-TRIAZA1FTRACYCLO[9.3.1.0_.04-~PENTADECA.2(10),3,5,8-TErRAENE HYDROCHLORIDE
Utilizing the methods described in Example 21 and 20, 4,5-dinitro-10-aza tricyclo[6.3.1.02'')dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester and neopentylamine were converted to the title compound. 'H NMR (400 MHz, DMSO-ds) s 7.31 (s ,1H), 7.27 (s ,1H), 7.02 (br s, , NH), 4.41 (t, J=13.0 Hz, 2H), 3.90 (s, 3H), 3.47-3.26 (m, 6H), 2.20 (m, 1 H), 2.00 (d, J=11.5 Hz, 1 H), 0.90 (s, 9H). t-Boc precursor APCI MS
m/e 384.2 [(M +
1)''). mp >250 °C.
6,7-DIMETHYL-6,8,14-TRIAZATETRA~CYCLO[10.3.1.0'-'-0~1-ID(ADECA.2(11 ),3,5,7,9~PENTAENE
HYDROCHLORIDE (Based on the following procedure: Jones, R. G.; McLaughlin, K.
C. Org.
Syn. 1963, 4, 824. b) Ehrlich, J., Bobert, M. T. J. Org. Chem. 1947, 522.) 4,5-Diamino-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (100 mg, 0.35 mmol) was warmed to 80 °C in H20 (5 mL). To this butane 2,3-dione (0.034 mL, 0.38 mmol) was added under Nz for 2 hours. The reaction was cooled to room temperature and extracted with EtOAc (3 x 40 ml). The combined organic layer was washed with H20 (2 x 30 ml), dried (Na2S04), filtered, concentrated and chromatographed on Silica gel to provide an oil (120 mg, 100%). The oil was dissolved in 2N HCI
MeOH (5 mL) and warmed to reflux for 30 minutes, then concentrated. Recrystallization from MeOH/Et20 provided a white powder (50 mg, 43%). (TLC EtOAc RI 0.14). 'H NMR (400 MHz, DMSO-ds) 8 7.85 (s, 2H), 3.50 (br s, 2H), 3.32 (d, J=12.5 Hz, 2H), 3.10 (d, J=12.5 Hz, 2H), 2.64 (s, 6H), 2.24 (m, 1H), 2.13 (d, J=11.0 Hz, 1H). t-Boc precursor APCI MS m/e 340.3 [(M +
1)'].
FXAMPI F ~~
5,8,14-TRIAZATETRACYCLO[10.3.1.0~~-".0'--~jHEXADECA-2(11 ),3.5,7,9-PENTAENE
HYDROCHLORIDE
A) 1-(4,5-Diamino-10-aza-tricyclo[6.3.1.0~=']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.0~~']dodeca-2(7).3,5-men-10-yl)-2,2.2-trifluoro-ethanone (3.0 g, 8.70 mmol) was hydrogenated in MeOH (30 ml) under H2 (45 psi) over Pd(OH)z (300 rrig of 20 wt%IC, 10%wt). After 2.5 hours the reaction was filtered through a Celite*pad and rinsed with MeOH (30 ml). The solution was concentrated to a light brown oil which crystallized (2.42 g, 96%). (TLC 10% MeOHICHZCI= R, 0.56). APCI MS m/e 286.2 [(M +
1 )']. mp 129-131 °C.
. B) 1 ~5,8,14-Triazatetracyclo[10.3.1.OZV'.0''-~lhexadeca-2(11),3,5,7,9-pentaene)-2,2,2-trifluoro-ethanone 1-(4,5-Diamino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (500 mg, 1.75 mmol) was stirred in THF (2 ml). This mixture was treated with Hs0 (2 mL) and glyoxal sodium bisulfite addition compound hydrate (931 mg, 3.50 mmol) then stirred at 55 °C for 2.5 hours. The reaction was cooled to room temperature and extracted with EtOAc (3 x 40 ml). The combined organic layer was washed with HZO (2 x 30 ml), dried (NaiSO,), filtered, concentrated and chromatographed on Silica gel to provide an off whtte powder (329 mg, 60%). (TLC 25% EtOAGhexanes R, 0.40). mp 164-166 °C.
C) 5,8,14-Triazatetracyclo[10.3.1.0~'-'.0'=-~]hexadeca-2(11),3,5,7,9-pentaene hydrochloride 1-(5,8,14-Triaiatetracyclo[10.3.1.02'".0''°jhexadeca-2( 11 ),3,5,7,9-pentaene)~2,2,2-trifluoro-ethanone (320 mg, 1.04 mmol) was scurried in MeOH (2.0 ml) and treated with Na2C03 (221 mg, 2.08 mmol) in H20 (2.0 ml). The mixture was warmed to 70 °C for 2 hours, then concentrated, treated with Hz0 (20 mL) and extracted with CH2CIz (3 x 10 ml). The organic layer was dried through a cotton plug and concentrated to give a light yellow oil (183 rng, 83%) which solidfied upon standing (mp 138-140 °C). This material was dissolved in MeOH (10 mL), treated with 3M HCUEtOAc (3 ml), concentrated and azeotroped with MeOH
*Trade-mark (2 x 20 mL) to give solids which were recrystallized from MeOH/Et20 to afford product as a white solid (208 mg, 97%). (TLC 5% MeOH/CHZCIz (NH3) R, 0.26). 'H NMR (400 MHz, CD30D) 8 8.94 (s, 2H), 8.12 (s, 2H), 3.70 (m, 2H), 3.54 (d, J=12.5 Hz, 2H), 3.35 (d, J=12.5 Hz, 2H), 2.49 (m, 1 H), 2.08 (d, J=11.0 Hz, 1 H). GCMS m/e 211 (M+). mp 225-230 °C.
14~1AETHYL-5,8,14TRIAZATETRACYCLO[10.3.1.0~-'-'.(x'-~HEXADECA-2(11),3,5,7,9-PEN'fAENE
HYDROCHLORIDE
5,8,14-Triazatetracyclo[10.3.1.02'".04'9]hexadeca-2(11),3,5,7,9-pentaene (207 mg, 0.98 mmol) was treated with 37% aqueous formalise solution (1 mL) and formic acid (1 mL) then warmed to 80 °C for 1 hour. The reaction was poured into water, made basic (NaOH, pH
~11) and extracted with EtOAc. The organic layer was dried (Na2S04), concentrated and chromatographed on Silica gel to provide a yellow solid. This was stirred in MeOH (2 mL) and treated with 3N HCI EtOAc (2 mL). After concentration the solids were recrystallized from MeOH/Et20 to afford product as a white solid (70 mg, 27%). (2% MeOH/CH2Clz (NH3) R, 0.47). 'H NMR (400 MHz, CDCI3) 8 8.71 (s, 2H), 7.80 (s, 2H), 3.37 (br s, 2H), 3.03 (m, 2H), 2.47 (m, 2H), 2.32 (m, 1 H), 2.18 (br s, 3H), 1.84 (d, J=11.0 Hz, 1 H). APCI
MS m/e 226.2 [(M +
1 )+]. mp >250 °C.
5-OXA-7,13-DIAZATETRACYCLO[9.3.1.02-~'-°.04'8]PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) 2,2,2-Trifluoro-1-(4-hydroxy-5-vitro-10-aza-tricyclo[6.3.1.0'-]dodeca-2(7),3,5-trien-10-yl)-ethanone 1-(4, 5-Dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-tries-10-yl)-2,2,2-trifluoro-ethanone (900 mg, 2.61 mmol) and potassium acetate (KOAc) (2.6 g, 26.1 mmol) were dissolved in DMSO (10 mL) and warmed with stirring to 100 °C for 16 hours. The mixture was cooled and diluted with H20 ( 50 mL) then extracted with 80% EtOAGhexanes (6 x 25 mL).
The organic layer was washed with Hz0 (3 x 20 mL), dried (NaZS04), filtered and concentrated and purified by chromatography to give an oil (575 mg, 70%). (TLC
50%
EtOAGhexanes (NH3) R, 0.56) B~ 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.0=]dodeca-2(7),3,5-trien-10-yl)-ethanone 2,2,2-Trifluoro-1-(4-hydroxy-5-vitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trim-10 yl)-ethanone (575 mg, 1.82 mmol) was hydrogenated in MeOH under a H2 atmosphere at (45 *.
psi) over 10%Pd/C (80 mg) for 1.5 hours then filtered through a Celite pad and concentrated to white solids (450 mg. 86%). (TLC 5% MeOH/CH2Clz (NH3) R, 0.6). 'H NMR (400 MHz, CD30D) b 6.67-6.59 (m, 2H), 4.12 (m, 1H), 3.73 (m, 1H), 3.73 (m, 1H), 3.51 (m, 1H), 3.07 (m, 2H), 2.24 (m, 1H), 1.94 (d, J=10.5 Hz. 1H). GCMS m/e 286 (M').
C~ 2,2,2-Trifluoro-1-(5-oxa-7,13-diazatetracyclo[9.3.1.02'-'°.0'=B]pentadeca-2(10),3,6,8-tetraene)-ethanone (Goldstein, S. W.; Darnbek, P. J. J. Het. Chern. 1990, 27, 335.) 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-ethanone (150 mg, 0.524 mmol), trimethyl orthoformate (0.19 mL, 1.73 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 18 mg, 0.07 mmol) and xylenes (10 mL) were combined under nitrogen and stirred at 135 °C for 18 hours. The mixture was cooled, treated with Hz0 and extracted with EtOAc. The extracts were dried (Na2S0,), filtered, concentrated and purified by chromatography to give an oil (110 mg, 71°~). (TLC
20°~ EtOAGhexanes R, 0.40) 5-Oxa-7,13-diazatetracyclo[9.3.1.OZ'-'°.0~=°]pentadeca-2( 10),3.6, 8-tetraene hydrochloride 2,2,2-Trifluoro-1-(5-oxa-7,13-diazatetracyclo[9.3.1.OZ''°.0''°jpentadeca-2( 10),3,6, 8-tetraene}-ethanone (110 mg, 0.37 mmol) was stirred in MeOH (5 mL) and treated with Na2C03 (78 mg, 0.74 mmol) in HZO (2 mL). The stirred mixture was warmed to 80 °C for 2 hours, concentrated to solids, diluted with H20 and extracted with EtOAc (3 x 40 mL).
The product was extracted into aqueous 1 N HCI solution (2 x 40 mL) which was washed with EtOAc then neutralized with saturated aqueous Na2C0~ solution to pH-10. The product was extracted with EtOAc (3 x 40 mL), dried (Na2S0,), concentrated and chromatographed on Silica gel to produce an oil. (TLC 5% MeOH/CHzCIZ (NH3) R, 0.19).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) then concentrated, stirred in a minimum of CHZCIz and saturated with hexanes: After 18 hours, the product was collected by filtration (55 mg, 63%). 'H NMR (400 MHz, CD30D) b 8.47 (s, 1 H), 7.70 (s, 1 H), 7.65 (s, 1 H), 3.41 (m, 2H), 3.30 (m, 2H), 3.10 (d, J=12.5 Hz, 2H), 2.47 (m, 1 H), 2.15 (d, J=11.0 Hz, 1 H). APCI MS rNe 201.03 [(M + 1 )'].
*Trade-mark 6-METHYL-5-OXA-7,13-DIAZATETRACYCLO[9.3.1.02''-°.04~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
A) 2,2,2-Trifluoro-1-(6-methyl 5-oxa-7,13-diazatetracyclo[9.3.1.02-'°.04=a entadeca-2(10),3,6,8-tetraene)-ethanone 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02']dodeca-2(7),3,5-trien-10-yl)-ethanone (150 mg, 0.524 mmol), methyl orthoacetate (0.34 mL, 1.83 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 20 mg, 0.08 mmol) and xylenes (10 mL) were combined under nitrogen and stirred at 135 °C for 18 hours. Workup, isolation and purification as in Example 28C provided the title compound (90 mg, 55%).
B) 6-Methyl-5-oxa-7,13-diazatetracyclo[9.3.1.02Wo.0~]pentadeca-2(10),3,6,8-tetraene hydrochloride 2,2,2-Trifluoro-1-(6-methyl 5-oxa-7,13-diazatetracyclo[9.3.1.02''°.0'''e]pentadeca 2(10),3,6,8-tetraene)-ethanone (90 mg, 0.30 mmol) was stirred in MeOH (5 mL) and treated with Na2C03 (61 mg, 0.58 mmol) in H20 (2 mL). The stirred mixture was warmed to 80 °C for 2 hours, concentrated to solids, diluted with H20 and extracted with EtOAc (3 x 40 mL). The solution was dried (Na2S04), concentrated, and chromatographed on Silica gel to produce an oil. (TLC 10% MeOH/CHZCIZ (NH3) Rf 0.18). 'H NMR (free base) (400 MHz, CDC13) 8 7.40 (s, 1H), 7.26 (s, 1H), 3.05-2.98 (m, 4H), 2.72 (d, J=12.8 Hz, 2H), 2.59 (s, 3H), 2.46 (m, 1H), 1.98 (d, J=10.5 Hz, 1 H).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) then concentrated, stirred in a minimum of CHzCIz and saturated with hexanes. After 18 hours, the product was collected by filtration (10 mg, 13%). APCI MS m/e 215.2 [(M + 1 )+], mp >250 °C.
2-FLUORO-N-(5-HYDROXY-10-AZA-TRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIEN-4-YL)-BENZAMiDE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2{7),3,5-trien-10-yl)-ethanone {150 mg, 0.524 mmol), 2-fluorobenzoyl chloride (0.07 mL, 0.576 mmol), pyridinium-p-toluenesulfonic acid (PPTS, 20 mg, 0.08 mmol), pyridine (0.046 mL, 0.576 mmol) and xylenes (5 mL) were combined under nitrogen and stirred at 135 °C
for 18 hours. After 24 hours, additional PPTS (50 mg) was added and the material stirred at 135 °C for an additional 24 hours. Workup as above provided crude product {145 mg, 0.375 mmol) which was combined with Na2C03(s) (80 mg, 0.75 mmol) in MeOH (5 mL) and HZO (2 mL) and heated to reflux. After 3 hours, the reaction was cooled and diluted with water then extracted with CHZCI2 (4 x 40 mL), dried through a cotton plug then chromatographed to remove baseline impurity (5% MeOH/CH2C12 (NH3)). The crude material was treated with excess 3N
HCI
EtOAc and concentrated, then dissolved in a minimum of MeOH and the solution was saturated with Et20 and stirred. After stirring 4 hours the product was collected by filtration (85 mg, 68%). 'H NMR (400 MHz, CD30D) b 7.99 (m, 2H), 7.59 (m, 1H), 7.36-7.23 (m, 2H}, 6.82 (s, 1 H), 2.99 (m, 4H), 2.78 (m, 2H), 2.35 (m, 1 H), 1.96 (d, J=10.5 Hz, 1 H). APCI MS m/e 313.1 [(M + 1 )+], mp 125-130 °C (subl.).
4~CHLORO-10,AZATRICYCLO(6.3.1.~2(>),3,5-1RIENE HYDROCHLORIDE
A) 1-(4-Chloro-10-aza-tricyclo[6.3.1.Oj'-]dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone Copper(I)chloride (CuCI) was prepared as follows: CuS04 (4.3 g) and NaCI (1.2 g) were dissolved in hot H20 (14 mL). sodium bisulfite (NaHS03) (1 g) and sodium hydroxide (NaOH) (690 mg) were dissolved in H20 {7 mL) and added to the hot acidic solution over 5 minutes. The precipitated white solids were filtered and washed with water.
1-(4-Amino-10-aza-tricyclo[6.3.1.OZ~']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (460 mg, 1.7 mmol) was dissolved in H20 (2 rnL) and concentrated HCI
solution{1 mL) then cooled to 0 °C and treated with a solution of sodium nitrite (NaN02) (275 mg) in H20 (1 mL) dropwise. To the resulting solution was added a CuCI (202 mg, prepared as described above, 2.04 mmol) in concentrated HCI solution (2 mL) over 10 minutes (gas evolution observed). The resulting solution was warmed to 60 °C for 15 minutes, then was cooled to room temperature and extracted with EtOAc (4 x 30 mL). After drying over NaZS04, the solution was filtered and concentrated to an oil which was filtered through a Silica pad to remove baseline material eluting with 50% EtOAc/hexanes to give an oil {470 mg, 95%).
B) 4-Chloro-10-azatricyclo(6.3.1.Oj'-]dodeca-2(7),3,5-triene hydrochloride 1-(4-Chloro-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (470 mg, 1.62 mmol) and NazC03 (344 mg, 3.24 mmol) in MeOH (30 mL) and H20 (10 mL) were heated to reflux. After 2 hours, the reaction was cooled and diluted with water then extracted with EtOAc {4 x 40 mL), dried (Na2S04), filtered and concentrated to a yellow oil. The crude material was treated with excess 3N HCI EtOAc and concentrated, then dissolved in a minimum of CHZCIZ and the solution was saturated with hexanes and stirred.
After stirring 4 hours the product was collected by filtration {155 mg, 42%).
'H NMR (free base) (400 MHz, CDCI3) 8 7.15 (m, 2H), 7.09 (d, J=8.0 Hz, 1 H), 3.00-2.94 (m, 4H), 2.68, (m, 2H), 2.38 (m, 1H), 1.92 (d, J=10.5 Hz, 1H).'H NMR (HCI salt) (400 MHz, DMSO-ds) 8 7.30 7.20 (m, 3H), 3.30-3.15 (m, 6H), 2.37 (m, 1 H), 1.89 (d, J=11.0 Hz, 1 H). APCI
MS m/e 194.1 [(M + 1 )+).
FXAMPI F ~~
10-AZATRICYCLO[6.3.1.0~2,7~]DODECA-2(7),3,5-TRIEN-4-YL CYANIDE
HYDROCHLORIDE
A) 1-(4-lodo-10-aza-tricyclo[6.3.1.Oz-']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone 1-(4-Amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-trien-10-yl)-2,2,2-trifluoro-ethanone (500 mg, 1.85 mmol) was dissolved in H20 (5 mL) and concentrated HZS04 solution (0.5 mL) then cooled to 0 °C and treated with a solution of sodium nitrite (NaNOz) (140 mg, 2.04 mmol) in HZO (2 mL) dropwise. Potassium iodide (460 mg, 2.78 mmol) in 1 N
solution (0.5 mL) was added over 10 minutes (reaction becomes dark red). The resulting solution was warmed to room temperature and stirred 18 hours. The reaction was quenched with NaHS03 and water (pH 2.5) then extracted with EtOAc (4 x 30 mL). After drying (NaZS04), the solution was filtered and concentrated to a yellow oil which was chromatographed on Silica gel to provide a yellow oil. (260 mg, 37%). (TLC 30%
EtOAc/hexanes R, 0.70). (A 5.4 g scale performed as above yielded 5 g, 67%).
B) 4-lodo-10-aza-tricyclo[6.3.1.OZ-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester 1-(4-lodo-10-aza-tricyclo[6.3.1.OZ'')dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (5 g, 13.1 mmol) and 37% saturated aqueous NH40H solution (50 mL) were stirred in MeOH (250 ml) for 2 hours then concentrated and azeotroped with MeOH (2 x 50 mL). The resulting product was stirred in 1,4-dioxane (75 mL) and treated with saturated NaZC03 solution (15 mL). To this was added di-t-butyldicarbonate (5.71 g, 26.2 mmol).
After stirring 18 hours the reaction was treated with H20 ( 50 mL) and extracted with CHZCIZ
(4 x 30 mL), dried (Na2S04), filtered, concentrated and chromatographed on Silica gel (TLC
20%
EtOAc/hexanes) to provide product as an oil (4.9 g, 98%).
C) 4-Cyano-10-aza-tricycio(6.3.1.0~']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester (Utilizing the methods described in: House, H. O.; Fischer, W. F.
J. Org. Chem.
1969, 3626. ) CuCN (108 mg, 1.21 mmol) and NaCN (59 mg, 1.21 mmol) were combined in dry DMF (6 mL) and warmed to 150 °C under NZ. Solution occurs in 20 minutes. To this was added 4-iodo-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (232 mg, 0.6 mmol) in DMF (3.5 mL) and the mixture was stirred for 18 hours at 150 °C.
The reaction was cooled and diluted with 50% saturated aqueous NaCI solution and extracted with 50% EtOAc/hexanes (3 x 30 mL). After drying (NazS04), filtration and concentration the product was isolated by chromatography (86 mg, 50%). (TLC 20% EtOAc/hexanes R~
0.28).
D) 10-Azatricyclo[6.3.1.0--2,7~]dodeca-2(7),3,5-men-4-vl cyanide hydrochloride 4-Cyano-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester was treated with 3N HCI EtOAc (6 mL) and warmed to reflux for 2 hours, then concentrated, dissolved in a minimum of MeOH which was saturated with Et20 and stirred 18 hours. The product was collected by filtration (49 mg, 73%). 'H NMR (400 MHz, DMSO-ds) b 9.66 (br s, NH), 7.86 (br s, NH), 7.74-7.70 (m, 2H), 7.49 (d, J=7.5 Hz, 1 H), 3.33-2.97 (m, 6H), 2.17 (m, 1 H), 2.01 (d, J=11.0 Hz, 1 H). GCMS m/e 184 (M'). mp 268-273 °C.
FX~~ADI G Q0.
3-(10-AZATRICYCLO(6.3.1.02-']DODECA-2(7),3,5-TRIEN-4-YL)-5-METHYL-1 2 4-OXADIAZOLE HYDROCHLORIDE
4-Cyano-10-aza-tricyclo[6.3.1.0z'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester (300 mg, 1.1 mmol) was stirred in EtOH (10 mL). To this hydroxyl amine hydrochloride (382 mg, 5.5 mmol) and NaOH (242 mg, 6.05 mmol) were added and the mixture was warmed to reflux. After 45 minutes, the reaction was cooled, diluted with H20 and extracted with EtOAc. The organic layer was dried (NaZS04) and concentrated to afford a yellow solid (110 mg, 0.35 mmol). This solid was dissolved in pyridine (1 mL) and treated with acetyl chloride (0.03 mL, 0.415 mmol) and warmed to 100°C for 18 hours. The reaction was cooled, treated with Hz0 and extracted with EtOAc. The organic extracts were washed with water and saturated aqueous NaCI solution, dried (Na2S04) and concentrated.
Chromatography on Silica gel afforded product (50 mg, 0.15 mmol). (25% EtOAclhexanes R, 0.18).
This product was treated with 2N HCI MeOH (10 mL), heated to 70 °C for 1 hour, cooled, concentrated and recrystallized from MeOH/Et20 to provide product (15 mg). APCI MS m/e 242.2 [(M + 1 )'].
EXAMPI F ~d 1-( 10-AZATRICYCLO[6.3.1.02--']DODECA-2(7),3, 5-TRIEN-4-YL)-1-ETHANONE
HYDROCHLORIDE
A) 1-(4-Acetyl-10-aza-tricyclo[6.3.1.Oz-']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (253 mg, 1.0 mmol) and AcCI (0.68 mL, 10 mmol) were dissolved in DCE (3 mL) and treated with aluminum chloride (AICI3) (667 mg, 5.0 mmol). The resulting yellow mixture was stirred for 30 minutes then poured over ice and saturated aqueous NaHC03 solution. After stirring 20 minutes the mixture was extracted with CHzCl2 (3 x 30 mL). The organic layer was dried through a cotton plug then concentrated to a orange-yellow oil (255 mg, 86%).
B) 4-Acetyl-10-aza-tricyclo[6.3.1.02-']dodeca-2(7),3,5-triene-10-carboxylic acid tert-bu I ester 1-{4-Acetyl-10-aza-tricycio[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (1.3 g, 4.37 mmol) and 37% aqueous NH40H solution (10 mL) were stirred in MeOH
(30 ml) for 3 hours, then concentrated and azeotroped with MeOH (2 x 50 mL).
(This product could be converted to an HCI salt directly: see the next example.) The resulting product was stirred in 1,4-dioxane (20 mL) and treated with saturated aqueous Na2C03 solution (5 mL). To this was added di-t-butyldicarbonate (1.91 g, 8.74 mmol). After stirring 2 hours, the reaction was treated with H20 (50 mL), extracted with CHzCIZ (4 x 30 mL), dried (Na2S04), filtered, concentrated and chromatographed to provide an oil (1.3 g, 100%). (TLC 40%
EtOAc/hexanes Rt 0.56).
C) 1-(10-Azatricyclo[6.3.1.OJ'-]dodeca-2(7},3,5-men-4-yl)-1-ethanone hydrochloride 4-Acetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tent-butyl ester (190 mg, 0.63 mmol) was treated with excess 3N HCI EtOAc and warmed to 70°C for 1 hour then concentrated and dissolved in a minimum of MeOH. The resulting solution was saturated with EtzO and stirred. After 18 hours the white crystalline product was collected by filtration (81 mg, 54%). 'H NMR (400 MHz, DMSO-ds) b 9.75 (br s, NH), 7.89 (s, 1H), 7.88 (d, J=8.0 Hz, 1 H), 7.74 (br s, NH), 7.44 (d, J=8.0 Hz, 1 H), 3.33 (br s, 2H), 3.22 (br s, 2H), 3.00 (br m, 2H), 2.54 (s, 3H), 2.17 (m, 1 H), 2.02 (d, J=11.0 Hz, 1 H). GCMS m/e 201 (M+). mp 198-202 °C.
10-AZATRICYCLO[6.3.1.Oz-~-'-]DODECA-2(7),3,5-TRIEN-4-OL HYDROCNLORI_DE
A) Acetic acid 10-trifluoroacetyl-10-aza-tricyclo[6 3 1 0~'jdodeca-2(7),3,5-men-4-y!
ester 1-(4-Acetyl-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (2.5 g, 8.41 mmol) and 3-chloroperoxybenzoic acid (m-CPBA) (7.5 g, 42 mmol) were stirred in CHZCIZ (20 mL) and warmed to 40°C for 18 hours. The mixture was cooled to room temperature, then treated with dimethylsulfide (MeZS) (3 mL, 40.8 mmol) and stirred 24 hours. The resulting mixture was poured into ice and saturated aqueous Na2C03 solution (100 mL) then extracted with Et20 (4 x 40 mL). The organic layer was washed saturated aqueous NaZC03 solution (3 x 40 mL) then dried (Na2S04), filtered and concentrated to afford an oil (1.83 g, 69%). (TLC EtOAc R, 0.80).
B) 2,2,2-Trifluoro-1-(4-hydroxy-10-aza-tricyclo[6.3.1.O~Ldodeca-2(7),3,5-men-10-yl)-ethanone Acetic acid 10-trifiuoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-men-4-yl ester (900 mg, 2.87 mmol) was stirred in MeOH (20 mL) and saturated aqueous NaHC03 solution (15 mL) for 48 hours. The mixture was concentrated, diluted with H20 and extracted with CH2CI2 (3 x 20 mL) then dried through a cotton plug. Chromatography on Silica gel provided pure product (420 mg, 54%). (TLC 5% MeOH/CHZCIZ R, 0.44). 'H NMR (400 MHz, CDCI3) b 7.05 (m, 1 H), 6.70 (m, 1 H), 6.62 (m, 1 H), 4.32 (m, 1 H), 3.84 (m, 1 H), 3.48 (m, 1 H), 3.21 (br s, 1 H), 3.16 (br s, 1 H), 3.09 (m, 1 H), 2.38 (m, 1 H), 1.97 (d, J=11.0 Hz, 1 H).
C) 10-Azatricycloj6.3.1.0~]dodeca-2(7),3,5-trien-4-of hydrochloride 2,2,2-Trifluoro-1-(4-hydroxy-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-ethanone (50 mg, 0.184 mmol) was dissolved in MeOH/H20 (3/1, 5 mL), treated with Na2C03(s) (40 mg, 0.369 mmol) and warmed to 65°C for 2 hours. The mixture was concentrated, diluted with Hz0 and extracted with CHzCIZ (3 x 20 mL) then dried through a cotton plug. Filtration through a Silica gel plug provided an oil (10%
MeOH/CHZCIZ) which was treated with 3N HCI EtOAc (3 mL) then concentrated, dissolved in a minimum of MeOH
which was saturated with Et20 and stirred. After 18 hours the white crystalline product was collected by filtration (10 mg, 26%).'H NMR (400 MHz, CDOD3) 8 7.16 (d, J=8.0 Hz, 1 H), 6.80 (d, J=2.0 Hz, 1H), 6.72 (dd, J=8.0,2.0 Hz, 1H), 3.32-3.28 (4H), 3.09 (dd, J=14.5,12.0 Hz, 2H), 2.32 (m, 1 H), 2.03 (d, J=11.0 Hz, 1 H). APCI MS m/e 176.2 j(M + 1 )+]. mp 308 (dec.) °C.
7-METHYL-5-OXA-6,13-DIAZATETRACYCLO[9.3.1.02''-°.0°~PENTADECA-2,4(8),6,9-TETRAENE HYDROCHLORIDE
A) 1-(4-Acetyl-5-hydroxy-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-trien-10-yl)-2,2 2-trifluoro-ethanone Acetic acid 10-trifluoroacetyl-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-men-4-yl ester (800 mg, 2.55 mmol) was combined with AICI3 (1.0 g, 7.65 mmol) and warmed to 170°C for 2 hours. The mixture was cooled and treated with 1 N aqueous HCI solution (20 mL), extracted with EtOAc and dried (NazS04). Chromatography affords an oil (190 mg, 24%).
(TLC EtOAc R, 0.75). 'H NMR (400 MHz, CDC13) 8 12.58 (s, 0.5H), 12.52 (s, 0.5H), 7.53 (s, 1 H), 6.86 (s, 1 H), 4.33 (m, 1 H), 3.91 (m, 1 H), 3.56 (m, 1 H), 3.28 (br s, 1 H), 3.24 (br s, 1 H), 3.14 (m, 1 H), 2.35 (m, 1 H), 1.97 (br d, J=11.2 Hz, 1 H).
B) 2,2,2-Trifluoro-1-[4-hydroxy-5-(1-hydroxyimino-ethyl)-10-aza-tricyclo(6.3.1.OZ-~'-]dodeca-2(7),3,5-men-10-yl]-ethanone 1-(4-Acetyl-5-hydroxy-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (190 mg, 0.605 mmol), hydroxylamine HCI (99 mg, 1.21 mmol) and NaOAc (118 mg, 1.21 mmol) were combined in MeOH (4 mL) and H20 (1 mL) and warmed to 65°C
for 18 hours. The mixture was cooled, diluted with H20 and extracted with EtOAc which was dried (Na2S04), filtered and concentrated to provide a yellow oil (177 mg, 93%).
C) 2,2,2-Trifluoro-7-Methyl-5-oxa-6,13-diazatetracyclo[9.3.1.02'-'°.0°=a entadeca-2,4(8),6,9-tetraene-ethanone The above oil, 2,2,2-trifluoro-1-[4-hydroxy-5-(1-hydroxyimino-ethyl)-10-aza tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl]-ethanone (177 mg, 0.54 mmol) was stirred in DCE (3 mL), treated with triethylamine (0.4 mL, 2.8 mmol) and acetic anhydride (Ac20) (0.3 mL, 2.8 mmol) then stirred 18 hours. The reaction was treated with HZO and extracted with EtOAc. The extracts were dried (Na2S04), filtered and concentrated to a yellow oil which was dissolved in anhydrous DMF (3 mL) and treated with 60% NaH in oil (32 mg, 1.08 mmol).
After stirring 18 hours, additional 60% NaH in oil was introduced (33 mg) and the mixture was stirred 2 hours. The reaction was quenched with H20 (5 mL) and extracted with 80%
EtOAc/hexanes (3 x 30 mL). The organic layer was washed with H20 (3 x 20 mL), dried (Na2S04), filtered and concentrated and chromatographed to provide an oil (40%
EtOAc/hexanes R, 0.56).
D) 7-Methyl-5-oxa-6,13-diazatetracyclo[9.3.1.OZ'-'°.0°=a]pentadeca-2,4(8),6,9-tetraene hydrochloride Utilizing the methods described in Example 9C, 2,2,2-Trifluoro-7-Methyl-5-oxa-6,13 diazatetracyclo[9.3.1.02''°.04'8]pentadeca-2,4(8),6,9-tetraene-ethanone was converted to the title compound. This was treated with 3N HCI EtOAc (3 mL), concentrated and dissolved in a minimum of CHZCIZ which was saturated with hexanes and stirred. After 18 hours the white crystalline product was collected by filtration (18 mg, 13% overall). 'H NMR
(400 MHz, DMSO-de) b 7.72 (s, 1 H), 7.63 (s, 1 H), 3.42-2.98 (m, 6H), 2.50 (s, 3H), 2.23 (m, 1 H), 2.08 (d, J=10.5 Hz, 1 H). APCI MS m/e 215.2 [(M + 1 )+].
~YA~IIDI C 'Z7 4-(2-Methyl-2H-pyrazol-3-yl)-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-trien_e hydrochloride and 4-(1-Methyl-1 H-pyrazol-3-yl)-10-aza-tricyclo[6 3 1 OZ'-'dodeca-2(7),3,5-triene hydrochloride 1-(4-Acetyl-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (1.0 g, 3.3 mmol) and dimethylformamide dimethylacetal (DMF-DMA) (4.0 g, 33.6 mmol) were warmed to 140°C for 18 hours. After cooling, a crystalline precipitate was filtered and rinsed with EtOAc (690 mg, 58%).
The above solid, 3-dimethylamino-1-(10-trifluoroacetyl-10-aza tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-4-yl)-propenone, (200 mg, 0.56 mmol) was dissolved in EtOH (2 mL) and treated with 5N HCI EtOH (0.1 mL) followed by methyl hydrazine (0.6 mmol). The resulting mixture was warmed to 70°C for 4 hours. The mixture was cooled, diluted with water and extracted with EtOAc, dried (NaZS04) and concentrated.
Chromatography on Silica gel provided a 311 mixture of regioisomeric products (130 mg, 68%). (TLC 50% EtOAc/hexanes R, 0.40).
The above oil (130 mg, 0.388 mmol) and Na2C03(s) (82 mg, 0.775 mmol) were stirred in MeOH (10 mL) and H20 (5 mL) for 18 hours. After cooling the reaction was diluted with water, extracted with CHzCl2 dried through a cotton plug and concentrated. The product was purified by chromatography on Silica gel and concentrated to an oil. The salt was generated with 2N HCI MeOH, concentrated and recrystallized from MeOHIEtOAc to provide a mixture of regioisomeric pyrrazoles (85 mg, 58%). (5% MeOH/CHzCl2 (NH3) R, 0.25). TFA-precursor APCI MS m/e 336.2 [(M + 1 ) +].
GxnnApl ~ asp 4,5-DICHLORO-10-AZATRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 1-(4,5-Dichloro-10-aza-tricyclo[6.3.1.02~'-]dodeca-2(7),3,5-men-10-yl)-2 2,2-trifluoro-ethanone (Based on Campaigne, E.; Thompson, W. J. Org. Chem. 1950, 72, 629.) 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (539 mg, 2.1 mmol) was stirred in CH2CI2 (5 mL) and treated with IC13 (s) (982 mg, 4.21 mmol).
The resulting orange solution was stirred 0.5 hours, poured into saturated aqueous NaHS03 solution (25 mL), extracted with CH2CIz (3 x 25 mL), dried through a cotton plug and concentrated to an oil (570 mg, 84%) (TLC 50% EtOAclhexanes R, 0.62).
B) 4,5-dichloro-10-azatricyclo[6.3.1.02=']dodeca-2(7),3,5-triene hydrochloride 1-(4,5-Dichloro-10-aza-tricycfo[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (570 mg, 1.75 mmol) was stirred in MeOH (25mL) and treated with NaZC03(s) (5 g, 47 mmol) in H20 (5 mL). The stirred mixture was warmed to 70°C for 4 hours, concentrated to solids, diluted with Hz0 and extracted with EtOAc (3 x 40 mL). The product was extracted into 1 N aqueous HCI solution (2 x 40 mL) which was washed with EtOAc then neutralized with saturated aqueous Na2C03 solution to pH~IO. Product was extracted with CHZCIZ
{3 x 40 mL), filtered through a cotton plug and concentrated to an oil (400 mg, 100%).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) and concentrated, then dissolved in a minimum of MeOH and which was saturated with Et20 and stirred 18 hours. The product was collected by filtration (210 mg, 45%). (TLC
50%
EtOAc/hexanes (NH3) R~ 0.08). 'H NMR (400 MHz, DMSO-de) 8 7.58 (s, 2H), 3.33-2.97 (m, 6H), 2.18 (m, 1H), 1.99 (d, J=10.5 Hz, 1H).'3C NMR (100 MHz,DMSO-ds) 8 141.02, 130.60, 126.58, 45.54, 40.55, 38.30. GCMS m/e 227, 229 (M+). mp 283-291 °C.
~X~AAPI ~ Z~
Iw"-f~'-DIN~THYL 10~iZATRICYCLO[6.3.1.0~]DODECAr2('n,3,5-TRIENE-0.,SULFONAMIDE
HYDROCHLORIDE
A) 10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02-']dodeca-2(7),3,5-triene-4-sulfonyl chloride 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (530 mg, 2.1 mmol) was added to chlorosulfonic acid (2 mL, 30 mmol) and stirred for 5 minutes.
The mixture was quenched with ice, extracted with EtOAc, dried (NaZS04), filtered and concentrated to provide an oil (640 mg, 87%). (TLC 30% EtOAclhexanes R, 0.15).
B) N4,N'--Dimethyl-10-azatricyclo[6.3.1.Oz=']dodeca-2(7),3,5-triene-4-sulfonamide hydrochloride 10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-sulfonyl chloride (320 mg, 0.9 mmol) was stirred in THF (10 mL) and treated with 40% MeZNH/Hz0 (1.5 mL).
After 10 minutes the mixture was concentrated and chromatographed on Silica gel (TLC 30%
EtOAc/hexanes R, 0.31 ) to provide an oil (256 mg, 78%). This material was dissolved in MeOH (6 mL) and NH40H (2 mL) and stirred 18 hours. The mixture was concentrated and azeotroped from MeOH (3x) The resulting oil was dissolved in MeOH and treated with 3N HCI
EtOAc (4 mL), concentrated, dissolved in a minimum of MeOH and which was saturated with EtzO and stirred 18 hours. The product was collected by filtration as a white powder (163 mg, 59%). (TLC 10% MeOH/ CHZCIz (NH3) R~ 0.54). 'H NMR (data, free base) (400 MHz, CDC13) 8 7.64 (m, 2H), 7.41 (d, J=8.0 Hz, 1 H), 3.30 (m, 2H), 3.20 (d, J=12.5 Hz, 2H), 3.07 (dd, J=12.5,2.2 Hz, 2H), 2.69 (s, 6H), 2.45, (m, 1 H), 2.00 (d, J=11.0 Hz, 1 H).
'3C NMR (100 MHz, CDCI3) 8 128,43, 124.16, 122,75, 46.67, 46.55, 42.11, 39,44, 37,81. GCMS m/e 266 (M+).
(data HCI salt) 'H NMR (400 MHz, DMSO-ds) 8 7.68-7.52 (3H), 3.38 (m, 2H), 3.24 (m, 2H), 3.04 (m, 2H), 2.58 (s, 6H), 2.22 (m, 1H), 2.04 (d, J=11.0 Hz, 1H). GCMS m/e 266 (M+). Anal.
Calcd. for C,3H,eNZO2HCl: C, 51.56; H, 6.32; N, 9.25. Found C, 51.36; H,6.09;
N,9.09.
FXAMPI F an 4-(1-PYRROLIDINYLSULFONYL)-10-AZATRICYCLO[6.3.1.02'-']DODECA-2(7),3,5-TRIENE HYDROCHLORIDE
The pyrrolidine analogue was prepared from 10-trifluoroacetyl-10-aza-tricyclo(6.3.1.0z'']dodeca-2(7),3,5-triene-4-sulfonyl chloride (320 mg, 0.9 mmol) as by substituting pyrroline in the coupling step described in Example 39B. The TFA
product was isolated as an oil (314 mg, 89%). Deprotection and conversion to the salt as in Example 39B
affords a white powder (189 mg, 63%). (TLC 10% MeOH/CH2ClZ (NH3) Rt 0.60).
(TLC 50%
EtOAc/hexanes R, 0.65). 'H NMR (400 MHz, CDCI3) 8 7.66 (d, J=8.0 Hz, 1 H), 7.64 (s, 1 H), 7.37 (d, J=8.0 Hz, 1 H), 3.30-3.15 (m, 8H), 3.00 (m 2H), 2.39 (m, 1 H), 1.98 (d, J=11.5 Hz, 1 H), 1.72 (m, 4H).'3C NMR (100 MHz, CDC13) 8 146.91, 144.08, 136.65, 127. 90, 124.18, 122.36, 50.43, 47.87, 46.80, 46.63, 42.11, 39.63, 25.10. APCI MS m/e 293 [(M + 1) '].
(data HCI salt) 'H NMR (400 MHz, DMSO-ds) 8 9.78 (br s, NH), 8.1 (br s, NH), 7.73 (d, J =1.5 Hz,1H), 7.66 (dd, J=8.0,1.5 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 3.39-3.01 (10H), 2.21 (m, 1H), 2.04 (d, J=11.0 Hz, 1H), 1.66 {m, 4H). GCMS m/e 292 (M''). Anal. Calcd. For C~3H~$NZOZHCL1/2MeOH: C, 54.07; H, 6.47; N, 8.51. Found C, 53.98; H,6.72; N, 8.12 FXAMP1 F d~
5,13-DIAZATETRACYCLO[9.3.1.02'-'°.0-°i]PENTADECA-2,.4(8) 9-TRIEN-HYDROCHLORIDE (The title compound was prepared following the procedures described in Quallich, G. J.; Morrissey, P. M. Synthesis 1993, 51-53, treating 4,5-dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester as an equivalent to an ortho fluoro phenyl moiety.) 'H NMR (400 MHz, DMSO-ds) b 10.42 (s, NH), 9.88 (br s, NH), 7.52 (br s, 1 H), 7.15 (s, 1 H), 6.79 (s, 1 H), 3.41 (d, J=5.0 Hz, 2H), 3.35-3.13 (m, 4H), 2.93 (m, 2H), 2.12 (m, 1 H), 1.95 (d, J=11.5 Hz, 1 H). APCI MS m/e 215.2 [(M + 1 )+].
FXAMPI ~ d~
6-OXO-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 O2~'-°._04~PENTADECA-2(10),3 6 8-TETRAENE HYDROCHLORIDE (For references, see: Nachman, R. J. J. Het. Chem.
1982, 1545.) 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-trien-10-yl)-ethanone (317 mg, 1.11 mmol) was stirred in THF (10 mL), treated with carbonyldiimidazole (269 mg, 1.66 mmol) and warmed to 60°C for 18 hours. The mixture was concentrated, diluted with CH2CIz (50 mL) and washed with 1 N aqueous HCI
solution (3 x 10 mL). The organic layer was dried through a cotton plug, concentrated and chromatographed on Silica gel (50% EtOAc/Hexanes) to provide an oil {130 mg). This material converted to the title compound by the methods described in Example 9C.'H NMR (400 MHz, DMSO-ds) b 11.78 (s, NH), 9.56 (br s, NH), 7.63 (br s, NH), 7.24 (s, 1H), 7.07 (s,1H), 3.26 (br s, 2H), 3.16 (br t, J=9.5 Hz, 1 H), 2.93 (br s, 1 H), 2.18 (m, 1 H), 1.97 (d, J=11.0 Hz, 1 H). APCI MS m/e 217.2 ((M + 1)'].
3-TRIFLUOROMETHYL-10-AZA-TRICYCLO(6 3 1 OZ--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE (See Grunewald, G. L.; Paradkar, V. M.; Pazhenchevsky, B.;
Pleiss, M.
A.; Sall, D. J.; Seibel, W. L.; Reitz, T. J. J. Org. Chem. 1983, 48, 2321-2327. Grunewald, G.
L.; Markovich, K. M.; Sall, D. J. J. Med. Chem. 1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-6-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) b 7.67-7.50 (3H), 3.65 (br s, 1H), 3.49-3.42 (m, 2H), 3.29 (s, 1H), 3.28-3.16 (m, 2H), 2.42 (m, 1H), 2.18 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 ((M + 1 )']. (HCI salt) mp 275-277 °C. Anal. Calcd. for C,zH~2F3N.HC1.113Hz0: C, 53.44; H, 5.11; N, 5.19. Found C. 53.73; H, 4.83; N, 5.16.
3-PHENYL-10-AZA-TRICYCLO[6.3.1.Oy]DODECA-2(7),3.5-TRIENE
HYDROCHLORIDE
A) 5-Fluoro-l,4-dihydro-l,4-methano-naphthalene and 5-iodo-l,4-dihydro-1,4-methano-naphthalene (Eisch, J. J.; Burlinson, N. E. J. Amer. Chem. Soc. 1976, 98, 753-761.
Paquette, L. A.;
Cottrell, D. M.; Snow, R. A. J. Amer. Chem. Soc. 1977, 99, 3723-3733.) Magnesium turnings (9.37 g, 385 mmol) were stirred in anhydrous THF (1000 mL) in a flame dried 21 3 neck round bottom flask equipped with a non-equalizing addition funnel with a Nz flow adapter, magnetic stirrer and efficient condenser equipped with a Nz flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle. 2,6-Difluoro-iodobenzene (0.3 g) was added followed by of 3N EtMgBr in THF (0.3 mL). The addition funnel was charged with an intimate mixture of cyclopentadiene (24.24 g, 367 mmol) and 2,6-difluoro-iodobenzene (88.0 g, 367 mmol). Small portions (~1 mL) of the intimate mixture were introduced to assist initiation (~4x). After -15 minutes, the reaction initiated (exotherm, and vapor condensation) and heating was maintained as necessary during the addition of the contents of the addition funnel. The reaction was then maintained at reflux for -1 hour (no SM by GCMS).
The reaction was cooled to room temperature and quenched with Hz0 (200 mL) followed by aqueous 1N HCI solution (200 mL) to dissolve the solids. Product was extracted with hexanes (4 x 150 mL). The combined organic layer was washed with saturated aqueous NaHC03 solution (150 mL), dried (Na2S0,), filtered through a Silica plug with hexanes rinse and concentrated to an oil (70 g). Chromatography on Silica gel eluting with hexanes provided two lots (9.0 and 21.0 g), which contained primarily 5-iodo-l,4-dihydro-l,4-methano-naphthalene. (TLC hexanes R, 0.63).
B~ 5-lodo-1 2,3 4-tetrahydro-l ,4-methano-naphthalene-2,3-diol 5-lodo-1,4-dihydro-l ,4-methano-naphthalene (20 g) and N-methyl morpholine N-oxide (17.61 g, 130 mmol) were stirred in acetone (90 mL) and Hz0 (13 m1). To this was added a solution of OsO, (0.2 mL, 2.5%wt. solution in t-BuOH, 0.02 mmol). After 144 hours, Florisil* (5 g) and saturated aqueous NaHS03 solution (3 mL) were added and stirred for 112 hour. The *Trade-mark miicture was filtered through a Celite pad and the filtrate concentrated to produce an oil which was purified by chromatography on Silica gel eluting with a gradient of hexanes to 100°~
EtOAc to provide a yellow solid (13.73 g). APCI MS mle 301.1 [(M - 1)').
C) 10-Benzyl-3-iodo-10-aza-tricyclo[6.3.1.02='ldodeca-2(7),3,5-triene 5-lodo-1,2,3,4-tetrahydro-1,4-methano-naphthalene-2,3-diol (8.33 g, 27.6 mmol) and Et,NBnCI (10 mg) were vigorously stirred in dichloroethane (25 mL) and Hz0 (75 mL) then treated with sodium periodate (6.17 g, 29.0 mmol). After 1.5 hours, the layers were separated and the aqueous layer extracted with DCE (2 x 40 mL). The combined organic layer was washed with Hz0 (4 x 30 mL) until no reaction to starch iodide paper was observed, then with saturated aqueous NaCI solution (30 mL). The organic layer was dried through a cotton plug and treated with benzyl amine (3.16 mL, 29.0 mmol) and stirred for 2 minutes then transferred to an addition funnel. This solution was added over -10 minutes to a vigorously stirred cooled (0 °C) mixture of NaHB(OAc)~ (18.72 g, 88.0 mmol) in DCE (150 mL).
After addition was complete, the mixture was stirred without cooling far 2 hours. The mixture was quenched with saturated aqueous NazCO~ solution (100 mL) and stirred for 1 hour, then the layers were separated and the aqueous layer was extracted with CH2CIz (3 x 50 rnL). The combined organic layer was washed with saturated aqueous NaCI solution (50 mL), dried through a cotton plug and concentrated. Chromatography on Silica gel provided an oil (6.3 g, 61%).
(TLC 5% EtOAclhexanes R, 0.10).'H NMR (400 MHz, CDCI3) 5 7.61 (d, J= 8.0 Hz, 1H), 7.28-7.22 (m, 3H), 7.13 (d, J=8.0 Hz,IH), 6.98-6.94 (m, 3H), 3.58 (AB dd, J=14.2 Hz, 2H), 3.26 (br s, 1H), 3.21 (br s, 1H), 3.04 (br d, J=10.2 Hz, 1H), 2.83 (br d, J=10.2 Hz, 1H), 2.47 (d, J=10.0 Hz, 1H), 2.39 (d, J=10.0 Hz, 1H), 2.34 (m, 1H), 1.72 (d, J=10.5 Hz, 1H). APCI
MS m/e 376.0 [(M + 1)'j~
D) 10-Benzyl-3-phenyl-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene (Far a discussion, see: Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483.) 10-Benzyl-3-iodo-10-aza-tricyclo[6.3.1.0~~'Jdodeca-2(7),3,5-triene (375.3 mg, 1.0 mmol), potassium acetate (785 mg, 8.0 mmol) and phenyl boronic acid (183 mg, 1.5 mmol) were combined in 1011 EtOH/Hz0 (5 mL). The mixture was degassed (3 vacuumM=
cycles), treated with tetrakis(triphenylphosphine)palladium(0) (57.5 mg, 0.05 mmol) and warmed to 90 °C for 18h. The reaction was cooled, diluted with Hz0 and extracted with Et20 (3 x 50 mL).
The organic layer was washed with brine (50 mL), dried (MgSO,), filtered and concentrated to provide an oil (180 mg, 55%). (TLC 4%EtOAc/hexanes R, 0.18). GCMS m/e 325 (M)'.
3-Phenyl-10-aza-tricyclo[6.3.1.Oz=~ldodeca-2(7),3,5-triene hydrochloride 'Trade-mark 10-Benzyl-3-phenyl-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene was converted into the title compound utilizing the conditions described in Example 2D. (TLC
10%
MeOH/CH2Cl2 (NH3) R~ 0.30). (data for free base) 'H NMR (400 MHz, CDCI3) b 7.46-7.15 (8H), 3.17 (br s, 1 H), 3.01 (m, 2H), 2.93 (d, J=13.0 Hz, 1 H), 2.72 (dd, J=10.5,2.5 Hz, 1 H), 2.63 (dd, J=10.5,2.5 Hz, 1 H), 2.41 (m, 1 H), 1.91 (d, J=10.5 Hz, 1 H). APCI MS m/e 236.2 [(M + 1 )+].
(HCI salt) mp 262-265 °C. Anal. Calcd. for C,~H,~N.HCL1/3Hz0: C, 73.26;
H, 6.86; N, 5.19.
Found C, 73.50; H, 6.77; N, 5.04.
3-HYDROXY-10-AZA-TRICYCLOf6.3.1.OZ--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 10-Benzyl-3-boronic acid-10-aza-tricyclo[6 3 1 OZ=']dodeca-2(7),3,5-triene 10-Benzyl-3-iodo-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-triene (3.0 g, 7.99 mmol) was stirred in anhydrous THF (40 mL) at -78 °C under nitrogen and treated dropwise with n BuLi (3.84 mL of 2.5M soln, in hexanes, 9.59 mmol). After 10 minutes, tri-isopropylborate (4.61 mL, 20.0 mmol) was added dropwise. After ~1/2 hour, the reaction was poured into saturated aqueous NaHC03 solution, stirred 5 minutes and extracted with EtOAc (3 x 50 mL) and concentrated. The residue was dissolved in 30% Et20/hexanes and extracted with 1 N
NaOH aqueous solution (4 x 50 mL). The combined aqueous basic layer was treated with concentrated HCI to achieve pH 8 and extracted with EtOAc (4 x 25 mL), dried (Na2S04) and stripped. Chromatography on Silica gel eluting first with 3% EtOAc/hexanes to remove non-polar components, then with 5% MeOH/CH2Cl2 provides the title compound. (TLC
25%
EtOAc/hexanes R, 0.60).
B) 10-Benzyl-3-hydroxy-10-aza-tricyclo[6.3.101]dodeca-2(7),3,5-triene 10-Benzyl-3-boronic acid-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene (140 mg, 0.48 mmol) dissolved in THF (5 mL) was treated with N-methylmorpholine-N-oxide (64.5 mg, 0.48 mmol) and brought to reflux for 1 hour. The reaction was concentrated and chromatographed on Silica gel to provide product. (TLC 25% EtOAclhexanes Rf 0.18). 'H
NMR (400 MHz, CDCI3) b 7.18-7.15 (3H), 7.04 (dd, J= 8.0,7.0 Hz, 1 H), 6.95 (m, 2H), 6.75 (d, J=7.0 Hz, 1H), 6.59 (dd, J=8.0,1.0 Hz, 1H), 3.53 (br s, OH), 3.51 (AB d, J=14.0 Hz, 2H), 3.28 (br s, 1H), 3.06 (br s, 1H), 2.91 (dd, J=8.5,1.5 Hz, 1H), 2.79 (ddd, J=8.5,1.5,1.5 Hz, 1H), 2.42 (d, J=11.0 Hz, 1 H), 2.39 (d, J=11.0 Hz, 1 H), 2.23 (m, 1 H), 1.65 (d, J=10.5 Hz, 1 H). APCI MS
m/e 266.5 [(M + 1 )'].
C) 3-Hydroxy-10-aza-tricyclo[6.3.1.0~)dodeca-2(7),3 5-triene hydrochloride 10-Benzyt-3-hydroxy-10-aza-tricyclo[6.3.1.02~')dodeca-2(7),3,5-triene (160 mg, 0.60 mmol) was converted into the title compound by the methods described in Example 1 D. 'H
NMR (400 MHz, CDCI3) 8 7.15 (dd, J=8.0,7.5 Hz, 1 H), 6.84 (d, J=7.5 Hz, 1 H), 6.76 (d, J=8.0 Hz, 1 H), 3.51 (br s, 1 H), 3.33-3.25 (3H), 3.16 (d, J=12.0 Hz, 1 H), 3.09 (d, J=12.0 Hz, 1 H), 2.29 (m, 1 H), 2.02 (d, J=11.0 Hz, 1 H). APCI MS m/e 175.8 [(M + 1 )+J. (HCI salt) mp 253-255 °C.
4,5-DIFLUORO-10-AZA-TRICYCLO[6.3 1 02='jDODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
The title compound was prepared by the methods described in Example 1 and 2 starting with 2,4,5-trifluorobromobenzene. 'H NMR (400 MHz, CDCl3) 8 7.31 (t, J=8.5 Hz, 2H), 3.48-3.13 (6H), 2.38 (m, 1 H), 2.11 (d, J=11.5 Hz, 1 H). APCI MS m/e 196.2 [(M
+ 1 ) ']. (HCI
salt) mp 301-303 °C. Anal. Calcd. for C"H"FZN.HC1.1/6H20: C, 56.30; H, 5.30; N, 5.97.
Found C, 56.66; H, 5.41; N, 5.96.
FX~AADI ~ ~~
6-ETHYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 OZ''-°.04~PENTADECA-2(10),3,6 TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-trien-10-yl)-ethanone and propionyl chloride were converted to the title compound following the procedures described in Example 30 and Goldstein, S. W.; Dambek, P. J. J. Het.
Chem.
1990, 27, 335. 'H NMR (400 MHz, CD30D) 8 7.64 (s, 1 H), 7.62 (s, 1 H), 3.48 (d, J=2.5 Hz, 2H), 3.41 (d, J=12.0 Hz, 2H), 3.20 (2H), 3.01 (q, J=7.5 Hz, 2H), 2.45 (m, 1 H), 2.17 (d, J=11.5 Hz, 1H), 1.42 (t, J=7.5 Hz, 3H). APCI MS m/e 229.2 [(M + 1)~).
6-ISOPROPYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 02''-°.0''~]PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~')dodeca-2(7), 3, 5-trien-10-yl)-ethanone and isobutyryl chloride were converted to the title compound following the procedures described in EXAMPLE 47. (TLC 25% EtOAc/hexanes R, 0.14). 'H NMR
(400 MHz, CD30D) 8 7.65 (2H), 3.49 (br s, 2H), 3.41 (d, J=12.0 Hz, 2H), 3.33-3.19 (3H), 2.45 (m, 1H), 2.18 (d, J=11.5 Hz, 1H), 1.45 (d, J=7.0 Hz, 6H). APCI MS m/e 243.2 [(M +
1)+]. (HCI salt) mp 249-251 °C.
~X~11API G AD
6-BENZYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 Oz''-°._04~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-trien-10-yl)-ethanone and phenyl-acetyl chloride were converted to the title compound following the procedures described in EXAMPLE 47. 'H NMR (400 MHz, CD30D) b 7.63 (s, 1H), 7.58 (s, 1 H), 7.36-7.24 (5H), 4.29 (s, 2H), 3.46 (d, J=2.5 Hz, 2H), 3.39 (d, J=12.0 Hz, 2H}, 3.18 (2H), 2.42 (m, 1 H), 2.15 (d, J=11.5 Hz, 1 H). APCI MS m/e 291.2 [(M + 1 )+~.
A) Acetic acid 10-trifluoroacetyl-10-aza-tricyclo[6 3 1 0~'jdodeca-2(7),3,5-men-4-y!
ester 1-(4-Acetyl-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (2.5 g, 8.41 mmol) and 3-chloroperoxybenzoic acid (m-CPBA) (7.5 g, 42 mmol) were stirred in CHZCIZ (20 mL) and warmed to 40°C for 18 hours. The mixture was cooled to room temperature, then treated with dimethylsulfide (MeZS) (3 mL, 40.8 mmol) and stirred 24 hours. The resulting mixture was poured into ice and saturated aqueous Na2C03 solution (100 mL) then extracted with Et20 (4 x 40 mL). The organic layer was washed saturated aqueous NaZC03 solution (3 x 40 mL) then dried (Na2S04), filtered and concentrated to afford an oil (1.83 g, 69%). (TLC EtOAc R, 0.80).
B) 2,2,2-Trifluoro-1-(4-hydroxy-10-aza-tricyclo[6.3.1.O~Ldodeca-2(7),3,5-men-10-yl)-ethanone Acetic acid 10-trifiuoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-men-4-yl ester (900 mg, 2.87 mmol) was stirred in MeOH (20 mL) and saturated aqueous NaHC03 solution (15 mL) for 48 hours. The mixture was concentrated, diluted with H20 and extracted with CH2CI2 (3 x 20 mL) then dried through a cotton plug. Chromatography on Silica gel provided pure product (420 mg, 54%). (TLC 5% MeOH/CHZCIZ R, 0.44). 'H NMR (400 MHz, CDCI3) b 7.05 (m, 1 H), 6.70 (m, 1 H), 6.62 (m, 1 H), 4.32 (m, 1 H), 3.84 (m, 1 H), 3.48 (m, 1 H), 3.21 (br s, 1 H), 3.16 (br s, 1 H), 3.09 (m, 1 H), 2.38 (m, 1 H), 1.97 (d, J=11.0 Hz, 1 H).
C) 10-Azatricycloj6.3.1.0~]dodeca-2(7),3,5-trien-4-of hydrochloride 2,2,2-Trifluoro-1-(4-hydroxy-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-ethanone (50 mg, 0.184 mmol) was dissolved in MeOH/H20 (3/1, 5 mL), treated with Na2C03(s) (40 mg, 0.369 mmol) and warmed to 65°C for 2 hours. The mixture was concentrated, diluted with Hz0 and extracted with CHzCIZ (3 x 20 mL) then dried through a cotton plug. Filtration through a Silica gel plug provided an oil (10%
MeOH/CHZCIZ) which was treated with 3N HCI EtOAc (3 mL) then concentrated, dissolved in a minimum of MeOH
which was saturated with Et20 and stirred. After 18 hours the white crystalline product was collected by filtration (10 mg, 26%).'H NMR (400 MHz, CDOD3) 8 7.16 (d, J=8.0 Hz, 1 H), 6.80 (d, J=2.0 Hz, 1H), 6.72 (dd, J=8.0,2.0 Hz, 1H), 3.32-3.28 (4H), 3.09 (dd, J=14.5,12.0 Hz, 2H), 2.32 (m, 1 H), 2.03 (d, J=11.0 Hz, 1 H). APCI MS m/e 176.2 j(M + 1 )+]. mp 308 (dec.) °C.
7-METHYL-5-OXA-6,13-DIAZATETRACYCLO[9.3.1.02''-°.0°~PENTADECA-2,4(8),6,9-TETRAENE HYDROCHLORIDE
A) 1-(4-Acetyl-5-hydroxy-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-trien-10-yl)-2,2 2-trifluoro-ethanone Acetic acid 10-trifluoroacetyl-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-men-4-yl ester (800 mg, 2.55 mmol) was combined with AICI3 (1.0 g, 7.65 mmol) and warmed to 170°C for 2 hours. The mixture was cooled and treated with 1 N aqueous HCI solution (20 mL), extracted with EtOAc and dried (NazS04). Chromatography affords an oil (190 mg, 24%).
(TLC EtOAc R, 0.75). 'H NMR (400 MHz, CDC13) 8 12.58 (s, 0.5H), 12.52 (s, 0.5H), 7.53 (s, 1 H), 6.86 (s, 1 H), 4.33 (m, 1 H), 3.91 (m, 1 H), 3.56 (m, 1 H), 3.28 (br s, 1 H), 3.24 (br s, 1 H), 3.14 (m, 1 H), 2.35 (m, 1 H), 1.97 (br d, J=11.2 Hz, 1 H).
B) 2,2,2-Trifluoro-1-[4-hydroxy-5-(1-hydroxyimino-ethyl)-10-aza-tricyclo(6.3.1.OZ-~'-]dodeca-2(7),3,5-men-10-yl]-ethanone 1-(4-Acetyl-5-hydroxy-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (190 mg, 0.605 mmol), hydroxylamine HCI (99 mg, 1.21 mmol) and NaOAc (118 mg, 1.21 mmol) were combined in MeOH (4 mL) and H20 (1 mL) and warmed to 65°C
for 18 hours. The mixture was cooled, diluted with H20 and extracted with EtOAc which was dried (Na2S04), filtered and concentrated to provide a yellow oil (177 mg, 93%).
C) 2,2,2-Trifluoro-7-Methyl-5-oxa-6,13-diazatetracyclo[9.3.1.02'-'°.0°=a entadeca-2,4(8),6,9-tetraene-ethanone The above oil, 2,2,2-trifluoro-1-[4-hydroxy-5-(1-hydroxyimino-ethyl)-10-aza tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl]-ethanone (177 mg, 0.54 mmol) was stirred in DCE (3 mL), treated with triethylamine (0.4 mL, 2.8 mmol) and acetic anhydride (Ac20) (0.3 mL, 2.8 mmol) then stirred 18 hours. The reaction was treated with HZO and extracted with EtOAc. The extracts were dried (Na2S04), filtered and concentrated to a yellow oil which was dissolved in anhydrous DMF (3 mL) and treated with 60% NaH in oil (32 mg, 1.08 mmol).
After stirring 18 hours, additional 60% NaH in oil was introduced (33 mg) and the mixture was stirred 2 hours. The reaction was quenched with H20 (5 mL) and extracted with 80%
EtOAc/hexanes (3 x 30 mL). The organic layer was washed with H20 (3 x 20 mL), dried (Na2S04), filtered and concentrated and chromatographed to provide an oil (40%
EtOAc/hexanes R, 0.56).
D) 7-Methyl-5-oxa-6,13-diazatetracyclo[9.3.1.OZ'-'°.0°=a]pentadeca-2,4(8),6,9-tetraene hydrochloride Utilizing the methods described in Example 9C, 2,2,2-Trifluoro-7-Methyl-5-oxa-6,13 diazatetracyclo[9.3.1.02''°.04'8]pentadeca-2,4(8),6,9-tetraene-ethanone was converted to the title compound. This was treated with 3N HCI EtOAc (3 mL), concentrated and dissolved in a minimum of CHZCIZ which was saturated with hexanes and stirred. After 18 hours the white crystalline product was collected by filtration (18 mg, 13% overall). 'H NMR
(400 MHz, DMSO-de) b 7.72 (s, 1 H), 7.63 (s, 1 H), 3.42-2.98 (m, 6H), 2.50 (s, 3H), 2.23 (m, 1 H), 2.08 (d, J=10.5 Hz, 1 H). APCI MS m/e 215.2 [(M + 1 )+].
~YA~IIDI C 'Z7 4-(2-Methyl-2H-pyrazol-3-yl)-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-trien_e hydrochloride and 4-(1-Methyl-1 H-pyrazol-3-yl)-10-aza-tricyclo[6 3 1 OZ'-'dodeca-2(7),3,5-triene hydrochloride 1-(4-Acetyl-10-aza-tricyclo[6.3.1.OZ'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (1.0 g, 3.3 mmol) and dimethylformamide dimethylacetal (DMF-DMA) (4.0 g, 33.6 mmol) were warmed to 140°C for 18 hours. After cooling, a crystalline precipitate was filtered and rinsed with EtOAc (690 mg, 58%).
The above solid, 3-dimethylamino-1-(10-trifluoroacetyl-10-aza tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-4-yl)-propenone, (200 mg, 0.56 mmol) was dissolved in EtOH (2 mL) and treated with 5N HCI EtOH (0.1 mL) followed by methyl hydrazine (0.6 mmol). The resulting mixture was warmed to 70°C for 4 hours. The mixture was cooled, diluted with water and extracted with EtOAc, dried (NaZS04) and concentrated.
Chromatography on Silica gel provided a 311 mixture of regioisomeric products (130 mg, 68%). (TLC 50% EtOAc/hexanes R, 0.40).
The above oil (130 mg, 0.388 mmol) and Na2C03(s) (82 mg, 0.775 mmol) were stirred in MeOH (10 mL) and H20 (5 mL) for 18 hours. After cooling the reaction was diluted with water, extracted with CHzCl2 dried through a cotton plug and concentrated. The product was purified by chromatography on Silica gel and concentrated to an oil. The salt was generated with 2N HCI MeOH, concentrated and recrystallized from MeOHIEtOAc to provide a mixture of regioisomeric pyrrazoles (85 mg, 58%). (5% MeOH/CHzCl2 (NH3) R, 0.25). TFA-precursor APCI MS m/e 336.2 [(M + 1 ) +].
GxnnApl ~ asp 4,5-DICHLORO-10-AZATRICYCLO[6.3.1.0'-]DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 1-(4,5-Dichloro-10-aza-tricyclo[6.3.1.02~'-]dodeca-2(7),3,5-men-10-yl)-2 2,2-trifluoro-ethanone (Based on Campaigne, E.; Thompson, W. J. Org. Chem. 1950, 72, 629.) 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (539 mg, 2.1 mmol) was stirred in CH2CI2 (5 mL) and treated with IC13 (s) (982 mg, 4.21 mmol).
The resulting orange solution was stirred 0.5 hours, poured into saturated aqueous NaHS03 solution (25 mL), extracted with CH2CIz (3 x 25 mL), dried through a cotton plug and concentrated to an oil (570 mg, 84%) (TLC 50% EtOAclhexanes R, 0.62).
B) 4,5-dichloro-10-azatricyclo[6.3.1.02=']dodeca-2(7),3,5-triene hydrochloride 1-(4,5-Dichloro-10-aza-tricycfo[6.3.1.OZ'']dodeca-2(7),3,5-men-10-yl)-2,2,2-trifluoro-ethanone (570 mg, 1.75 mmol) was stirred in MeOH (25mL) and treated with NaZC03(s) (5 g, 47 mmol) in H20 (5 mL). The stirred mixture was warmed to 70°C for 4 hours, concentrated to solids, diluted with Hz0 and extracted with EtOAc (3 x 40 mL). The product was extracted into 1 N aqueous HCI solution (2 x 40 mL) which was washed with EtOAc then neutralized with saturated aqueous Na2C03 solution to pH~IO. Product was extracted with CHZCIZ
{3 x 40 mL), filtered through a cotton plug and concentrated to an oil (400 mg, 100%).
The oil was dissolved in MeOH and treated with 3N HCI EtOAc (4 mL) and concentrated, then dissolved in a minimum of MeOH and which was saturated with Et20 and stirred 18 hours. The product was collected by filtration (210 mg, 45%). (TLC
50%
EtOAc/hexanes (NH3) R~ 0.08). 'H NMR (400 MHz, DMSO-de) 8 7.58 (s, 2H), 3.33-2.97 (m, 6H), 2.18 (m, 1H), 1.99 (d, J=10.5 Hz, 1H).'3C NMR (100 MHz,DMSO-ds) 8 141.02, 130.60, 126.58, 45.54, 40.55, 38.30. GCMS m/e 227, 229 (M+). mp 283-291 °C.
~X~AAPI ~ Z~
Iw"-f~'-DIN~THYL 10~iZATRICYCLO[6.3.1.0~]DODECAr2('n,3,5-TRIENE-0.,SULFONAMIDE
HYDROCHLORIDE
A) 10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02-']dodeca-2(7),3,5-triene-4-sulfonyl chloride 1-(10-Aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone (530 mg, 2.1 mmol) was added to chlorosulfonic acid (2 mL, 30 mmol) and stirred for 5 minutes.
The mixture was quenched with ice, extracted with EtOAc, dried (NaZS04), filtered and concentrated to provide an oil (640 mg, 87%). (TLC 30% EtOAclhexanes R, 0.15).
B) N4,N'--Dimethyl-10-azatricyclo[6.3.1.Oz=']dodeca-2(7),3,5-triene-4-sulfonamide hydrochloride 10-Trifluoroacetyl-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-4-sulfonyl chloride (320 mg, 0.9 mmol) was stirred in THF (10 mL) and treated with 40% MeZNH/Hz0 (1.5 mL).
After 10 minutes the mixture was concentrated and chromatographed on Silica gel (TLC 30%
EtOAc/hexanes R, 0.31 ) to provide an oil (256 mg, 78%). This material was dissolved in MeOH (6 mL) and NH40H (2 mL) and stirred 18 hours. The mixture was concentrated and azeotroped from MeOH (3x) The resulting oil was dissolved in MeOH and treated with 3N HCI
EtOAc (4 mL), concentrated, dissolved in a minimum of MeOH and which was saturated with EtzO and stirred 18 hours. The product was collected by filtration as a white powder (163 mg, 59%). (TLC 10% MeOH/ CHZCIz (NH3) R~ 0.54). 'H NMR (data, free base) (400 MHz, CDC13) 8 7.64 (m, 2H), 7.41 (d, J=8.0 Hz, 1 H), 3.30 (m, 2H), 3.20 (d, J=12.5 Hz, 2H), 3.07 (dd, J=12.5,2.2 Hz, 2H), 2.69 (s, 6H), 2.45, (m, 1 H), 2.00 (d, J=11.0 Hz, 1 H).
'3C NMR (100 MHz, CDCI3) 8 128,43, 124.16, 122,75, 46.67, 46.55, 42.11, 39,44, 37,81. GCMS m/e 266 (M+).
(data HCI salt) 'H NMR (400 MHz, DMSO-ds) 8 7.68-7.52 (3H), 3.38 (m, 2H), 3.24 (m, 2H), 3.04 (m, 2H), 2.58 (s, 6H), 2.22 (m, 1H), 2.04 (d, J=11.0 Hz, 1H). GCMS m/e 266 (M+). Anal.
Calcd. for C,3H,eNZO2HCl: C, 51.56; H, 6.32; N, 9.25. Found C, 51.36; H,6.09;
N,9.09.
FXAMPI F an 4-(1-PYRROLIDINYLSULFONYL)-10-AZATRICYCLO[6.3.1.02'-']DODECA-2(7),3,5-TRIENE HYDROCHLORIDE
The pyrrolidine analogue was prepared from 10-trifluoroacetyl-10-aza-tricyclo(6.3.1.0z'']dodeca-2(7),3,5-triene-4-sulfonyl chloride (320 mg, 0.9 mmol) as by substituting pyrroline in the coupling step described in Example 39B. The TFA
product was isolated as an oil (314 mg, 89%). Deprotection and conversion to the salt as in Example 39B
affords a white powder (189 mg, 63%). (TLC 10% MeOH/CH2ClZ (NH3) Rt 0.60).
(TLC 50%
EtOAc/hexanes R, 0.65). 'H NMR (400 MHz, CDCI3) 8 7.66 (d, J=8.0 Hz, 1 H), 7.64 (s, 1 H), 7.37 (d, J=8.0 Hz, 1 H), 3.30-3.15 (m, 8H), 3.00 (m 2H), 2.39 (m, 1 H), 1.98 (d, J=11.5 Hz, 1 H), 1.72 (m, 4H).'3C NMR (100 MHz, CDC13) 8 146.91, 144.08, 136.65, 127. 90, 124.18, 122.36, 50.43, 47.87, 46.80, 46.63, 42.11, 39.63, 25.10. APCI MS m/e 293 [(M + 1) '].
(data HCI salt) 'H NMR (400 MHz, DMSO-ds) 8 9.78 (br s, NH), 8.1 (br s, NH), 7.73 (d, J =1.5 Hz,1H), 7.66 (dd, J=8.0,1.5 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 3.39-3.01 (10H), 2.21 (m, 1H), 2.04 (d, J=11.0 Hz, 1H), 1.66 {m, 4H). GCMS m/e 292 (M''). Anal. Calcd. For C~3H~$NZOZHCL1/2MeOH: C, 54.07; H, 6.47; N, 8.51. Found C, 53.98; H,6.72; N, 8.12 FXAMP1 F d~
5,13-DIAZATETRACYCLO[9.3.1.02'-'°.0-°i]PENTADECA-2,.4(8) 9-TRIEN-HYDROCHLORIDE (The title compound was prepared following the procedures described in Quallich, G. J.; Morrissey, P. M. Synthesis 1993, 51-53, treating 4,5-dinitro-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene-10-carboxylic acid tert-butyl ester as an equivalent to an ortho fluoro phenyl moiety.) 'H NMR (400 MHz, DMSO-ds) b 10.42 (s, NH), 9.88 (br s, NH), 7.52 (br s, 1 H), 7.15 (s, 1 H), 6.79 (s, 1 H), 3.41 (d, J=5.0 Hz, 2H), 3.35-3.13 (m, 4H), 2.93 (m, 2H), 2.12 (m, 1 H), 1.95 (d, J=11.5 Hz, 1 H). APCI MS m/e 215.2 [(M + 1 )+].
FXAMPI ~ d~
6-OXO-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 O2~'-°._04~PENTADECA-2(10),3 6 8-TETRAENE HYDROCHLORIDE (For references, see: Nachman, R. J. J. Het. Chem.
1982, 1545.) 2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-trien-10-yl)-ethanone (317 mg, 1.11 mmol) was stirred in THF (10 mL), treated with carbonyldiimidazole (269 mg, 1.66 mmol) and warmed to 60°C for 18 hours. The mixture was concentrated, diluted with CH2CIz (50 mL) and washed with 1 N aqueous HCI
solution (3 x 10 mL). The organic layer was dried through a cotton plug, concentrated and chromatographed on Silica gel (50% EtOAc/Hexanes) to provide an oil {130 mg). This material converted to the title compound by the methods described in Example 9C.'H NMR (400 MHz, DMSO-ds) b 11.78 (s, NH), 9.56 (br s, NH), 7.63 (br s, NH), 7.24 (s, 1H), 7.07 (s,1H), 3.26 (br s, 2H), 3.16 (br t, J=9.5 Hz, 1 H), 2.93 (br s, 1 H), 2.18 (m, 1 H), 1.97 (d, J=11.0 Hz, 1 H). APCI MS m/e 217.2 ((M + 1)'].
3-TRIFLUOROMETHYL-10-AZA-TRICYCLO(6 3 1 OZ--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE (See Grunewald, G. L.; Paradkar, V. M.; Pazhenchevsky, B.;
Pleiss, M.
A.; Sall, D. J.; Seibel, W. L.; Reitz, T. J. J. Org. Chem. 1983, 48, 2321-2327. Grunewald, G.
L.; Markovich, K. M.; Sall, D. J. J. Med. Chem. 1987, 30, 2191-2208.) The title compound was prepared by the methods described in Example 1 and 2 starting with 2-fluoro-6-trifluoromethylbromobenzene. 'H NMR (400 MHz, CD30D) b 7.67-7.50 (3H), 3.65 (br s, 1H), 3.49-3.42 (m, 2H), 3.29 (s, 1H), 3.28-3.16 (m, 2H), 2.42 (m, 1H), 2.18 (d, J=11.5 Hz, 1 H). APCI MS m/e 228.2 ((M + 1 )']. (HCI salt) mp 275-277 °C. Anal. Calcd. for C,zH~2F3N.HC1.113Hz0: C, 53.44; H, 5.11; N, 5.19. Found C. 53.73; H, 4.83; N, 5.16.
3-PHENYL-10-AZA-TRICYCLO[6.3.1.Oy]DODECA-2(7),3.5-TRIENE
HYDROCHLORIDE
A) 5-Fluoro-l,4-dihydro-l,4-methano-naphthalene and 5-iodo-l,4-dihydro-1,4-methano-naphthalene (Eisch, J. J.; Burlinson, N. E. J. Amer. Chem. Soc. 1976, 98, 753-761.
Paquette, L. A.;
Cottrell, D. M.; Snow, R. A. J. Amer. Chem. Soc. 1977, 99, 3723-3733.) Magnesium turnings (9.37 g, 385 mmol) were stirred in anhydrous THF (1000 mL) in a flame dried 21 3 neck round bottom flask equipped with a non-equalizing addition funnel with a Nz flow adapter, magnetic stirrer and efficient condenser equipped with a Nz flow adapter. The flask was stirred and warmed to reflux by a removable heating mantle. 2,6-Difluoro-iodobenzene (0.3 g) was added followed by of 3N EtMgBr in THF (0.3 mL). The addition funnel was charged with an intimate mixture of cyclopentadiene (24.24 g, 367 mmol) and 2,6-difluoro-iodobenzene (88.0 g, 367 mmol). Small portions (~1 mL) of the intimate mixture were introduced to assist initiation (~4x). After -15 minutes, the reaction initiated (exotherm, and vapor condensation) and heating was maintained as necessary during the addition of the contents of the addition funnel. The reaction was then maintained at reflux for -1 hour (no SM by GCMS).
The reaction was cooled to room temperature and quenched with Hz0 (200 mL) followed by aqueous 1N HCI solution (200 mL) to dissolve the solids. Product was extracted with hexanes (4 x 150 mL). The combined organic layer was washed with saturated aqueous NaHC03 solution (150 mL), dried (Na2S0,), filtered through a Silica plug with hexanes rinse and concentrated to an oil (70 g). Chromatography on Silica gel eluting with hexanes provided two lots (9.0 and 21.0 g), which contained primarily 5-iodo-l,4-dihydro-l,4-methano-naphthalene. (TLC hexanes R, 0.63).
B~ 5-lodo-1 2,3 4-tetrahydro-l ,4-methano-naphthalene-2,3-diol 5-lodo-1,4-dihydro-l ,4-methano-naphthalene (20 g) and N-methyl morpholine N-oxide (17.61 g, 130 mmol) were stirred in acetone (90 mL) and Hz0 (13 m1). To this was added a solution of OsO, (0.2 mL, 2.5%wt. solution in t-BuOH, 0.02 mmol). After 144 hours, Florisil* (5 g) and saturated aqueous NaHS03 solution (3 mL) were added and stirred for 112 hour. The *Trade-mark miicture was filtered through a Celite pad and the filtrate concentrated to produce an oil which was purified by chromatography on Silica gel eluting with a gradient of hexanes to 100°~
EtOAc to provide a yellow solid (13.73 g). APCI MS mle 301.1 [(M - 1)').
C) 10-Benzyl-3-iodo-10-aza-tricyclo[6.3.1.02='ldodeca-2(7),3,5-triene 5-lodo-1,2,3,4-tetrahydro-1,4-methano-naphthalene-2,3-diol (8.33 g, 27.6 mmol) and Et,NBnCI (10 mg) were vigorously stirred in dichloroethane (25 mL) and Hz0 (75 mL) then treated with sodium periodate (6.17 g, 29.0 mmol). After 1.5 hours, the layers were separated and the aqueous layer extracted with DCE (2 x 40 mL). The combined organic layer was washed with Hz0 (4 x 30 mL) until no reaction to starch iodide paper was observed, then with saturated aqueous NaCI solution (30 mL). The organic layer was dried through a cotton plug and treated with benzyl amine (3.16 mL, 29.0 mmol) and stirred for 2 minutes then transferred to an addition funnel. This solution was added over -10 minutes to a vigorously stirred cooled (0 °C) mixture of NaHB(OAc)~ (18.72 g, 88.0 mmol) in DCE (150 mL).
After addition was complete, the mixture was stirred without cooling far 2 hours. The mixture was quenched with saturated aqueous NazCO~ solution (100 mL) and stirred for 1 hour, then the layers were separated and the aqueous layer was extracted with CH2CIz (3 x 50 rnL). The combined organic layer was washed with saturated aqueous NaCI solution (50 mL), dried through a cotton plug and concentrated. Chromatography on Silica gel provided an oil (6.3 g, 61%).
(TLC 5% EtOAclhexanes R, 0.10).'H NMR (400 MHz, CDCI3) 5 7.61 (d, J= 8.0 Hz, 1H), 7.28-7.22 (m, 3H), 7.13 (d, J=8.0 Hz,IH), 6.98-6.94 (m, 3H), 3.58 (AB dd, J=14.2 Hz, 2H), 3.26 (br s, 1H), 3.21 (br s, 1H), 3.04 (br d, J=10.2 Hz, 1H), 2.83 (br d, J=10.2 Hz, 1H), 2.47 (d, J=10.0 Hz, 1H), 2.39 (d, J=10.0 Hz, 1H), 2.34 (m, 1H), 1.72 (d, J=10.5 Hz, 1H). APCI
MS m/e 376.0 [(M + 1)'j~
D) 10-Benzyl-3-phenyl-10-aza-tricyclo[6.3.1.02=']dodeca-2(7),3,5-triene (Far a discussion, see: Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483.) 10-Benzyl-3-iodo-10-aza-tricyclo[6.3.1.0~~'Jdodeca-2(7),3,5-triene (375.3 mg, 1.0 mmol), potassium acetate (785 mg, 8.0 mmol) and phenyl boronic acid (183 mg, 1.5 mmol) were combined in 1011 EtOH/Hz0 (5 mL). The mixture was degassed (3 vacuumM=
cycles), treated with tetrakis(triphenylphosphine)palladium(0) (57.5 mg, 0.05 mmol) and warmed to 90 °C for 18h. The reaction was cooled, diluted with Hz0 and extracted with Et20 (3 x 50 mL).
The organic layer was washed with brine (50 mL), dried (MgSO,), filtered and concentrated to provide an oil (180 mg, 55%). (TLC 4%EtOAc/hexanes R, 0.18). GCMS m/e 325 (M)'.
3-Phenyl-10-aza-tricyclo[6.3.1.Oz=~ldodeca-2(7),3,5-triene hydrochloride 'Trade-mark 10-Benzyl-3-phenyl-10-aza-tricyclo[6.3.1.0z~']dodeca-2(7),3,5-triene was converted into the title compound utilizing the conditions described in Example 2D. (TLC
10%
MeOH/CH2Cl2 (NH3) R~ 0.30). (data for free base) 'H NMR (400 MHz, CDCI3) b 7.46-7.15 (8H), 3.17 (br s, 1 H), 3.01 (m, 2H), 2.93 (d, J=13.0 Hz, 1 H), 2.72 (dd, J=10.5,2.5 Hz, 1 H), 2.63 (dd, J=10.5,2.5 Hz, 1 H), 2.41 (m, 1 H), 1.91 (d, J=10.5 Hz, 1 H). APCI MS m/e 236.2 [(M + 1 )+].
(HCI salt) mp 262-265 °C. Anal. Calcd. for C,~H,~N.HCL1/3Hz0: C, 73.26;
H, 6.86; N, 5.19.
Found C, 73.50; H, 6.77; N, 5.04.
3-HYDROXY-10-AZA-TRICYCLOf6.3.1.OZ--']DODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
A) 10-Benzyl-3-boronic acid-10-aza-tricyclo[6 3 1 OZ=']dodeca-2(7),3,5-triene 10-Benzyl-3-iodo-10-aza-tricyclo(6.3.1.02'']dodeca-2(7),3,5-triene (3.0 g, 7.99 mmol) was stirred in anhydrous THF (40 mL) at -78 °C under nitrogen and treated dropwise with n BuLi (3.84 mL of 2.5M soln, in hexanes, 9.59 mmol). After 10 minutes, tri-isopropylborate (4.61 mL, 20.0 mmol) was added dropwise. After ~1/2 hour, the reaction was poured into saturated aqueous NaHC03 solution, stirred 5 minutes and extracted with EtOAc (3 x 50 mL) and concentrated. The residue was dissolved in 30% Et20/hexanes and extracted with 1 N
NaOH aqueous solution (4 x 50 mL). The combined aqueous basic layer was treated with concentrated HCI to achieve pH 8 and extracted with EtOAc (4 x 25 mL), dried (Na2S04) and stripped. Chromatography on Silica gel eluting first with 3% EtOAc/hexanes to remove non-polar components, then with 5% MeOH/CH2Cl2 provides the title compound. (TLC
25%
EtOAc/hexanes R, 0.60).
B) 10-Benzyl-3-hydroxy-10-aza-tricyclo[6.3.101]dodeca-2(7),3,5-triene 10-Benzyl-3-boronic acid-10-aza-tricyclo[6.3.1.02'']dodeca-2(7),3,5-triene (140 mg, 0.48 mmol) dissolved in THF (5 mL) was treated with N-methylmorpholine-N-oxide (64.5 mg, 0.48 mmol) and brought to reflux for 1 hour. The reaction was concentrated and chromatographed on Silica gel to provide product. (TLC 25% EtOAclhexanes Rf 0.18). 'H
NMR (400 MHz, CDCI3) b 7.18-7.15 (3H), 7.04 (dd, J= 8.0,7.0 Hz, 1 H), 6.95 (m, 2H), 6.75 (d, J=7.0 Hz, 1H), 6.59 (dd, J=8.0,1.0 Hz, 1H), 3.53 (br s, OH), 3.51 (AB d, J=14.0 Hz, 2H), 3.28 (br s, 1H), 3.06 (br s, 1H), 2.91 (dd, J=8.5,1.5 Hz, 1H), 2.79 (ddd, J=8.5,1.5,1.5 Hz, 1H), 2.42 (d, J=11.0 Hz, 1 H), 2.39 (d, J=11.0 Hz, 1 H), 2.23 (m, 1 H), 1.65 (d, J=10.5 Hz, 1 H). APCI MS
m/e 266.5 [(M + 1 )'].
C) 3-Hydroxy-10-aza-tricyclo[6.3.1.0~)dodeca-2(7),3 5-triene hydrochloride 10-Benzyt-3-hydroxy-10-aza-tricyclo[6.3.1.02~')dodeca-2(7),3,5-triene (160 mg, 0.60 mmol) was converted into the title compound by the methods described in Example 1 D. 'H
NMR (400 MHz, CDCI3) 8 7.15 (dd, J=8.0,7.5 Hz, 1 H), 6.84 (d, J=7.5 Hz, 1 H), 6.76 (d, J=8.0 Hz, 1 H), 3.51 (br s, 1 H), 3.33-3.25 (3H), 3.16 (d, J=12.0 Hz, 1 H), 3.09 (d, J=12.0 Hz, 1 H), 2.29 (m, 1 H), 2.02 (d, J=11.0 Hz, 1 H). APCI MS m/e 175.8 [(M + 1 )+J. (HCI salt) mp 253-255 °C.
4,5-DIFLUORO-10-AZA-TRICYCLO[6.3 1 02='jDODECA-2(7),3,5-TRIENE
HYDROCHLORIDE
The title compound was prepared by the methods described in Example 1 and 2 starting with 2,4,5-trifluorobromobenzene. 'H NMR (400 MHz, CDCl3) 8 7.31 (t, J=8.5 Hz, 2H), 3.48-3.13 (6H), 2.38 (m, 1 H), 2.11 (d, J=11.5 Hz, 1 H). APCI MS m/e 196.2 [(M
+ 1 ) ']. (HCI
salt) mp 301-303 °C. Anal. Calcd. for C"H"FZN.HC1.1/6H20: C, 56.30; H, 5.30; N, 5.97.
Found C, 56.66; H, 5.41; N, 5.96.
FX~AADI ~ ~~
6-ETHYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 OZ''-°.04~PENTADECA-2(10),3,6 TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02'']dodeca-2(7), 3, 5-trien-10-yl)-ethanone and propionyl chloride were converted to the title compound following the procedures described in Example 30 and Goldstein, S. W.; Dambek, P. J. J. Het.
Chem.
1990, 27, 335. 'H NMR (400 MHz, CD30D) 8 7.64 (s, 1 H), 7.62 (s, 1 H), 3.48 (d, J=2.5 Hz, 2H), 3.41 (d, J=12.0 Hz, 2H), 3.20 (2H), 3.01 (q, J=7.5 Hz, 2H), 2.45 (m, 1 H), 2.17 (d, J=11.5 Hz, 1H), 1.42 (t, J=7.5 Hz, 3H). APCI MS m/e 229.2 [(M + 1)~).
6-ISOPROPYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 02''-°.0''~]PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~')dodeca-2(7), 3, 5-trien-10-yl)-ethanone and isobutyryl chloride were converted to the title compound following the procedures described in EXAMPLE 47. (TLC 25% EtOAc/hexanes R, 0.14). 'H NMR
(400 MHz, CD30D) 8 7.65 (2H), 3.49 (br s, 2H), 3.41 (d, J=12.0 Hz, 2H), 3.33-3.19 (3H), 2.45 (m, 1H), 2.18 (d, J=11.5 Hz, 1H), 1.45 (d, J=7.0 Hz, 6H). APCI MS m/e 243.2 [(M +
1)+]. (HCI salt) mp 249-251 °C.
~X~11API G AD
6-BENZYL-5-OXA-7,13-DIAZATETRACYCLO[9 3 1 Oz''-°._04~PENTADECA-2(10),3,6,8-TETRAENE HYDROCHLORIDE
2,2,2-Trifluoro-1-(4-hydroxy-5-amino-10-aza-tricyclo[6.3.1.02~']dodeca-2(7),3,5-trien-10-yl)-ethanone and phenyl-acetyl chloride were converted to the title compound following the procedures described in EXAMPLE 47. 'H NMR (400 MHz, CD30D) b 7.63 (s, 1H), 7.58 (s, 1 H), 7.36-7.24 (5H), 4.29 (s, 2H), 3.46 (d, J=2.5 Hz, 2H), 3.39 (d, J=12.0 Hz, 2H}, 3.18 (2H), 2.42 (m, 1 H), 2.15 (d, J=11.5 Hz, 1 H). APCI MS m/e 291.2 [(M + 1 )+~.
Claims (16)
1. A compound of the formula R1 is hydrogen, (C1 -C6)alkyl, unconjugated (C3-C6)alkenyl, XC(=O)R13, benzyl or -CH2CH2-O-(C1-C4)alkyl;
R2 and R3 are selected, independently, from hydrogen, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, nitro, amino, halo, cyano, SO q(C1-C6)alkyl wherein q is zero, one or two, (C1-C6)alkylamino-, [(C1-C6)alkyl]2amino-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, aryl-(C0 -C3)alkyl- or aryl-(C0-C3)alkyl-O-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C0-C3)alkyl- or heteroaryl-(C0-C3)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, X2(C0-C6)alkyl- and X2(C1-C6)alkoxy-(C0-C6)alkyl-, wherein X2 is absent or X2 is (C1-C6)alkylamino- or [(C1-C6)alkyl]2amino-, and wherein the (C0-C6)alkyl- or (C1-C6)alkoxy-(C0-C6)alkyl- moieties of said X2(C0-C6)alkyl- or X2(C1-C6)alkoxy-(C0-C6)alkyl- contains at least one carton atom, and wherein from one to three of the carbon atoms of said X2(C0-C6)alkyl- or (C1-C6)alkoxy-(C1-C6)alkyl- moieties may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C0-C6)alkyl- or (C1-C6)alkoxy-(C0-C6)alkyl- may be optionally substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C0-C3)alkyl- and said heteroaryl-(C0-C3)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, independently selected from (C1-C6)alkyl optionally substituted with from one to seven fluorine atoms, (C1-C6)alkoxy optionally substituted with from two to seven fluorine atoms, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, nitro, cyano, amino, (C1-C6)alkylamino-, [(C1-C6) alkyl]2amino-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13 and -XC(=O)R13;
or R2 and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, that are selected, independently, from (C1 -C6) alkyl optionally substituted with from one to seven fluorine atoms, (C1 -C6) alkoxy optionally substituted with from one to seven fluorine atoms, nitro, cyano, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, amino, (C1 -C6)alkylamino and ((C1 -C6) alkyl]2amino, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13 and -XC(=O)R13;
wherein R4, R5, R6, R7, R8 and R13 are selected, independently, from hydrogen and (C1 -C6) alkyl, or R5 and R6, or R7 and R8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C1-C6)alkylene;
with the proviso that (a) at least one of R1, R2 and R3 must be the other than hydrogen, and (b) when R2 and R3 are both hydrogen, R1 cannot be hydrogen, (C1-C6)alkyl, or unconjugated (C3-C6)alkenyl; or a pharmaceutically acceptable salt thereof;
R2 and R3 are selected, independently, from hydrogen, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, nitro, amino, halo, cyano, SO q(C1-C6)alkyl wherein q is zero, one or two, (C1-C6)alkylamino-, [(C1-C6)alkyl]2amino-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, aryl-(C0 -C3)alkyl- or aryl-(C0-C3)alkyl-O-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C0-C3)alkyl- or heteroaryl-(C0-C3)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, X2(C0-C6)alkyl- and X2(C1-C6)alkoxy-(C0-C6)alkyl-, wherein X2 is absent or X2 is (C1-C6)alkylamino- or [(C1-C6)alkyl]2amino-, and wherein the (C0-C6)alkyl- or (C1-C6)alkoxy-(C0-C6)alkyl- moieties of said X2(C0-C6)alkyl- or X2(C1-C6)alkoxy-(C0-C6)alkyl- contains at least one carton atom, and wherein from one to three of the carbon atoms of said X2(C0-C6)alkyl- or (C1-C6)alkoxy-(C1-C6)alkyl- moieties may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C0-C6)alkyl- or (C1-C6)alkoxy-(C0-C6)alkyl- may be optionally substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C0-C3)alkyl- and said heteroaryl-(C0-C3)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, independently selected from (C1-C6)alkyl optionally substituted with from one to seven fluorine atoms, (C1-C6)alkoxy optionally substituted with from two to seven fluorine atoms, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, nitro, cyano, amino, (C1-C6)alkylamino-, [(C1-C6) alkyl]2amino-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13 and -XC(=O)R13;
or R2 and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, that are selected, independently, from (C1 -C6) alkyl optionally substituted with from one to seven fluorine atoms, (C1 -C6) alkoxy optionally substituted with from one to seven fluorine atoms, nitro, cyano, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, amino, (C1 -C6)alkylamino and ((C1 -C6) alkyl]2amino, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13 and -XC(=O)R13;
wherein R4, R5, R6, R7, R8 and R13 are selected, independently, from hydrogen and (C1 -C6) alkyl, or R5 and R6, or R7 and R8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C1-C6)alkylene;
with the proviso that (a) at least one of R1, R2 and R3 must be the other than hydrogen, and (b) when R2 and R3 are both hydrogen, R1 cannot be hydrogen, (C1-C6)alkyl, or unconjugated (C3-C6)alkenyl; or a pharmaceutically acceptable salt thereof;
2. A compound according to claim 1, wherein R2 and R3, together with the benzo ring of formula I, form a bicyclic ring system selected from the following:
wherein R10 and R17 are selected, independently, from (C0-C6)alkyl- and (C1-C6)alkoxy-(C0-C6)alkyl- wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; nitro, cyano, halo, amino, (C1-C6) alkylamino-, [(C1-C6) alkyl]2amino-, -CO2R4, - CONR5R6, - SO2NR7R8, - C(=O)R13, -XC(=O)R13, phenyl and monocyclic heteroaryl, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and wherein R4, R5, R6, R7, R8 and R13 are as defined in claim 1.
wherein R10 and R17 are selected, independently, from (C0-C6)alkyl- and (C1-C6)alkoxy-(C0-C6)alkyl- wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; nitro, cyano, halo, amino, (C1-C6) alkylamino-, [(C1-C6) alkyl]2amino-, -CO2R4, - CONR5R6, - SO2NR7R8, - C(=O)R13, -XC(=O)R13, phenyl and monocyclic heteroaryl, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and wherein R4, R5, R6, R7, R8 and R13 are as defined in claim 1.
3. A compound according to claim 1, wherein R2 and R3 do not, together with the benzo ring of formula I, form a bicyclic or tricyclic ring system.
4. A compound according to claim 1, wherein one or both of R2 and R3 are -C(=O)R13 wherein R13 is (C1-C6) alkyl.
5. A compound according to claim 1, wherein one of R2 and R3 is -COR13 wherein R13 is (C1-C6) alkyl or (C1-C3) alkyl optionally substituted with from one to seven fluorine atoms.
6. A compound according to claim 1, wherein one of R2 and R3 is CF3, fluoro, cyano or C2F5.
7. A pharmaceutical composition for use in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising (a) an amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use and (b) a pharmaceutically acceptable carrier.
8. A use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal.
9. A pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine and/or tobacco products, alcohol, benzodiazepines, barbituates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising (a) an amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition and (b) a pharmaceutically acceptable carrier.
10. A use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for treating a disorder or a condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine and/or tobacco products, alcohol, benzodiazepines, barbituates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal.
11. A compound of the formula:
wherein P is hydrogen, methyl, COOR16 (wherein R16 is (C1-C6) alkyl, allyl or 2, 2, 2-trichloroethyl) , -C(=O) NR5R6 (wherein R5 and R6 are each independently hydrogen or (C1-C6) alkyl or R5 and R6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone), -C(=O)H, -C(=O)(C1-C6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, benzyl or t-butoxycarbonyl, and R14 and R15 are selected, independently, from hydrogen, (C1-C6)alkyl optionally substituted with from one to seven fluorine atoms, -C(=O)(C1-C6)alkyl, cyano, hydroxyl, nitro, amino, -O(C1-C6)alkyl and halo; with the proviso that R14 and R15 can not both be hydrogen when P is hydrogen or methyl.
wherein P is hydrogen, methyl, COOR16 (wherein R16 is (C1-C6) alkyl, allyl or 2, 2, 2-trichloroethyl) , -C(=O) NR5R6 (wherein R5 and R6 are each independently hydrogen or (C1-C6) alkyl or R5 and R6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone), -C(=O)H, -C(=O)(C1-C6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, benzyl or t-butoxycarbonyl, and R14 and R15 are selected, independently, from hydrogen, (C1-C6)alkyl optionally substituted with from one to seven fluorine atoms, -C(=O)(C1-C6)alkyl, cyano, hydroxyl, nitro, amino, -O(C1-C6)alkyl and halo; with the proviso that R14 and R15 can not both be hydrogen when P is hydrogen or methyl.
12. A pharmaceutical composition for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, which comprises (a) an amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use, and (b) a pharmaceutically acceptable carrier.
or a pharmaceutically acceptable salt thereof, that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use, and (b) a pharmaceutically acceptable carrier.
13. A pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amylotropic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions; dependencies on, or addiction to, nicotine and/or tobacco products, alcohol, benzodiazepines, barbituates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, which comprises:
a) an amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof; that is effective in treating such disorder or condition, and b) a pharmaceutically acceptable carrier.
a) an amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof; that is effective in treating such disorder or condition, and b) a pharmaceutically acceptable carrier.
14. A compound of the formula:
wherein R2 and R3 are defined as in claim 1; and P' is COOR16 (wherein R16 is allyl, 2,2,2-trichloroethyl or (C1-C6) alkyl) , -C (=O) NR5R6 (wherein R5 and R6 are each independently hydrogen or (C1-C6) alkyl or R5 and R6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone) , -C (=0) H, -C (=O) (C1-C6) alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, benzyl, or t-butoxycarbonyl.
wherein R2 and R3 are defined as in claim 1; and P' is COOR16 (wherein R16 is allyl, 2,2,2-trichloroethyl or (C1-C6) alkyl) , -C (=O) NR5R6 (wherein R5 and R6 are each independently hydrogen or (C1-C6) alkyl or R5 and R6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone) , -C (=0) H, -C (=O) (C1-C6) alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, benzyl, or t-butoxycarbonyl.
15. A pharmaceutical composition according to claim 7 or 12, in a container carrying a written matter which states that the pharmaceutical composition is to be used for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal.
16. A pharmaceutical composition according to claim 9 or 13, in a container carrying a written matter which states that the pharmaceutical composition is to be used for treating the disorder or condition defined in claim 9 or 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7024597P | 1997-12-31 | 1997-12-31 | |
| US60/070,245 | 1997-12-31 | ||
| PCT/IB1998/001813 WO1999035131A1 (en) | 1997-12-31 | 1998-11-13 | Aryl fused azapolycyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2316921A1 CA2316921A1 (en) | 1999-07-15 |
| CA2316921C true CA2316921C (en) | 2004-12-07 |
Family
ID=22094096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002316921A Expired - Lifetime CA2316921C (en) | 1997-12-31 | 1998-11-13 | Aryl fused azapolycyclic compounds |
Country Status (52)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA003190B1 (en) * | 1997-12-31 | 2003-02-27 | Пфайзер Продактс Инк. | Aryl fused azapolycyclic compounds |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| BR0012793A (en) | 1999-07-28 | 2002-04-30 | Univ Leland Stanford Junior | Methods for inducing angiogenesis by administering nicotine or another nicotine receptor agonist |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| DK1383733T3 (en) * | 2001-04-20 | 2008-06-09 | Pfizer Prod Inc | Process for Preparation of 1,3-Substituted Domains and Aryl-Joined Azapolycyclic Compounds |
| DOP2002000390A (en) * | 2001-05-14 | 2003-03-15 | Pfizer Prod Inc | SALT CITRATE 5.8 14-HIEZATETRACICLO [10.3.1.0 2.11. 0.4.9] HEXADECA-2 (11), 3,5,8,9, PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME |
| JP3779682B2 (en) * | 2001-05-14 | 2006-05-31 | ファイザー・プロダクツ・インク | 5,8,14-Triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2 (11), 3,5,7,9-pentane tartrate and pharmaceutical composition thereof |
| CA2468705A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| EP1451202B1 (en) | 2001-11-30 | 2008-08-20 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| DE60218885T2 (en) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Oral pharmaceutical dosage forms of 5,8,14-triazatetra-cyclo- (10.3.1.0 (2,11) .0 (4,9) -hexadeca-2 (11), 3,5,7,9-pentaene with controlled release |
| DK1572127T4 (en) | 2002-02-14 | 2014-11-24 | Univ Leland Stanford Junior | Enzyme processing of foods for celiac disease |
| US7320788B2 (en) * | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
| US8143210B2 (en) * | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| WO2003096979A2 (en) * | 2002-05-14 | 2003-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| US7265093B2 (en) * | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
| US7202216B2 (en) * | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| DK1565421T3 (en) * | 2002-11-20 | 2008-09-22 | Pfizer Prod Inc | Process for the preparation of indane -1,3-dicarboxylic acid |
| DK1563300T3 (en) * | 2002-11-20 | 2012-07-23 | Univ Leland Stanford Junior | Diagnostic procedure for celiac disease |
| WO2004048318A1 (en) * | 2002-11-25 | 2004-06-10 | Pfizer Products Inc. | Improved process for the preparation of 1,3-substituted indenes |
| KR20050101177A (en) * | 2003-01-15 | 2005-10-20 | 화이자 프로덕츠 인크. | Process for the preparation of aryl fused polycyclic lactams |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| EP1633358A1 (en) * | 2003-05-20 | 2006-03-15 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
| DE602004015986D1 (en) * | 2003-06-04 | 2008-10-02 | Pfizer Prod Inc | PREPARATION OF SUBSTITUTED CHINOXALINES FROM DIANILINES WITH 2,3-DIHYDROXY-1,4-DIOXANE |
| CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| ATE443705T1 (en) * | 2003-07-21 | 2009-10-15 | Pfizer Prod Inc | NICOTINE DEPENDENCE REDUCING HETEROARYL CONDENSED AZAPOLYCYCLIC COMPOUNDS |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US7579313B2 (en) * | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
| US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| US7534426B2 (en) * | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
| US7628985B2 (en) * | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
| WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
| US7766018B2 (en) * | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
| JP2008531540A (en) * | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | Preparation of high purity substituted quinoxaline |
| US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
| WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| AU2007231072A1 (en) * | 2006-03-27 | 2007-10-04 | Pfizer Products Inc. | Varenicline standards and impurity controls |
| CA2650211A1 (en) * | 2006-04-24 | 2007-11-01 | Prizer Products Inc. | Asymmetric membranes for drug delivery devices |
| US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| WO2008060487A2 (en) * | 2006-11-09 | 2008-05-22 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
| EP2136833B1 (en) * | 2007-03-16 | 2019-05-01 | The Board of Trustees of the Leland Stanford Junior University | Combination enzyme therapy for digestion of dietary gluten |
| WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
| WO2009101185A2 (en) * | 2008-02-15 | 2009-08-20 | Medichem, S.A. | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE |
| US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| US9463190B2 (en) * | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| WO2009143347A2 (en) * | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
| WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| EP2334679A1 (en) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
| EP2204369A1 (en) | 2008-12-22 | 2010-07-07 | Medichem, S.A. | Process for preparing varenicline and intermediates for use therein |
| US8063032B2 (en) | 2009-02-11 | 2011-11-22 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| EP2440187A2 (en) | 2009-06-10 | 2012-04-18 | Actavis Group PTC ehf. | Amorphous varenicline tartrate co-precipitates |
| WO2010151524A1 (en) | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
| MX2012002827A (en) * | 2009-09-11 | 2012-04-10 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof. |
| WO2011110954A1 (en) | 2010-03-09 | 2011-09-15 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| KR101109389B1 (en) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | A printed circuit board and a method of manufacturing the same |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| US20120004239A1 (en) | 2010-06-11 | 2012-01-05 | Medichem, S.A. | Process for Preparing Quinoxaline Derivatives |
| JPWO2013002365A1 (en) | 2011-06-30 | 2015-02-23 | 東レ株式会社 | Antidiarrheal |
| ITMI20111413A1 (en) * | 2011-07-28 | 2013-01-29 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF VARENICLINA |
| ES2426838B1 (en) | 2012-04-20 | 2014-05-07 | Genetracer Biotech S.L | Method to predict success in quitting tobacco use in response to drug treatment |
| ES2426517B1 (en) | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Method to predict the safety of a drug treatment |
| CN103570502A (en) * | 2012-07-18 | 2014-02-12 | 上海科胜药物研发有限公司 | Preparation method for varenicline intermediate |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| CN103992272B (en) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | A kind of pentazocine hydrochloride ester, Its Preparation Method And Use |
| KR20160126697A (en) | 2015-04-24 | 2016-11-02 | 한미정밀화학주식회사 | Novel crystalline varenicline oxalate hydrate, preparation method thereof, and pharmaceutical composition comprising same |
| KR20160143407A (en) | 2015-06-05 | 2016-12-14 | 한미정밀화학주식회사 | Novel varenicline mucate, crystalline form thereof, and method of preparation thereof |
| KR101724301B1 (en) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | Novel crystal form I of varenicline salicylate and its preparing method |
| CN106674194B (en) * | 2016-12-14 | 2019-03-05 | 山东省联合农药工业有限公司 | A kind of nicotinic insecticide of structure novel and its preparation method and application |
| TWI775817B (en) | 2017-03-03 | 2022-09-01 | 南韓商西梯茜生命工學股份有限公司 | Orally administered formulation containing inclusion complex of varenicline or pharmaceutically acceptable salt thereof |
| KR102463733B1 (en) | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | Pharmaceutical composition comprising Varenicline Oxalate with improved content uniformity and stability |
| WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
| KR20200034293A (en) | 2018-09-21 | 2020-03-31 | 한미약품 주식회사 | Varenicline formulation for controlled-release |
| TW202206078A (en) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| CN113956255A (en) * | 2020-07-20 | 2022-01-21 | 威智医药有限公司 | Preparation method of varenicline intermediate, varenicline and salt thereof |
| WO2022035434A1 (en) | 2020-08-14 | 2022-02-17 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
| US11040983B1 (en) | 2020-08-14 | 2021-06-22 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
| WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
| WO2022222019A1 (en) * | 2021-04-20 | 2022-10-27 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Total synthesis of varenicline |
| CN113277993B (en) * | 2021-06-06 | 2023-07-21 | 湖南第一师范学院 | Synthesis method of Tafamidis and derivatives thereof |
| WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
| EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
| US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
| WO2023244584A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
| CH644116A5 (en) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | IMIDAZOLE DERIVATIVES. |
| EP0853621A1 (en) † | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| EA003190B1 (en) * | 1997-12-31 | 2003-02-27 | Пфайзер Продактс Инк. | Aryl fused azapolycyclic compounds |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| SK15952000A3 (en) * | 1998-04-29 | 2002-06-04 | Pfizer Products Inc. | Aryl fused azapolycyclic compound, the use thereof and pharmaceutical compositions based thereon |
| ATE394401T1 (en) * | 1999-01-29 | 2008-05-15 | Abbott Lab | DIAZABICYCLO DERIVATIVES AS NICOTINE-ACETYLCHOLINE RECEPTOR LIGANDS |
| FR2788982B1 (en) * | 1999-02-02 | 2002-08-02 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| JP3779682B2 (en) * | 2001-05-14 | 2006-05-31 | ファイザー・プロダクツ・インク | 5,8,14-Triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2 (11), 3,5,7,9-pentane tartrate and pharmaceutical composition thereof |
| DOP2002000390A (en) * | 2001-05-14 | 2003-03-15 | Pfizer Prod Inc | SALT CITRATE 5.8 14-HIEZATETRACICLO [10.3.1.0 2.11. 0.4.9] HEXADECA-2 (11), 3,5,8,9, PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME |
| CA2468705A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| DE60218885T2 (en) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Oral pharmaceutical dosage forms of 5,8,14-triazatetra-cyclo- (10.3.1.0 (2,11) .0 (4,9) -hexadeca-2 (11), 3,5,7,9-pentaene with controlled release |
| EP1451202B1 (en) * | 2001-11-30 | 2008-08-20 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
-
1998
- 1998-11-13 EA EA200000592A patent/EA003190B1/en not_active IP Right Cessation
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/en not_active IP Right Cessation
- 1998-11-13 UA UA2000063807A patent/UA66825C2/en unknown
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/en active Pending
- 1998-11-13 SK SK971-2000A patent/SK286886B6/en not_active IP Right Cessation
- 1998-11-13 PT PT98950274T patent/PT1044189E/en unknown
- 1998-11-13 CN CNB988128195A patent/CN1324013C/en not_active Expired - Lifetime
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en active IP Right Grant
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/en not_active IP Right Cessation
- 1998-11-13 PL PL341824A patent/PL209404B1/en unknown
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 AT AT98950274T patent/ATE386024T1/en active
- 1998-11-13 IL IL13672798A patent/IL136727A0/en active Protection Beyond IP Right Term
- 1998-11-13 RS YUP-403/00A patent/RS50069B/en unknown
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/en active IP Right Review Request
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/en not_active Expired - Lifetime
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/en not_active Expired - Lifetime
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/en not_active IP Right Cessation
- 1998-11-13 SI SI9830902T patent/SI1044189T2/en unknown
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/en unknown
- 1998-11-13 HU HU0100949A patent/HU230297B1/en active Protection Beyond IP Right Term
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/en not_active Expired - Lifetime
- 1998-11-13 NZ NZ504482A patent/NZ504482A/en not_active IP Right Cessation
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/en active Pending
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/en unknown
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/en unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/en unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/en unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/en unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/en unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 TW TW087121748A patent/TW513412B/en not_active IP Right Cessation
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/en not_active IP Right Cessation
- 1998-12-28 EG EG161298A patent/EG23816A/en active
- 1998-12-29 AR ARP980106715A patent/AR017967A1/en active IP Right Grant
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/en unknown
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/en unknown
- 1998-12-30 MA MA25409A patent/MA26589A1/en unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/en active
-
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/en unknown
-
2000
- 2000-05-26 IS IS5514A patent/IS5514A/en unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/en unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/en not_active IP Right Cessation
- 2000-06-30 HR HR20000445A patent/HRP20000445B1/en not_active IP Right Cessation
-
2001
- 2001-04-09 HK HK01102476A patent/HK1031878A1/en not_active IP Right Cessation
-
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 HR HR20050506A patent/HRP20050506A2/en not_active Application Discontinuation
-
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/en not_active IP Right Cessation
-
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
-
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/en unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/en unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/en unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I2/en unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/en active Active
-
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2316921C (en) | Aryl fused azapolycyclic compounds | |
| US6605610B1 (en) | Aryl fused azapolycyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20181113 |